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ABSTRACT 
Heart transplantation has enjoyed a spectacular success over the past 25 years. Prior to 
1980 less than 350 operations were carried out with an overall one year survival of less than 
60%. In 1995 more than 3,000 transplants were performed with a one year survival of 83%. 
However, growth and improved survival have both plateaued over the last few years; the 
former because of the falling donor supply and the latter, in part, because of the use of less 
suitable donors in an effort to offset the problem of supply. 
Much attention has been focused on the drama of the surgery and the intricacies of 
immunological manipulation whilst little effort has been devoted to the area of donor 
management, despite the fact that primary graft failure is responsible for as many post 
transplant deaths as either infection or rejection. Optimum preservation of the donor heart 
has also provided a difficult challenge, such that, despite a considerable scientific effort little 
advance has been achieved to extend the 4 hour safe storage limit which has remained in 
place over the past 20 years. 
In this dissertation the problem has been approached by combining laboratory based 
preservation models with an objective regime of donor management. A sensitive isolated 
small animal working heart model was developed and used to characterise cardioplegic 
induction. Subsequently, the model was used to examine the interaction of oxygen content 
with the mode of delivery, during preservation. 
Finally, a number of representative solutions were combined with the most promising 
oxygen delivery method. These studies served to illustrate the utility of controlled laboratory 
studies and offer the prospect of more than doubling post storage function. 
The development of a rigorous donor management regime was also shown to be capable of 
reducing the variance in haemodynamic parameters by up to 44% whilst safely increasing 
the donor pool by approximately 30%. It is the contention of this thesis that the only 
prospect of improving the current impasse with the supply of donor hearts in sufficient 
quantity and of acceptable quality, is by the combination of appropriate laboratory models 
with controlled clinical trials. 
CH1 INTRODUCTION 
CHAPTER 1 
INTRODUCTION 
1.1 HISTORICAL BACKGROUND 
The concept of cardiac transplantation can be traced back to ancient myths and 
legends. However, the concept could only be turned into reality with the development 
of vascular surgical techniques in the early part of this century, cardiopulmonary 
bypass in 1954 and the means of managing rejection in the late 1960's. 
Figure IA Depiction of the first Heart Transplant from Chinese Mythology circa 500 BC 
The first reported attempts at experimental heart transplantation were by Carrel and 
Guthrie in 19051, when they transplanted the heart of a puppy into the neck of a larger 
dog. Ventricular contractions started after about 1 hour of reperfusion and the heart 
continued to beat for a further 2 hours before intraventricular thrombosis forced the 
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experiment to be terminated. The crucial factor of donor coronary perfusion was 
simplified in 1933 when Mann 2 and co-workers developed a technique of cervical 
transplantation. Numerous investigators have subsequently used modifications of the 
Mann technique to study problems of heart transplantation, and the response of the 
denervated heart to pharmacological agents and physiological stress. Histological 
examination of the excised hearts demonstrated infiltration with lymphocytes, 
mononucleocytes and polymorphs, suggesting that graft failure resulted from 
undefined factors relating to tissue specificity rather than surgical technique. These 
were the first references to immunology and rejection. 3 
Between 1940 and 1956 Demikhov4, working in the Soviet Union, developed a canine 
intrathoracic heart transplant model which exhibited survival times of up to 32 days. 
The development of orthotopic models came in 1953 when Neptune5 and others 
reported the transplantation of heart-lung blocks, using surface cooling and circulatory 
arrest of the recipient. In 1959 Cass and Brock6 reported six attempts at 
autotransplantation and homotransplantation, where both atria were left intact in the 
recipient, thus simplifying the procedure. This procedure was described independently 
1 year later at Stanford by Lower and Shumway7, who obtained the first consistently 
successful results. With further modifications, made by Barnard8, the technique is now 
used in most clinical centres as the basis for orthotopic heart transplantation. 
These latter experiments were all conducted using the support of a pump-oxygenator 
system. In 1965 Kondo9 and colleagues described a technique utilising profound 
hypothermia of both donor and recipient, by surface cooling. Transplantation took 
place during the 45 minutes of circulatory arrest. Following completion of the 
anastamoses, the recipient was rewarmed again using surface warming and warm 
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saline irrigation of the heart. This technique showed moderate success - one animal 
survived for 112 days - but was abandoned in favour of the more controlled conditions 
provided by the heart-lung machine. 
By the mid - 1960's a considerable fund of knowledge had been acquired, particularly 
with respect to immunosuppression10'", and the increasing experimental success 
enjoyed by a number of groups world-wide, set the scene for the first human operation. 
One such group, at the University of Mississippi, attempted the first cardiac xenograft, 
when they transplanted a chimpanzee heart into the chest of a dying patient, in 
196412. Early function was good but the heart developed congestive failure shortly after 
weaning from the heart-lung machine. 
The first successful human heart transplant took place in Cape Town, unexpectedly, on 
the 3rd of December, 196713. The patient was a 57 year old man with ischaemic heart 
disease. The surgery was successful and the heart functioned satisfactorily until the 
patient succumbed to a Pseudomonas pneumonitis on the 18th post operative day. At 
autopsy the heart showed signs of mild to moderate rejection. The first patient who 
could realistically be described as a long term survivor was operated on in Cape Town, 
1 month later and lived an active life until he died from the hitherto undescribed 
14 complication of chronic rejection, eighteen months later. 
The preservation technique used for this first and subsequent early procedures 
consisted of placing the donor on cardiopulmonary bypass and instituting whole body 
cooling, in the adjacent operating theatre to the one in which the recipient operation 
was taking place. The donor heart was removed when the core temperature reached 
18°C and connected within minutes to a side limb of the bypass circuit used to support 
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the recipient. It was a further 10 years before distant donor heart procurement became 
feasible with the adoption of cold hyperkalaemic cardioplegia, developed for 
myocardial protection in routine cardiac surgery, together with hypothermic storage 
and transport of donor hearts15. This allowed a safe preservation time of some 4 
hours, adding a considerable logistical challenge to the conduct of clinical heart 
transplantation. 
This first pioneering operation initiated hectic activity in cardiac transplantation world- 
wide. Over the proceeding 12 months, 102 transplants were performed in 17 countries 
by 64 surgical teams. The results were appalling, with a mean survival of only 29 days. 
By the end of 1969, very few groups were persisting with active cardiac transplant 
programmes and in some countries this attitude was reinforced by a moratorium 
imposed by the healthcare providers. Some of those centres which persisted, most 
notably Stanford University, initiated a sustained research programme which achieved 
significant understanding and advances. The most significant of these was the 
development of an endomyocardial biopsy technique for the detection of rejection16, 
the classification of rejection and the use of improved immunosuppressants, in 
particular Cyclosporin A". At the same time a public education programme was 
launched to establish an awareness of the need for donor organs and the concept of 
brain death was ultimately established18. 
In the subsequent 25 years heart transplantation enjoyed a spectacular success, with 
overall activity increasing to more than 3,000 operations per year, with a1 year survival 
rate of 83%19 
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Figure 1B Histogram showing the rapid increase in activity in the 1980s followed 
by decline in recent years as the donor supply became limiting. 
However, both the activity and survival rates have remained static over the past few 
years, with the donor supply remaining the major limiting factor in the provision of 
5 
transplantation as a more widespread therapy. 
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Figure 1C Actuarial survival in the six year eras between 1975 and 1993. 
Following an initial marked improvement in both acute and longer term 
survival, there has been little further improvement in recent years. 
1.2 CURRENT STATUS 
During the past 25 years much research effort has been focused on the surgical and 
immunological aspects of transplantation, with comparatively little attention being 
directed to the issue of optimal donor heart retrieval. This is somewhat surprising since 
data from the International Heart Transplant Registry has consistently shown that 
primary graft failure ranks on a par with both infection and rejection as an early cause 
of death20. 
9 12 15 18 21 24 27 30 33 36 
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The importance of good donor heart function, immediately following transplantation, 
cannot be over emphasised. During the course of cardiac transplantation, donor hearts 
undergo a sequence of five key events; initial donor management, cardioplegic 
induction, storage, global ischaemia during implantation, and reperfusion. Despite a 
plethora of published laboratory studies into improved donor heart preservation, little 
advance in the 4 hour safe preservation time, which has been the case for the past 20 
years, has been achieved. The ISHLT Register19 reports an Odds Ratio of 1.1 per hour 
of ischaemic time, up to 4 hours, after which there is insufficient data since most 
centres limit themselves to this time. A number of groups have shown, experimentally, 
improved metabolic preservation for up to 40 hours21-30 by means of different 
solutions22-24'26,27,29, by the use of perfusion systems21,25 or by some form of 
7 
Rejection 
15% 
CH1 INTRODUCTION 8 
conditioning30. However, tentative clinical extensions of clinical preservation times have 
not met with success. This is in stark contrast to progress in the clinical preservation 
times achieved for other transplantable organs where kidneys are routinely stored for 
more than 36 hours31 and livers for more than 12 hours32. 
There are probably two major reasons for this discrepancy; firstly donor hearts are 
required to perform a high level of work within a short time of implantation and 
secondly there are some significant differences in the metabolic features, with respect 
to both energy pathways33 and natural defence mechanisms 34.35 of the myocardium. 
The heart contains a number of disparate tissue subtypes - contractile, conductive, 
connective and vascular, all of which have different susceptibilities to tissue injury. 
Whilst the majority of investigators have focused on the quantitatively dominant 
contractile tissue, failure of electrical conduction or vascular performance is equally 
crucial in this dynamic organ. Equally important, the biochemical and biophysical 
reactions within these tissues show heterogeneous responses to cooling. Whilst 
cellular energy processes such as phosphorylation, may decline rapidly, and active 
cation transport in particular, processes involving diffusion may be reduced to a lesser 
extent, and this is further compounded by the phase transitions which cell membranes 
undergo, in response to a decrease in temperature. 
The heart can be viewed as a chemodynamic machine which liberates energy stored in 
chemical bonds to perform mechanical work. The main substrates from which this 
chemical energy is liberated, are fatty acids, glucose, pyruvate and lactate, which are 
broken down into 2-carbon fragments which enter the Krebs cycle. Hence the heart is 
essentially an aerobic organ, rich in the respiratory enzymes, with limited energy 
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storage capacity, a high energy requirement and an intolerance for toxic metabolites, 
including protons. This makes the organ peculiarly susceptible to ischaemic damage. 
There is now convincing evidence that oxygen-derived free radicals are important 
mediators of myocardial damage3` resulting from the ischaemia/reperfusion sequence. 
Free radical production is consequently expected to occur in the course of the 
transplantation procedure in which hearts are subjected to two superimposed periods 
of global ischaemia. Thiol groups, linked either to the tripeptide glutathione or to 
various proteins, play a key role in the defence of tissues against oxygen toxicity. In 
the heart there is a shift of the cellular thiol pool towards oxidation, leaving the 
myocardium more vulnerable to free radical damage. Curiously there is also a marked 
reduction in Defence Antagonist Factor (DAF) in myocardial tissues35. Since DAF 
provides a natural defence against autologous complement attack on tissues, and 
many of the processes involved in organ retrieval and subsequent transplantation are 
known to activate complement, this leaves the heart in a particularly vulnerable state. 
All of the above does not mean that the problem is intractable, merely that it is difficult 
and requires an individual solution. 
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Figure 1E Comparative preservation times for solid organs36 
It is somewhat surprising to note that there is currently no specifically designed 
cardiac transplant preservation solution or technique available. Each centre has 
merely adopted techniques used in their routine cardiac practice, for donor heart 
preservation. Since the conditions prevailing during donor heart preservation are very 
different to those in routine heart surgery, it is not altogether surprising that these 
techniques are not very efficient or reliable. In order to establish what the range of 
techniques are and to get some idea of what differences there may be in the clinical 
outcomes associated with these techniques, the author undertook an international 
survey (Appendix A)37. This examined the issues of; donor pre-treatment, 
cardioplegic induction, donor heart storage methods, transport medium and 
reperfusion techniques. Whilst the results of this survey were somewhat 
compromised by the availability of Centre outcomes only, rather than individual patient 
KIDNEY LIVER PANCREAS LUNG HEART 
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outcomes, it did reveal the wide disparity in techniques currently employed and gave 
some pointers to those which may hold out the promise of improved functional 
preservation. 
Twenty-seven percent of respondents reported using some form of donor pre- 
treatment. More than 90% reported using a single flush cardioplegic induction with 
the use of eight different generic types of cardioplegic solution, only 5% of which were 
oxygenated. Six different types of storage media were used and melting ice was the 
coolant used by 66% of Centres. Storage temperatures ranged between 0- 7° C, 
with 78% of respondents reporting the use of 40 C cooling. Some 55% of Centres 
reported the use of some form of reperfusion modification. There was an overall 30 
day mortality rate of 9.6%. The only clear outcome from this survey was that saline 
provided better functional preservation than other solutions, as a storage medium, 
and a suggestion of a trend towards benefits from multiple dose blood cardioplegia. 
Following the publication of this survey, the International Society now routinely collects 
some of this donor related data as part of the Registry. 
The results of the survey strengthened the anecdotal impression that donor heart 
preservation is being carried out using the default methods borrowed from routine 
cardiac surgery, albeit with a few modifications in some cases. The systems employed 
pay scant regard for the different conditions prevailing during heart storage and rely 
mostly on the metabolic benefits of hypothermia, without taking into account the 
potential harmful effects of low temperature flush/store techniques38. A default 40 C 
temperature is also employed mainly because of the convenience of using melting ice 
rather than for any good scientific reason. Thus the data obtained from the Registry 
pointed to the serious consequences of inadequate donor heart retrieval and the 
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survey demonstrated the diversity of preservation methods in current clinical use and 
the lack of any transplant specific technique. 
1.3 PROSPECTS FOR IMPROVED DONOR HEART PRESERVATION 
It has already been pointed out above, that the donor supply currently represents the 
most significant factor limiting the availability of heart transplantation as a therapy. In 
addition it would seem that the supply is actually diminishing, due principally to 
changes in road safety measures, and is only likely to be minimally improved by 
changes in social attitudes to transplantation. It is therefore imperative that the best 
use is made of this scarce resource. 
An issue which has received little attention, is that of donor management. There is a 
sparse but significant literature, going back to the 1960's which links brain injury to 
myocardial dysfunction and even necrosis3941 and this subject is comprehensively 
covered in Chapter 2. Anyone involved in the practical business of organ retrieval will 
also attest to the practical difficulties in managing brain-dead donors, due to their 
haemodynamic and metabolic instability. Following close correspondence with 
previous colleagues working with animal models of brain death in Cape Town42, the 
author proposed a series of clinical studies aimed at improving peri-operative donor 
heart function, with the goal of improving the retrieval rate and the functional capacity 
of donor hearts prior to preservation. 
Taking into account the results of the survey, it seems clear that little of the large body 
of laboratory based research into improved methods of preservation, has become 
established in clinical transplant practice. This suggests that the models used do not 
reflect the clinical situation and/or that the effects of clinical brain death and 
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subsequent management overshadow any advantage which may potentially be 
offered by improved preservation techniques. The author therefore decided to 
address the problem from two distinct but complimentary approaches; that of 
improved clinical management and the establishment of improved laboratory models. 
1.4 AIMS 
The aims of this thesis are: 
a) To develop a method for characterising donor heart function in the donor and 
using this to guide donor management, with the object of producing hearts with 
optimal function, prior to excision and storage. 
b) To develop and refine laboratory models for developing and evaluating 
potentially improved cardiac preservation techniques. 
C) Identify potential solutions and techniques which might offer the prospect of 
improved preservation by critically appraising current clinical methodologies. 
d) To explore the potential for combining these clinical and laboratory methods 
with the object of realising an advance in the efficacy and safety of current 
clinical donor heart preservation methods. 
1.5 ORGANISATION OF THESIS 
Since the underlying premise behind this thesis is that a synthesis of laboratory and 
clinical studies holds out the best prospect of making a significant advance, it follows 
that the organisation of the work should be similarly organised. 
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In Part 1 the issues of brain death and donor management are discussed along with 
the results of the implementation of specific interventions in the management of 
clinical cardiac donors. The development of a rigorous donor management regime 
was shown to be capable of reducing the variance in haemodynamic function in 
donors, prior to excision, by up to 44%, whilst allowing the safe retrieval rate to be 
increased by up to 30%43 (Chapter 3). 
In Part 2a number of laboratory based models and studies are described, leading to 
a proposal for achieving a real advance in donor heart preservation by the 
combination of these two elements. A sensitive small animal working heart model 
was developed which was then adapted into a large animal and/or human working 
heart model to provide a pre-clinical screening device (Chapter 4). The small animal 
working heart model was also used to develop and characterise cardioplegic induction 
(Chapter 5). The model was further used to show that the combination of a method for 
enhanced oxygen delivery together with an improved preservation solution, holds out 
the prospect of more than doubling post storage function, compared with the current 
clinical technique (Chapter 6). Subsequently the model was also used to demonstrate 
it's potential as a screening method for a number of different techniques and solutions 
to provide improved donor heart functional preservation, during storage (Chapter 7). 
In the General Discussion, the author has attempted to bring together the knowledge 
gained from these two arenas of study and suggest some synergies and potentially 
fruitful avenues of further investigation. 
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15 
Since much of the work described in Part 1 of this thesis is of a clinical nature, the 
author was assisted in his endeavours by the clinical team. This team of surgeons, 
anaesthetists and technicians tended to change every six months or so, as members 
rotated through the service. The author was responsible for proposing, initiating and 
sustaining these studies, with the financial assistance of a number of British Heart 
Foundation Grants (of which the author was the grant holder), as detailed in the 
Acknowledgements. Statistical advice was also obtained, as acknowledged. The 
Survey was conducted under the auspices of the International Society and the two 
senior surgeons at Papworth, however the work was undertaken by the author. 
1.7 SUMMARY 
The stimulus for this thesis arose out of the frustrations experienced by the author, with 
the inadequacies of current methods for donor heart preservation, as experienced 
during more than 20 years of working in the field. The nature of the problems 
encountered would appear to be of two distinct kinds; those related to the management 
of brain-dead donors and the condition of donor hearts prior to preservation, and 
secondly those aspects which relate to preservation techniques, per se. The studies 
described in this thesis were therefore undertaken in both the clinical setting and in the 
laboratory. 
Central to this thesis, therefore, is the contention that the best prospect of improving 
the current impasse with the supply of human donor hearts, in numbers which come 
closer to satisfying demand, and of a quality which allows rapid rehabilitation of the 
recipient, is by the combination of appropriate laboratory models with improved clinical 
donor management techniques. It is the opinion of the author that the work described 
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in this thesis demonstrates the feasibility of achieving a significant improvement over 
the current status of heart preservation for transplantation. 
CH2 BRAIN DEATH AND DONOR MANAGEMENT 
CHAPTER 2 
BRAIN DEATH AND DONOR MANAGEMENT 
2.1 BACKGROUND 
17 
Patients with irreversible brain injury constitute the main source of donor organ 
material. There is, however, extensive clinical and experimental evidence to show 
that the process of brain death results in cardiac damage. The adverse effects of 
brain death on the heart were demonstrated as early as 1954'44 when subendocardial 
haemorrhages in the myocardium of patients dying from intracranial lesions was noted. 
More recent studies in both experimental animals45'46 and in clinical donors47'48 have 
suggested that brain death has major histopathological and functional effects. 
Consequently, without specific intervention, circulatory collapse will usually take place 
within 72 hours of brain death. 49 
Two major effects of brain death have been observed in experimental studies. The first 
is a series of major electrocardiographic, haemodynamic and histopathological 
changes which take place during and immediately following the agonal period46 39,50 -53 
The second consists of significant endocrine changes, which in turn result in major 
metabolic changes46' 39,50 53 
A sudden increase in intracranial pressure or the sudden onset of cerebral ischaemia 
leads to a series of major pathophysiological changes which have collectively been 
referred to as the autonomic storm39,51'54. The immediate consequence of brain death 
is a predominance of parasympathetic activity manifested by bradycardia progressing 
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to sinus standstill. This is then followed by a sinus tachycardia and multiple ectopic 
activity of multifocal origins as the sympathetic system dominates39.55,56This is usually 
followed by a further period of sinus tachycardia accompanied by marked ischaemic 
changes, probably induced by endogenous catecholamine release, coronary artery 
spasm and high systemic vascular resistance (SVR) induced by increased sympathetic 
activity. This ischaemia frequently results in some myocardial damage, especially in 
the subendocardium. The sequence then settles down to a bradycardia, often with 
dysrhythmias, associated with the loss of myocardial energy storesM. 
The haemodynamic changes during this process reflect the body's attempts to 
compensate for the intracranial changes taking place during coning" (Cushing's 
reflex). Significant and often massive increases in SVR, caused by the sympathetically 
induced peripheral vasoconstriction, brings about a redistribution of blood volume into 
the capacitance vessels, leading to a rapid accumulation within the great veins and 
right atrium. The right ventricle is usually able to adjust to this acute increase in preload 
whilst the left is not, often giving rise to complete standstill in pulmonary blood flow53 
This is probably the genesis of the so called neurogenic pulmonary oedema. 
In approximately 75% of experimental animals undergoing brain death, 
histopathological changes develop in the left ventricular wa1152. These consist of 
contraction bands, focal coagulative necrosis and myocytolysis. This myocardial 
damage may be reflected in electrocardiographic abnormalities, manifested as pseudo 
infarct patterns, the most serious of which are Q waves and J waves, where there is 
concomitant hypothermia56. Histopathological examination usually reveals widespread 
injury even in hearts which do not exhibit such ECG changes3s. 57 61 Animal studies 
have pointed toward an association between the mode of death and high energy 
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substrate levels57 and there is also evidence that the more acute and the greater the 
rise in intracranial pressure prior to brain death, the greater is the catecholamine 
release, and the more severe is the resulting impairment of myocardial function59 
In animal studies the thyroid hormones, plasma free triiodothyronine (T3) and thyroxine 
(T4), together with plasma cortisol and insulin, fall significantly within a few hours of the 
onset of brain death50. Antidiuretic hormone (ADH) also disappears from the plasma 
within a few hours. Whilst ADH is not crucial to the maintenance of vascular tone in 
normal patients, the absence of vasomotor impulses in brain death would seem to 
result in a dependency on ADH. These changes in circulating hormones are 
associated with a reduction in myocardial energy stores as well as a significant 
increase in myocardial lactate5'4. In addition, functional testing of these hearts 
demonstrates a deterioration in myocardial function as evidenced by significant 
reductions in cardiac output, stroke volume, and left ventricular developed pressure6o 
These findings of abnormal hormonal changes and anaerobic metabolism have been 
confirmed in human donorss' although the correlation with function has been less 
clear. 
In 1982, following acute graft failure in two recipients who had received hearts from 
apparently normal donors, a study of myocardial preservation during transplantation 
was initiated at Papworth Hospital in an effort to determine whether this failure had 
resulted from inadequate myocardial protection during storage or from some other 
cause. The primary determinants of myocardial function used in this study were; 
quantitative birefringence measurements (an indirect measurement of myocardial 
contractility) on biopsy specimens 62 häemodynamic function, and survival. Of 172 
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human donor hearts studied just prior to excision, biopsy assessment revealed 
significant myocardial injury in 73 (42%)63 of these hearts. 
Following their studies of experimental brain death, Novitzky and Cooper demonstrated 
that HRT was associated with a return to aerobic metabolism and myocardial 
functional improvement 47,50,52.55,64.67 However, HRT was subsequently investigated by 
a number of other investigators 66-71 with controversial findings. In all of these studies an 
understanding of the possible contribution of HRT to outcomes has been difficult to 
ascertain because of the lack of a convenient objective measure of cardiac function 
during the retrieval procedure. 
The effects of appropriate haemodynamic donor management have become clearer in 
recent years72"74. In a study of brain-dead humans a Japanese group were able to 
demonstrate a 20 fold increase in physiological survival with the use of arginine 
vasopressin and noradrenaline49, to maintain homeostasis. 
The use of HRT and more specific donor management techniques seemed, to the 
author, to be a potentially useful approach. The following series of studies was 
therefore devised to explore and characterise a method for improving the number and 
quality of retrieved donor hearts. 
2.2 THE PILOT STUDIES 
Patients and Methods 
All donors were brain dead, on ventilatory support and with no transplant specific 
contra-indications (age, viral disease, infection) in their recent medical histories. Any 
incidence of hypotension had been corrected with fluid replacement and/or inotropic 
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support. The age, sex, cause of death and duration of ventilatory support of the 
donors is shown in Table 2.1. 
TABLE 2.1 
Comparison of Donor Data in the Four Pilot Study Groups 
GROUP SEX 
MF 
AGE 
Years 
CAUSE 
OF DEATH 
THO 
ISCH 
TIME 
Mins 
VENTILATOR 
Hrs 
A n=12 93 30(17-39) 831 169 58 (16-130) 
B n=12 10 2 28(17-42) 831 170 79 (19-160) 
C n=6 24 29(16-43) 231 154 65 (24-170) 
D n=12 84 26(13-47) 543 178 103 (2-240) 
Group A= Control Group. Group B= Bolus T3 (2 µg/hr) 
Group C= Bolus T3 (4 gg/15 mins) Group D= Bolus + Infusion 
Causes of Death: 
T= Trauma 
O= Other (Respiratory arrest, overdose, viral meningitis, tumour or neurological 
operative death) 
H= Sub-arachnoid Haemorrhage 
ISCH TIME = Ischaemic Time 
Study I 
Study of the Effect of Hormonal Pre-treatment Therapy (as described by 
Novitzky and Cooper (2µg T3, Cortisol and Insulin) 
In this prospective randomised study, 24 donors were separated into two groups: 
Group A Twelve donors formed the untreated control group. 
Group B Twelve donors received hourly intravenous bolus infusions of 
tniodothyronine (2 µg T3) and cortisol (100 mg) with blood glucose 
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levels assessed half-hourly by the Dextrostix test and normalised with 
Insulin. 
Donors received 2-3 infusions according to the duration of multi-organ 
retrieval; 4 donors received 2 infusions, 8 donors received 3 infusions. 
Additionally, in accordance with standard protocol at the time, all donors received 1g 
Methylprednisolone (as a membrane stabiliser)74 in addition to the hormonal pre- 
treatment described above. 
Novitsky and Cooper reported on a sequential study in which 21 HRT donors were 
compared with 26 previous donors in whom all other management strategies remained 
unchanged. The HRT group received hourly bolus injections of 2 . ig T3,100 mg 
cortisol and 10 - 30 IU of insulin for between 3-8 hours prior to organ retrieval. There 
was a return to normal serum levels of T3, cortisol and insulin in the HRT group which 
also demonstrated a 53% increase in arterial pressure, a 35% decrease in central 
venous pressure and an 88% decrease in inotropic requirement. All 21 donor hearts 
were successfully transplanted 62. 
Study 2 
Study of the Effect of an Increased Dosage of T3 
In this non-randomised study the effects of increasing the T3 dosage, in an attempt to 
normalise serum levels, was explored. 
Group C Six consecutive donors received a bolus injection of 4 µg T3 every 15 
minutes ( up to a maximum of 20 µg) and blood glucose levels were 
normalised with insulin half-hourly. 
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Study 3 
Study of the effect of a bolus followed by an infusion of T3 
In this non-randomised study, the effects of T3 combining a loading dose of T3 followed 
by a continuous infusion, was studied. 
Group D Twelve consecutive donors received a bolus injection of 4 µg T3 
followed by a continuous infusion at 4 µg/hr and insulin was given as 
described in Group C. 
Assessment of the Effect of Hormonal Pre-treatment 
On arrival at the donor hospital, blood samples were obtained hourly from all donors 
for the assessment of free T3, plasma cortisol and plasma lactate. Inotropic support 
was given to maintain the mean arterial pressure above 60 mmHg with a central 
venous pressure of 6-10 mmHg. The requirement for inotropic support (Dopamine) 
of the donor heart both before and after transplantation was compared in all groups. 
Haemodynamic status of recipients was compared in Groups A and B by the 
following assessments: Cardiac index (Cl) 
Stroke Work Index (SWI) 
Pulmonary Vascular Resistance (PVR) 
Cardiac outputs were measured by thermodilution (mean of three measurements) 
and cardiac pressures by conventional fluid filled manometer lines connected to 
Medex transducers and Heilige pressure amplifiers. 
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Cl was defined as: 
Cardiac Output/Body Surface Area (l. min''. m 2). 
SW/ was defined as: 
Stroke Volume Index x (Mean Aortic - Mean Central Venous Pressure) x 
0.0136 g. m. m 2. 
PVR was defined as: 
(Mean Pulmonary Artery Pressure - Mean Pulmonary Capillary Wedge 
Pressure)/Cardiac Output x 79.9 (dynes. sec. cm"5). 
Biopsy assessments were made at intervals during, and one week and one month 
following, transplantation to compare the effect of pre-treatment on myocardial 
function in the treated and the control groups. 
Biopsy Assessment 
The technique of Quantitative Birefringence Measurements (QBM) is one which had 
been developed by one of my colleagues (Dr. Darracott) as a tool for monitoring 
intra-operative myocardial protection75. Assessment by QBM is based on the 
contractile response of muscle fibres in myocardial biopsies, to added ATP and 
calcium, and the effect this has on transmitted polarised light. This test was selected 
because clinically and experimentally it had been shown to correlate with 
physiological assessment at cardiac catheterization, to be capable of monitoring 
myocardial protection during open heart surgery76 and transplantation" and to 
provide a reliable index of postoperative myocardial function78. We had also been 
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monitoring donor hearts for some years with QBM, with the intention of investigating 
the potential for making the technique portable. 
Biopsy Sequence 
Biopsies were taken from the apex of the left ventricle with a Tru-cut biopsy needle 
at 5 time intervals during transplantation: 
1) prior to donor heart excision 
2) after cardioplegic arrest with St Thomas' cardioplegia solution and 
subsequent excision 
3) on arrival at the recipient hospital following storage and transport 
4) at the end of transplantation before removal of the aortic clamp 
5) before the recipient chest was closed (Reperfusion). 
Right ventricular endomyocardial biopsies were taken 1 week and 1 month following 
transplantation (biopsies 6 and 7), at the same time as biopsies were taken for 
rejection monitoring. 
All recipients received similar anti-rejection therapy comprising Cyclosporin A, 
Azathioprine and steroids. 
Preparation of Specimens 
The biopsies were immediately frozen in liquid nitrogen and stored for up to 4 weeks 
at -70°C. The specimens were then sectioned in a cryostat at -30°C. The 
birefringence of the muscle fibres in freshly cut sections was measured under a 
62 polarising microscope before and after the addition of ATP and calcium. 
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In normal muscle there is a great increase in birefringence following the addition of 
ATP and calcium due to increased orientation of the myosin micelles as the muscle 
fibres contract. In damaged or ischaemic muscle, this response is diminished. As in 
previous studies, donor hearts with a birefringence ratio of 1.15 or less were classed 
as Poor and those above 1.40 as Good 76,77 
Statistical Analysis 
Results are expressed as means and standard errors of the mean (SEM) or 
frequencies for categorical variables. Analyses of the changes in QBM, T3, cortisol, 
lactate and glucose levels, through time within the groups were done with paired 
Students' t-tests. For Study data concerning T3, cortisol, lactate, glucose levels and 
haemodynamic measurements were compared between the groups by unpaired 
Students' t-test. Data concerning pre- and postoperative inotropic support of the 
donor hearts was analysed by the McNemar test for paired data. Comparison of 
QBM results and T3 levels among the four groups at each time point was done by a 
One-Way Analysis of Variance. 
2.3 RESULTS 
Study I (The infusion of 2 µg T3i 100 mg cortisol and insulin) 
Groups A and B: 12 untreated and 12 pre-treated donors. 
Free T3 
Initially, 19 of the 24 donors in this study had T3 levels below the normal range (3.1 
to 8.0 pg/ml). At excision the T3 level had improved in only one pre-treated donor in 
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Group B (Table 2.2). Mean plasma T3 levels remained subnormal in both Group A 
and Group B (1.3 ± 0.5 and 2.6 ± 0.6 pg/ml) respectively, (Table 2.2). 
TABLE 2.2 
The Effects of the Various Thyroxine Regimes on Serum Levels of T3 
GROUPS T3 CORTISOL LACTATE GLUCOSE 
pg/ml nmol/I mmol/I mmol/I 
MEAN (SEM) MEAN (SEM) MEAN (SEM) MEAN (SEM) 
Group A 
Initial 1.5 (0.3) 661 (225) 2.0 (0.3) 8.5 (1.5) 
Final 1.3 (0.5) 1277 (151) 2.6 (0.5) 10.9 (2.2) 
Group B 
Initial 2.1 (0.3) 271 (61) 2.3 (0.5) 8.8 (1.0) 
Final 2.6 (0.6) 1057 (150) 2.6 (0.4) 7.8 (1.5) 
Normal Values 3.1-8.0 220 - 770 0.6-2.4 2.5-6.6 
Plasma Cortisol 
At the beginning of this study there was a wide variation in plasma cortisol in the 
donors (28-2000 nmol/l, normal range 220-770 nmol/I) probably due to the fact that 
some had been treated with steroids in the ICU. Unexpectedly, during the study 
period control Group A showed an increase in plasma cortisol levels similar to that of 
pre-treated Group B. Since all of the donors had routinely received 
Methylprednisolone it is likely that this unexpected increase was due to the effects of 
this glucocorticoid. It was therefore difficult to separately assess the effect of pre- 
treatment with cortisol. 
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Levels rose slightly in both groups, a mean of 2.0 ± 0.3 to 2.6 ± 0.5 mmol/I in Group 
A and 2.3 ± 0.5 to 2.6 ± 0.4 mmol/I in Group B. Since both groups had a degree of 
lactic acidosis, at the time of excision, this suggests a degree of anaerobic 
metabolism. 
Blood Glucose 
Control values were slightly elevated in both groups 8.4 ± 1.5 and 8.8 ± 1.0 mmol/I 
respectively. Levels rose to 10.9 ± 2.2 mmol/l in control Group A at excision and 
were slightly above normal in pre-treatment Group B; 7.8 ± 1.5 mmol/I. The 
difference in mean change between the two groups was not significant (p = 0.106). 
Requirement for Inotropic Support 
Before excision: 8 donors in each group were on dopamine support (Table 2.3). 
The mean dosage in control Group A increased from 5.9 ± 1.4 to 9.5 ± 3.1 
pg. kg-'. min' by completion of excision. In contrast, only 3 donors in pre-treatment 
Group B continued to need support at a mean dosage of 3.3 ± 0.7 1 µg. kg"'. min"'. 
These differences were significant with respect to both the numbers and the dosage 
(p<0.05). 
Following transplantation: The improvement seen in Group B was not maintained 
post transplant since 6/12 needed dopamine support (3.0 ± 0.5 µg. kg-'. min-'). 
However, the requirement in Group A had improved since only 2/12 required support 
(3 and 8 µg. kg-'. min-1 respectively). This difference was not significant. 
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GROUP A GROUP B GROUP C GROUP D 
Initial Numbers 8/12 8112 5/6 8/12 
Mean Dose (SEM) 5.9 (1.4) 3.9 (0.4) 5.0 (0) 6.0 (1.2) 
Range 1-14 2-5 2-12 
Explant Numbers 8/12 3/12 4/6 4/12 
Mean Dose (SEM) 9.5 (3.1) 3.3 (0.7)* 4.5 (1.0) 3.3 (0.8) 
Range 1-20 2-4 3-7 1-5 
Recipient Numbers 2/12 6/12 3/6 1/12 
Mean Dose (SEM) 4.0 (1.0) 3.0 (0.5) 4.0 (1.0) 6.0 (0) 
Range 3-5 2-4 2-5 
" p<U. Ub 
This table shows the differences in both the numbers of patients requiring Dopamine 
support at the beginning and the end of the retrieval, and the differences in Dopamine dose 
requirements (µg. kg-'. min"'). The last row shows the impact of this on their respective 
recipients 
Haemodynamic Measurements 
Following transplantation there were no significant differences in Cardiac Index (CI), 
Stroke Work Index (SWI) or Pulmonary Vascular Resistance (PVR) between the 
treated and untreated hearts. These parameters were chosen as they represent 
classical clinical indices of cardiac function and load. The PVR is particularly significant 
in cardiac transplantation because of the impact of increased loads on the post- 
ischaemic right ventricle. 
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GROUPS CI SWI PVR 
I. m 1. m 2 g. m. m"Z dynes. sec. cm"5 
Group A 3.38 22.49 206.4 
Range 2.0-4.6 17.7-38.0 136 - 272 
Group B 3.23 28.52 175.2 
Range 1.9-4.7 12.7-32.4 72 - 280 
Normal Values 3.6 30 64 
This table shows the post transplant function of the two groups of donor hearts. 
There were no statistical differences between the groups. 
Biopsy Assessment 
Figure 2A illustrates the typical trend observed in the earlier studies of deterioration 
throughout the peri-operative procedure, with some recovery during cardiac 
rewarming and at chest closure. However, it is clear that there were significant 
differences between the treatment groups: 
At excision: Myocardial function as assessed by QBM was similar in Groups A and 
B 1.31 ± 0.04 and 1.31 ± 0.06 respectively. 
After transport: Both groups deteriorated significantly during storage to 1.15 ± 0.04 
(p < 0.005) and 1.19 ± 0.05 (p<0.01) respectively. However, whilst there was some 
recovery in Group A by the final biopsy (mean value 1.25 ± 0.04), the deterioration in 
Group 8 continued to the end of implantation (deteriorated from 1.28 ± 0.05 at the 
onset of storage to 1.16 ± 0.03 at the end of implantation, p<0.002). The 
depressed myocardial function detected in these hearts by QBM at the end of 
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implantation was reflected by the fact that 6 needed inotropic support before 
weaning off cardiopulmonary bypass, compared with only 2 in Group A. However, 
Group B hearts had also shown significant improvement by the final biopsy (mean 
value 1.22 ± 0.04, p=0.05). Ischaemic times were similar in Groups A (169, range 
95 - 223 mins) and B (171, range 127 - 217 mins), p=0.413. 
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Figure 2A A histogram depicting the changes in QBM during the five peri-operative 
stages of heart transplantation, in the four groups; A- Controls, B- Bolus 2 
µg, C- Bolus 4 µg, D- Infusion. All hearts show a decrease in QBM with 
ischaemia. This is most evident in the high T3 dose group (C). A clear 
improvement is seen with the constant infusion group (D), which is sustained 
throughout the transplant procedure. 
Study 2 (The effect of an increased dosage of T3) 
Since the previous study had shown that a bolus of 2 µg/hr of T3 was insufficient to 
normalise plasma T3 levels in most donors, in contrast to the results reported by 
Novitzky et al50,60,61,79 the effect of increasing the dosage of T3 was tested. 
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(Group C) Intermittent boluses of 4 µg T3 administered every 15 minutes 
Initial free T3 levels were subnormal in all 6 donors in this group (mean value 1.65 t 
0.32 pg/ml). After the first bolus 3 donors had T3 levels within the normal range 
(mean 5.17 ± 1.2 pg/ml) and remained normal. A fourth donor had normal levels 
after the third bolus. The remaining two failed to normalise even after cumulative 
doses of 16 µg and 20 µg, the maximum doses given. QBM failed to reveal any 
beneficial effect of hormonal pre-treatment (mean value at excision 1.21 ± 0.07, 
Figure 2A). Only 4 hearts were biopsied after implantation but, as in Group B, these 
hearts deteriorated throughout the period of ischaemia (157 ± 19,120 - 200 mins) to 
a mean value of 1.10 ± 0.06. Three of these hearts needed inotropic support after 
implantation (Table 2.4). Biopsies at the end of transplantation were incomplete 
(inadequate specimens (2), not attempted (2)). 
Study 3 (Group D) A bolus injection of 4 µg T3 followed by an infusion of 
4µg /hr. 
Samples for the assessment of free T3 were obtained from only 9 of the 12 
consecutive donors studied. One had normal free T3 levels before treatment and a 
further 2 normalised following treatment. At the beginning of the study eight donors 
were receiving dopamine support, mean dose 6±1.2 µg. kg-'. min"' which was 
reduced to 4 who were receiving 3±0.8 µg. kg"'. min"' at excision. QBM indicated 
good myocardial function in these hearts at excision (mean value 1.39 ± 0.05) and 
deterioration during ischaemia (166 ± 12,91 - 219 mins) only just reached 
significance (mean value 1.23 ± 0.04, p=0.05). Only one heart needed inotropic 
support at the end of implantation and QBM in the final biopsies (mean 1.35 ± 0.06) 
were not significantly different from QBM at excision, (p = 0.92). 
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Biopsy Assessment of Myocardial Function Following Transplantation 
QBM of endomyocardial biopsies taken 1 week and 1 month after transplantation 
were compared with values in biopsies taken at transplantation to see whether there 
were any differences in the groups. These results are illustrated in Figure 2B, which 
includes mean values for the previous 172 donors, for comparison. 
In all groups QBM one week and one month after transplantation were not 
significantly different from the control biopsy (1) taken from the donor heart before 
excision. 
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Figure 2B 
Histogram showing the changes in QBM with time, following transplantation. The four 
groups, A- Group Controls, B- Bolus 2 µg, C- Bolus 4 µg, D- Infusion, are 
compared with the historical total group of hearts retrieved before the donor 
management regime was instituted. There were no significant differences between the 
group controls and the historical controls. The high dose T3 group (C) seemed to 
make a partial recovery within 1 week of transplantation. The peri-operative 
improvement seen in the Infusion group (D) is maintained up to at least 1 month post 
transplant, demonstrating that the benefit is sustained. 
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Early Mortality 
There were 5 early deaths in this group of 42 patients, none of which could be 
directly attributed to donor organ dysfunction. 
Group A I Acute Rejection 
Group B 1 Acute Rejection 
Group C I Acute Rejection 
Group D 1 Acute Rejection 
1 Haemorrhage 
QBM indicated that myocardial function in the ten surviving recipients of hearts in 
Group D remained better up to one month after transplantation than that of the other 
3 groups (mean value 1.39 ± 0.05 compared with 1.27 ± 0.05,1.27 ± 0.04 and 1.24 ± 
0.03 for groups A, B and C respectively). Moreover, QBM in these hearts achieved 
the values of normal myocardium which were defined in earlier studies76,77, as 
opposed to the preceding groups which never attained normal QBM. 
Conclusions 
This series of pilot studies indicated that the use of an infusion of T3 was beneficial. 
The use of a single bolus of T3 (Group B) was not associated with any discernible 
benefit, whilst the use of multiple bolus injections (Group C) may well have been 
harmful (decreased QBM post storage). However, it would seem that there is a clear 
benefit from the infusion regime employed in Group D. 
The experience gained during the conduct of these studies, also made it apparent 
that in order to manage these patients optimally, it was necessary to institute 
comprehensive haemodynamic monitoring. It was therefore decided to source 
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suitable portable haemodynamic monitoring equipment and to add a cardiac trained 
anaesthetist to the Donor Team, whose responsibility it would be to take over donor 
management during the retrieval procedure. It also became clear that whilst 
haemodynamic assessment seemed impractical at first, this could be readily 
accomplished, given the experience gained. This was further enhanced by the 
development of a simple functional guideline in collaboration with the author's 
colleague, Charles Potter (Bibliography F). 
2.4 THE MANAGEMENT REGIME 
In reviewing the above experience and the literature, at this stage, the donor 
management strategy outlined below was formulated. Having initiated this regime it 
was decided to review the data at intervals of approximately every 50 donor 
procedures. 
There are four main problem areas which need to be addressed in caring for the 
brain-dead donor: 
I Cardiovascular Dysfunction 
This may be due to hypotension secondary to volume depletion, loss of 
vasomotor tone, endocrine depletion, hypoxia, electrolyte imbalances or 
direct myocardial dysfunction. 
2 Respiratory Dysfunction 
Pneumonia, aspiration, pneumothoraces, pulmonary oedema and pulmonary 
collapse commonly occur in donors, and may all contribute to a deterioration 
in respiratory function with subsequent hypoxaemia. 
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Impaired thyroid hormone release has been discussed above and posterior 
pituitary dysfunction has been recognised to be common57 in brain dead 
donors. The absence of vasomotor impulses in brain death seem to result in 
a dependency on ADH, which has synergistic action with adrenaline49. Insulin 
deficiency is also common with resultant diabetes insipidus and subsequent 
large urinary volume and electrolyte lossesSO. There may also be an 
associated limitation of intracellular glucose as a substrate. 
4 Hypothermia 
Brain death produces a loss of hypothalamic temperature control, effectively 
rendering the donor poikilothermic. Active warming is required to maintain 
core temperatures above 35°C81. 
Strategy: 
A. Ventilate to normocarbia (4.5 - 5.5 kPa) using large tidal volumes (15 ml/kg) 
with either a low respiratory rate or deadspace. 
B. Use a minimal inspired oxygen consistent with adequate oxygen delivery 
(arterial saturation > 98%). 
C. Ensure clear airway using tracheal suction and check position of 
endotracheal tube. Check for bilateral air entry. 
D. Prepare following access IV lines: 
i) Left arterial (radial or brachial). 
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ii) Right internal jugular triple lumen. 
iii) Right internal jugular Swan-Ganz introducer. 
E. Use the above lines in the following manner: 
i) Swan Introducer - Blood products and colloids. 
ii) Small triple lumen line - ADH/Adrenaline infusion. 
iii) Middle triple lumen line - T3 and insulin infusions. 
iv) Large triple lumen line - Inotropes and dilators. 
Use warming coil for all administered fluids. 
F. Target the following status with reference to the Nomogram (Bibliography F): 
i) Cardiac Index > 2.6 I. min"1. m"2 
ii) SVR 800 - 1200 dynes. sec 
1. cm-5 
iii) LV Stroke Work Index > 20 g. m. m"2 
iv) At minimum preload (< 10 mmHg) 
G. Measure baseline haemodynamics and if in HRT category proceed as below: 
H. Use ADH/Adrenaline to increase afterload (max. 5 IU/hr) 
Use Sodium Nitroprusside to decrease afterload (max 4 µg. kg 1. min-1) 
Use Dopamine if all else fails to produce an adequate output. 
1. Use Dextrose/Saline/Potassium to replace urinary losses. 
Use colloid to increase preload. 
Use whole blood or packed cells to keep HCT 30 - 35%. 
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J. Measure blood glucose and infuse Insulin on the following basis: 
Blood Suaar Insulin Infusion 
> 15 mmols 5.5 IU/hr 
8- 15 mmols 3.5 IU/hr 
4-8 mmols 1.5 IU/hr 
<4 mmols GIK 1.5 ml. kg-'. hr' 
K. Triiodothyronine - Give bolus of 4 µg followed by an infusion of 3 µg/hr. 
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L. Vasopressin - Give 1 Unit followed by an infusion of 1 U/hr. Titrate to SVR up 
to a maximum of 5 U/hr. (Use Nomogram for guidance - Bibliography F). 
2.5 ASSESSMENT 
It was decided to divide all potential donors into three groups based on initial 
functional evaluation. Those which had normal function would be managed without 
any hormone supplements. Those donors showing marginal function would receive 
the HRT as outlined above. Those donors showing markedly impaired function would 
receive both HRT and be placed on supportive bypass (CPS), if they met the 
additional criteria for this group; age < 45 years, no sepsis and no obvious cardiac 
disease. The choice of haemodynamic limits for each classification was based on 
experience in the field of mechanically assisted circulation82. The details and results 
of this approach are presented in Chapter 3. 
2.6 DISCUSSION 
The most common cause of brain death in human cardiac donors is head trauma, 
with subsequent intracranial haemorrhage and diffuse swelling. An intracranial 
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vascular accident, such as haemorrhage or ischaemic stroke, is the next most 
common event. In both these cases, there is an increasing mass effect in the brain, 
compression of brain tissue and subsequent venous congestion, increasing turgor, 
transentorial herniation, brain stem compression and subsequent infarction. Clinical 
brain death is diagnosed, following the establishment of specific pre-conditions, and 
is now well established in the western world as being synonymous with the death of 
83 the individual in that the condition is irreversible 
The deleterious effects of catecholamines on the heart have been widely recognised 
for a long time as have the cardiotoxic effects of amines. Overproduction of 
endogenous catecholamines derived from adrenal pheochromocytomas84, tetanus 
toxin induced overstimulation85, raised intracranial pressure86, cocaine abuse87 and 
the effects of drowning88 may all produce myocyte necrosis. There is also evidence 
that coronary vasospasm is associated with catecholamine excess leading to acute 
myocardial ischaemia. 89 
It is therefore not surprising that the early descriptions of an association between 
neurological injury and myocardial damage would have implications for those 
engaged in heart transplantation. In 1954 Smith and Tomlinson44 noted 
subendocardial haemorrhage in the myocardium of patients dying from intracranial 
lesions. Burch and co-workers90 reported specific electrocardiographic abnormalities 
simulating myocardial ischaemia in patients following intracranial haemorrhage, 
traumatic brain injury, grand mal seizures, encephalitis, brain tumour and meningitis. 
They pointed out that, "It is reasonable to assume that a heart removed from a donor 
with extensive brain damage is abnormal and that such injury would be 
superimposed upon whatever structural and biochemical abnormalities occurred 
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during the terminal illness" e. g., as a result of hypoxia, electrolyte disorders, acid- 
base imbalance, administration of catecholamines etc72. Greenshoot and 
Reichenbach39, after studying the myocardium of patients dying from subarachnoid 
haemorrhage, reported histological evidence of myocardial injury in all cases. 
Experimentally they showed that stimulation of the midbrain reticular formation 
produced ECG changes and myocardial injury in cats, and as cells adjacent to 
intramyocardial nerves were worst damaged, they proposed that this necrosis was 
due to the release of catecholamines from the adrenergic nerve endings in the heart. 
Heggtveit in 197091 studied the myocardium of 100 patients dying from cerebral 
haemorrhage or head injury, having excluded those with evidence of significant 
thoracic injury, shock or coronary disease, and found that "one half of the hearts 
exhibited gross subendocardial haemorrhages". He warned that in the selection of 
donor hearts, the presence and severity of 'neurogenic heart lesions' should be 
assessed as far as possible "since such occult cardiac damage may conceivably 
contribute to the failure of some transplants and obscure or complicate the 
histological manifestation of rejection in others". In 1986 Novitzky et al45 reported 
that if the hearts of baboons were denervated prior to the induction of brain death, 
myocardial injury did not occur. They suggested that endogenous catecholamines 
released during the process of dying resulted in increased calcium uptake by the 
cells, thus inducing myocyte necrosis; they also postulated that such damage 
occurring in donor hearts might result in early failure after transplantation. 
Electrocardiographic assessment forms part of the screening of donors prior to organ 
donation. Yet in spite of satisfactory ECGs, 42% of the 172 donor hearts in the 
original study79 had significant myocardial injury as assessed by QBM in biopsies 
taken shortly before excision. This was not surprising since Samuels41 reviewing the 
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problems of neurogenic heart disease in 1987 stated that "electrocardiographic 
abnormalities improve, often dramatically so, with brain death", thus underlining the 
unreliable nature of ECG analysis in the donor. Blum58 induced angina-like ECG 
disturbances following hypothalamic stimulation in non-brain dead cats and squirrel 
monkeys and reported that myocardial necrotic and haemorrhagic pathology evolved 
with recurrence or prolonged duration of the stimulus. He observed that in both 
patients and experimental animals there were great individual and significant 
interspecies differences in response to the CNS stimulus. 
In the earlier study of myocardial preservation during transplantation it was not 
possible to determine whether the poor myocardial function detected by QBM in a 
proportion of the donor hearts before excision was mediated by cerebral damage or 
whether it resulted from inadequate supportive measures after brain death. More 
recent work by Flamang's group shows that the important feature of brain death is 
the rate of intracranial pressure rise, prior to brain death. The more acute, the 
greater the catecholamine release and the more severe is the resultant impairment 
of myocardial function59. Given the lack of evidence for this damage on post 
transplant biopsies, it seems likely that this damage can be resolved with time. It 
may be that the severely damaged hearts self select themselves before donation 
takes place, or particular management regimes may help to resolve the damage. 
All these studies have therefore suggested that the success of a transplant operation 
could be improved by some form of donor pre-treatment to prevent or reverse the 
harmful effects of brain death. Novitzky and Cooper observed significant reductions 
in the circulating levels of insulin, glucagon, thyroxine and cortisol in baboons and 
pigs following brain death and increased anaerobic metabolism42,55,64,85 Following 
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replenishment of these hormones T3 levels normalised and there was a return to 
aerobic metabolism and myocardial function improved. In 21 donors pre-treated and 
monitored for 3-8 hours before retrieval they recorded improved ECGs and a 
significant reduction in their need for inotropic support55. In a subsequent study of 
70 donors85 they reported that hormonal pre-treatment allowed them to salvage 
some donor hearts which would previously have been considered unsuitable and 
that the haemodynamic stability resulting from this therapy allowed them to maintain 
5 donors overnight and transplant the organs the following morning. There were no 
deaths from low output failure amongst recipients of these hearts. 
Various groups68-77 have verified the fact that, following brain death, serum T3 levels 
are often abnormal. Koller68 studied 82 patients treated in ICU for head injury and 
noted that their T3 levels were in the lower normal range. These levels remained 
stable in the 46 who survived, but fell to subnormal levels in the remainder by the 
time of organ retrieval. Howlett 92 found subnormal T3 levels in 81 % of donors 
studied at the time of organ donation, which was comparable to the 86% who had 
abnormal values in the studies reported above. Some groups have attempted to 
correlate donor T3 levels with the need for inotropic support of the heart before and 
after transplantation. Gifford67 found no differences in this respect when comparing 
hearts from donors with subnormal versus undetectable levels of T3. In contrast 
Wahlers64 compared hearts from donors with normal and subnormal T3 levels and 
found that the dosage and duration of inotropic support was significantly greater in 
the latter following transplantation. Montero" found abnormal T3 levels in 86% of 
donors and then did ultrastructural studies measuring the number of T3 receptors 
present in the myocardium. He found that patients with a low serum T3 had a low 
number of occupied T3 nuclear receptors and that the degree of myocardial damage 
CH2 BRAIN DEATH AND DONOR MANAGEMENT 
43 
correlated with the reduction in occupied receptors. None of these studies tested the 
effect of the replacement therapy advocated by Novitzky and colleagues. 
More recently it has become recognised that chemical hypothyroidism is relatively 
common in critically ill patients68 and that this can result in profound left ventricular 
dysfunction, particularly when in association with myocardial ischaemia70. This 
finding has been underlined by the observation that the combination of cerebral 
injury and subsequent donor organ preservation ischaemia has a harmful effect on 
donor kidneys93 and hearts61, particularly with respect to right heart function94. 
Although there was a reduction in the need for inotropic support in each of the three 
groups of donors following pre-treatment with T3 in the above pilot studies, the 
requirement for inotropic support before and after transplantation did not correlate 
with donor serum levels. However, this treatment regime, whilst following the dosage 
recommended by Novitsky et al, was only instituted for 1-3 hours, due to local 
constraints, compared with 3-8 hours accomplished by Novitsky's group. 
Macoviack71 in discussing whether thyroid hormone replacement was beneficial 
concluded that "there appears to be no rationale for giving human cardiac allograft 
donors any form of thyroid hormone replacement when careful fluid, electrolyte and 
glucose balance is maintained in combination with generally meticulous donor 
management". However the results of his own study of 22 donors compared poorly 
with that of Novitzky and Coopers' since after a period of "meticulous management" 
2 hearts became unsuitable for transplantation and 2 recipients died from cardiac 
failure (one due to recipient pulmonary hypertension). Novitzky's control study of 26 
carefully managed donors had yielded similar results to those of Macoviack, but the 
CH2 BRAIN DEATH AND DONOR MANAGEMENT 44 
superior clinical outcome of the next 70 hearts in which he incorporated hormonal 
pre-treatment into pre-transplant care indicated that it did confer an additional 
benefit. 
The reasoning behind switching to an infusion was both as a result of Novitsky's 
observation that an increased dose was sometimes required to obtain a therapeutic 
effect, and an attempt to stabilise serum levels. QBM indicated that donors receiving 
the infusion regime exhibited good myocardial function at excision and that these 
hearts remained better than those in the other groups throughout transplantation. 
This improved function was not a temporary response induced by any inotropic 
effect of T3, since QBM in endomyocardial biopsies taken one week and one month 
after transplantation remained good. The fact that only one of these hearts had 
needed support after implantation confirmed the biopsy assessment of good 
myocardial function in this group of hearts. 
2.7 CONCLUSION 
In reviewing the results of the above studies and the literature, there would seem to 
be a clear case for using T3 in those donors who demonstrate impaired function. The 
addition of ADH and insulin is more speculative but would seem to be justified in the 
light of the available evidence. 
The hypothesis was therefore that the use of a standardised donor management 
strategy, based on objective functional measurements, would allow a safe increase 
in the numbers of donor hearts retrieved and in the post transplant functional quality 
of these hearts. The realisation of this goal is described in the next chapter (Chapter 
3). 
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DONOR HEART RESUSCITATION STUDIES 
3.1 BACKGROUND 
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Transplant medicine has enjoyed a high profile image since its inception, but this has 
largely been focused on the drama of the surgery and the intellectual challenges 
imposed by the necessity of immunological manipulation. Donor management on the 
other hand, is probably the most neglected area of transplant medicine. During the pilot 
studies into possible methods of reversing the adverse metabolic effects of brain 
death, it became clear that an overall systematic approach was required and that 
central to this was objective patient monitoring. The literature suggests that failure to 
provide adequate physiological support to potential donors accounts for at least 25% of 
lost donor organs72. 
New road safety laws and the compulsory wearing of seat belts, have had, and 
continue to have, an impact on the number of solid organ donors95 (Figure 3A) in most 
western countries. In some countries, including the UK, there is an increasing under- 
resourcing of intensive care beds, which probably also has an impact on cadaveric 
organ referral 96. 
Early graft failure accounts for approximately 34% of acute deaths in heart transplant 
recipients19. In addition there is undoubtedly a further significant number of patients 
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who are compromised by poor graft function, related to inadequate donor management 
and/or preservation. 
CADAVERIC SOLID ORGAN DONORS 
U. K. 1989 - 1994 
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Figure 3A Changes in Causes of Death for Cadaveric organ donors in the UK, showing 
the downward trend in donors from traumatic deaths (mainly road traffic 
accidents), over the past 5 years. There has been a partial corresponding 
increase in donors from Intracranial haemorrhage, over the same time span, 
but an overall reduction in total numbers. 
Source: UKTSSA. 
Prompted by this increasing shortfall of donor organs, several centres have reported 
extensions to the "classical" donor criteria with respect to age97, ischaemic time" 
inotropic support99, adverse haemodynamics100, size mis-matching101, cause of 
021 05death104 and infection1. Whilst some of these experiments have been successful 
in individual cases, most have not, especially when more than one contraindication is 
present106 
89 90 91 92 93 94 
CH3 DONOR HEART RESUSCITATION STUDIES 47 
The aim of the work described in this chapter was to explore the hypothesis advanced 
in Chapter 2; that the quantity and quality of retrieved donor hearts could be 
substantially improved by adopting a strategy of donor management based on 
objective functional monitoring together with specific standardised interventions. 
3.2 MATERIALS AND METHODS 
Between October 1990 and October 1993,150 multi-organ donors were fully 
instrumented during the retrieval operation107. This involved transport to the donor 
hospital of specially sourced compact monitoring equipment and the institution of 
invasive arterial, internal jugular venous, and Swan-Ganz pulmonary artery 
catheterisation, as soon as the donor arrived in the operating room. Ventilation, fluid 
replacement and electrolytes were optimised and the first set of measurements 
performed. Further optimisation73 was carried out whilst the cardiac surgeon performed 
a median stemotomy and visually examined the thoracic organs. 
During this inspection a comprehensive set of measurements was performed. 
Classification of the donor was carried out according to the criteria in Table 3.1. Those 
donors judged to be Marginal were started on the HRT regime described in Chapter 2. 
Those donors who fell into the Cardio-pulmonary Support (CPS) category were 
electively placed on support bypass in addition to receiving HRT (Bibliography E). The 
basis for this classification is discussed in Chapter 2. 
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TABLE 3.1 
CLASSIFICATION OF POTENTIAL CARDIAC DONORS 
INTO THREE FUNCTIONAL GROUPS BASED ON 
HAEMODYNAMIC PARAMETERS 
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MEASUREMENT STANDARD HRT CPS 
CARDIAC INDEX (I. min" . m) > 2.6 < 2.5 <2.0 
CVP (mmHg) <10 >10 > 15 
PCWP (mmHg) <10 >10 > 15 
LV POWER (Wafts) 
or LV Stroke Work Index g. m. m"2 
> 0.6 
> 20 
< 0.6 
< 20 
< 0.4 
<15 
L! (µg. kg" . min) NIL > 1.0 > 8.0 
CVP = Central Venous Pressure 
PCWP = Pulmonary Capillary Wedge Pressure 
LV Power = Left Ventricular Static Power 
Inotropes = Dopamine or Dobutamine 
During the splanchnic dissection further sets of measurements were taken, and these 
were used in conjunction with the Functional Nomogram (Bibliography F) as a guide to 
management. Once the splanchnic dissection was completed, and with the cardiac 
surgeon back at the table, the final set of measurements was taken as a basis for 
donor organ acceptance (Table 3.2). 
TABLE 3.2 
TRANSPLANT ACCEPTANCE GUIDELINES 
Mean Arterial Pressure > 60 mmHg 
Central Venous Pressure < 12 mmHg 
Pulmonary Capillary Wedge Pressure < 12 mmHg 
Left Ventricular Stroke Work Index > 15 g. m. m" 
Inotropes <5 µg. kg . min 
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These minimum acceptance criteria are based on studies of survival of patients in 
cardiogenic shock108,109 and those used as entry criteria for patients requiring 
mechanical ventricular assist devices82. 
In order to provide some idea of major events which take place during a multiorgan 
retrieval operation, the following summary outlines the activities of the Thoracic and 
Abdominal Teams. The timing is related to a hypothetical operation starting at 8 am. 
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TABLE 3.3 
SUMMARY OF MAJOR EVENTS DURING MULTI-ORGAN RETRIEVAL 
TIME THORACIC TEAM ABDOMINAL TEAM 
0800h Team arrives-contacts base hospital 
0815h ICU assessment and transport of donor 
to theatre 
0840h Placement of lines/Swan Ganz Catheter 
0900h Sternotomy-Inspection of Organs Team arrives 
Optimisation-Baseline measurements 
0920h Bronchoscopy/Lavage Dissection starts 
1040h Heparinisation Dissection complete 
1050h Placement of Pulmonary artery Cannula 
Innominate and Tracheal dissection 
Prostacylin infusion starts 
1100h Placement of cardioplegia cannula 
1110h Cannulation of abdominal 
Aorta, Portal Vein, IVC 
1120h Division of SVC/Clamp IVC 
Clamp Asc. Aorta/run Cardioplegia Run Aortic and Portal 
Topical cold perfusions. Vent IVC 
1125h Run pulmonary infusion Complete dissection 
Topical cold of Abdominal organs 
1130h Complete dissection of H-L block 
1135h Move organs to back table 
1140h Inspect for congenital defects 
Staple trachea 
1145h Divide organs and package Move liver to back bench 
Coeliac perfusion 
1155h Organs boxed for transport Kidneys on back bench 
and perfused 
1200h Organs packaged 
50 
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Of the 150 multi-organ donors, there were 133 which yielded transplantable thoracic 
organs; 87 heart and 46 heart and lung blocks, together with splanchnic organs. 
Seventeen donors were not used; 9 on the grounds of dysfunction which was 
refractory to all of our resuscitative efforts, and 8 on the grounds of cardiac disease 
(Table 3.5). 
There were 52/150 donors which fell well outside (Table 3.4) our acceptance 
guidelines once comprehensive monitoring was in place and the data available (Table 
3.2). On initial inspection 33/52 of these were identified; 21 on the grounds of low mean 
arterial pressure (mean 47 mmHg), 10 on the grounds of a high CVP (mean 18 mmHg) 
and 2 requiring high inotropic support (25 µg. kg"'. min"'). Figure 3B illustrates the 
individual and mean values at the start and end of the procedure for these groups, 
compared with the mean values for the remaining donors. 
One donor was not used because of palpable coronary disease and one because of 
refractory dysfunction. 
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Figure 3B Graphical representations of the peri-operative changes in those parameters 
measured without the need of invasive monitoring and which formed the basis 
of classification into Suitable and Marginal groups. The horizontal line 
represents the minimal acceptable value for transplant acceptance, in each 
case. 
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With full monitoring there were a further 19/52 who fell well outside our acceptance 
guidelines; 13 on the grounds of high pulmonary capillary wedge pressure (mean 19.8 
mmHg), and 6 on the grounds of a low stroke work index (12.8 g. m. m-2). Figure 3C 
illustrates the individual and mean values at the start and end of the procedure for 
these groups, compared with the mean values for the remaining donors. In the 13 
patients with high PCWPs there was also a significant left/right imbalance; mean CVP 
10.2 mmHg with a mean PCWP of 19.8 mmHg, which would not have been detected 
without full monitoring. 
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Figure 3C Graphical representations of the peri-operative changes in those parameters 
measured with the use of invasive monitoring and which formed the basis of 
classification into Suitable and Marginal groups. The horizontal line 
represents the minimal acceptable value for transplant acceptance, in each 
case. 
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Six of these donor hearts were not used; 2 because of coronary disease, I because 
of left ventricular hypertrophy and 3 because of refractory dysfunction. 
Forty four of the 52 marginal donor organs were successfully transplanted. Of the 8 
hearts not transplanted; 4/8 were inotrope dependent and the remaining 4 had 
evidence of cardiac disease (coronary disease 3, left ventricular hypertrophy 1) despite 
acceptable function (Table 3.5). Table 3.4 gives the comprehensive data set for the 52 
initially Marginal donors. 
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TABLE 3.4 
Comprehensive data on the 52 initially marginal donors 
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Pt Num AoP CVP INOTROPES PCWP LVSWI NOT USED DEATHS 
mmHg mmHg mmHg . m'' 
1 62 8 0 10 12.8 CVA Day 16 
2 51 6 0 9 15.5 
3 53 5 0 9 18.7 
4 52 1 0 4 16.1 
5 53 1 5 4 36.7 
6 35 6 5 7 13.8 
7 39 6 0 7 13.9 
8 48 6 2.5 10 19.6 LVH 
9 60 15 5 17 6.1 Infection Day 16 
10 50 2 0 5 6.5 
11 42 5 14 3 14.9 
12 40 0 4 2 20.1 
13 44 0 12 7 16.2 
14 49 3 5 1 21.2 
15 54 12 2.5 8 18.9 
16 51 4 3.0 8 35.6 
17 53 9 5 11 18.9 
18 46 1 5.5 2 18.9 
19 48 0 0 3 33.6 
20 50 4 2.5 6 22.5 
21 26 1 15 7 7.9 
22 85 15 0 15 50.0 
23 60 16 8 19 22.1 Tamponade 3 mths 
24 81 17 6.5 20 39.4 
25 62 18 5 23 15.6 Infection 14 mths 
26 114 16 0 20 53.4 
27 60 26 5 11 19.0 
28 79 19 8 19 27.5 
29 62 20 6 20 28.9 
30 65 16 16 9 18.9 
31 112 18 4 24 49.2 
32 56 9 20 7 27.2 Inotrope dep 
33 60 1 30 11 67.1 
34 55 7 0 22 20.2 
35 140 11 0 17 50.3 
36 71 13 6 20 16.3 LVH 
37 80 13 0 19 34.8 
38 117 9 0 17 96.6 
39 86 10 0 18 24.3 
40 92 10 5 23 42.3 ARDS Day 1 
41 65 9 10 24 26.1 
42 76 11 12 17 26.3 Inotrope dep 
43 75 10 6 16 19.6 CAD 
44 66 14 7 22 38.4 CAD 
45 81 8 2.5 25 15.7 Inotrope dep 
46 84 6 0 18 21.5 
47 63 7 20 20 10.1 Arrythmia 12 days 
48 62 6 3 13 14.4 
49 65 10 2.5 11 11.0 
50 72 10 0 11 13.5 Inotrope dep 
51 78 3 2.5 6 13.3 
52 62 12 0 14 14.9 
Shading indicates basis for classification: LVH = Left Ventricular Hypertrophy CAD = Coronary Artery Disease 
CVA = Cardio Vascular Accident ARDS = Adult Respiratory 
Distress Syndrome 
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Figure 3D illustrates the changes in inotrope support for the entire group, together with 
each of the marginal groups. The horizontal lines provide reference points from the 
initially Suitable group. Overall, 63% of donors initially required inotropic support with a 
mean dose of 6.8 µg. kg-1. min-1, which reduced to 45% requiring a mean dose of 4.8 
gg. kg 1. min-', at the end of the retrieval procedure. (Dopamine and Dobutamine were 
the only inotropes used, and distinctions between the two were not made, for the 
purposes of this study. ) 
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Figure 3D 
Graphical representations of the peri-operative changes in the concommitant 
requirements for inotropes in the major classification groups. This illustrates that in all 
but the LVSWI group there was an improvement in function in the face of reduced 
inotropic drive. 
The horizontal lines provide reference points from the initially Suitable group. 
Categories refer to the primary grounds for classification as Unsuitable. 
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Of the 150 donors, 98 were within or close to our haemodynamic criteria on inspection. 
Nine were not transplanted; 4 on the grounds of significant coronary artery disease, 3 
became inotrope dependent, I developed right heart failure during the procedure and I 
was poisoned with an overdose of lignocaine. This means that only 5% overall, were 
refractory to the management regime. 
TABLE 3.5 
Donor Outcomes 
Inspection Monitoring Tx Not Tx 
Disease Function 
Total 
Meet Guidelines 117 98 89 45 9 
19 
Marginal 33 \52 44 44 8 
TOTALS 150 150 133 89 17 
Transplanted Organs : 87 Hearts 46 Heart/ Lung 
This table illustrates the evolution of the two groups during the retrieval procedure: - 
19 initially suitable donors moved into the marginal group when the results of 
invasive monitoring were available. There were 17 donor organs which were not 
transplanted, distributed as shown, some because of cardiac disease which 
became apparent at operation and some because of ongoing cardiac dysfunction. 
Overall there were 133 donors yielding transplantable hearts (and 76 lungs). The 
mean haemodynamic data is shown in Table 3.6. Initial values are those obtained 
following placement of a Swan Ganz catheter at the beginning of the procedure and 
Final values refer to those obtained following HRT therapy and immediately prior to 
retrieval. Values showing statistically significant changes are indicated with the 
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relevant p value (paired T test). The table illustrates very clearly that not only is there a 
general improvement in haemodynamics, but that there is also a significant reduction 
in standard deviation across the measured parameters and which reaches statistical 
significance in five of these (F test). 
TABLE 3.6 
DONORS YIELDING TRANSPLANTABLE HEARTS 
PARAMETER INITIAL (SD) FINAL (SD) 
Heart rate bpm 109 (19.2) 106 (18.2) 
AoP mmHg 74.8 (21.3) 74.8 (13.4)*** 
CVP mmHg 7.5 (4.7) 6.9 (4.0) 
PAP mmHg 18.2 (6.5) 15.4*** (5.0)* 
PCWP mmHg 9.9 (5.3) 8.9* (3.9)** 
Co I/min 6.9 (2.7) 6.0** (2.3) 
CI I. min"1. m"2 3.9 (1.6) 3.4** (1.3) 
SVR dynes. s. cm 5 881 (401) 1016** (410) 
PVR dynes. s. cm-5 104 (58.4) 92 (48.9) 
LVSWI g. m. m-2 31.7 (15.9) 29.4 (12.8)* 
RVSWI g. m. m-2 4.2 (2.8) 3.0** (2.1)*** 
LVPo Watts 1.0 (0.5) 0.9 (0.4) 
SI ml. bf 1. m-2 35.7 (12.8) 32.8 (2.4) 
Inotrope µg. kg'. min"1 6.8 4.8 (see text) 11 
*= p<0.01 ** = p<0.001 *** = p<0.0001 
AOP = Arterial pressure 
CVP = Central Venous Pressure 
PAP = Pulmonary Artery Pressure 
PCWP = Pulmonary Capillary Wedge Pressure 
CO = Cardiac Output 
Cl = Cardiac Index 
SVR = Systemic Vascular Resistance 
PVR = Pulmonary Vascular Resistance 
LVSWI = Left Ventricular Stroke Work Index 
RVSWI = Right Ventricular Stroke Work Index 
LVPo = Left Ventricular Static Power 
SI = Stroke Index. 
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Outcomes 
Initially Suitable Donors 
The overall survival in the group of 89 recipients who received organs from initially 
Suitable donors is shown below. 
TABLE 3.7 
SURVIVAL 
SUITABLE DONORS 
68/89 (76%) Alive and Well 13-48 months 
post transplant 
11/89 (12%) 30 Day Mortality 
3 Elevated PVR Heart 
3 Graft Failure I Heart, 2 Heart/Lung 
1 Pancreatitis Heart/Lung 
1 Infection Heart/Lung 
1 CVA Heart 
1 Arrythmia Heart 
1 Pulmonary Embolus Heart 
10/89 (11%) Late Deaths 
2 CVA 7& 25 months Heart & Heart/Lung 
1 Pancreatitis 3 months Heart 
4 Coronary Disease 5,7,9,16 months Heart 
I Malignancy 4 months Heart 
I Multi-organ failure 3 months Heart/Lung 
1 Infection 4 months Heart/Lung 
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Initially Marginal Donors 
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The overall survival in the group of 44 recipients who received hearts from Marginal 
donors is shown below. 
TABLE 3.8 
SURVIVAL 
MARGINAL DONORS 44/52 Transplanted 
37/44 (84%) Alive and Well 13-48 months 
post transplant 
5144 (11 %) 30 day mortality 
Arrythmia Heart 
Infection Heart 
Acute Respiratory Distress Heart 
Cerebrovascular Event Heart and Lung 
Infection Heart/Lung and Liver 
2/44 (5%) Late Deaths 
Tamponade 3 months Heart 
Infection 14 months Heart and Lung 
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As is evident from the above, only one of these deaths could be directly attributed to a 
cardiac cause. These results compare well with the International Registry 30 day 
mortality figures of 9.8% (hearts) and 21 % (heart and lung) and 1 year Registry 
mortality figures of 78% (hearts) and 60% (heart and lung)19. Actuarial survival curves 
show no difference between these two groups and the Registry survival curve, using 
data since 1985 (Figure 3E). 
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Figure 3E Survival curves show no differences, over the first two years post transplant, 
between the Suitable and Marginal groups and between these and the 
International Registry data covering the same time period. 
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Of the patients surviving to discharge there were 80 heart and 38 heart-lung recipients. 
Time to discharge was similar for the heart recipients irrespective of the donor group 
(25 days in the Suitable group compared with 23.6 days in the Marginal group). 
However, in the heart-lung recipients there was a significant difference (p = 0.03,2- 
tailed T test) between the two groups in which those recipients receiving hearts from 
initially marginal donors had a shorter hospital stay (27.7 days) compared with those 
receiving hearts from suitable donors (36.4 days). Their mean length of hospital stay is 
shown in Figure 3F. 
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Figure 3F There were no differences in hospital stay between the two donor groups in 
Heart Transplant recipients, however those Heart-Lung recipients who 
received donor organs from the Marginal (managed) donors had a shorter 
and less complicated hospital stay. The reason for this is unclear. 
Heart Heart-Lung 
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There were, however some differences between the Heart and the Heart-Lung donors 
as illustrated in Table 3.9. These were; that heart donors were on average 3.5 years 
older than heart-lung donors, the heart donors were significantly bigger (p<0.03), and 
that there were 60% males in the heart donor group compared with only 48% in the 
heart-lung group. However, it is unclear why a smaller female donor should apparently 
respond better to our donor management regime. 
TABLE 3.9 
DEMOGRAPHIC DIFFERENCES BETWEEN HEART AND HEART-LUNG DONORS 
HEARTS HEART & LUNGS 
All Donors 87 (65%) 46 (35%) 
Average Age (yrs) 34.1 30.6 
Body Surface Area (m) 1.83 1.74 
Male Donors 52 (60%) 22 (48%) 
Average Age (yrs) 33.6 28.2 
Body Surface Area (m 1.92 1.82 
Female Donors 35 (40%) 24 (52%) 
Average Age (yrs) 35.0 32.8 
Body Surface Area (m) 1.70 1.67 
3.4 DISCUSSION 
The donor management regime, described in this chapter, has been developed over 
the past four years, as detailed in Chapter 2. This was originally inspired by the Cape 
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Town group79, who investigated the hormonal consequences of brain death with 
subsequent influence by publications from Japan, with respect to the key role of 
vasopressin49 in maintaining somatic survival for more than a few days following brain 
death. The importance of changing the focus of management from that of minimising 
the effects of cerebral trauma prior to the patient becoming a donor to that of optimal 
cardiovascular support, has been recognised elsewhere' 0,111, but a crucial change in 
the regime described above has been the inclusion of a cardiac trained anaesthetist, 
who is skilled in the management of cardiovascular instability, as a member of the 
donor team, and the use of objective haemodynamic monitoring on which to base 
management and selection decisions has been central to the application of this 
strategy. The use of continuous infusions of HRT as opposed to bolus doses, has also 
been shown to be important. However, there are still a small number of donors (5% in 
this group) who are refractory to this management regime. The author has recently 
investigated the potential for physiologically resuscitating these donors using 
normothermic support bypass, with some success (Bibliography E)12. 
The finding that heart-lung recipients of HRT managed donors leave hospital 
significantly earlier than those donors receiving standard management, is surprising. 
Whilst there are some differences in demographics, as shown in Table 3.9, the causes 
of death and the ischaemic times were comparable between the groups. However, the 
heart-lung group of patients is much more susceptible to minor changes in medical 
management, in general, and may consequently be demonstrating some subtle 
functional benefit from HRT, as yet not identified. 
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Given the interactive nature of pre-load, after-load and inotrope therapy on cardiac 
function, it is difficult to find a single comprehensive descriptor of donor heart function. 
However, in this approach, marginal donors have been differentiated on the basis of 
wide deviation from the general acceptance criteria despite being classified according 
to the first major condition by which they fail (Table 3.4). This study did not seek to 
delineate the effects of HRT from optimal routine management. However, there is 
considerable evidence from the pilot studies to attest to the efficacy of HRT (Chapter 
2). 
What is clear, however, is that an overall comprehensive approach, which combines 
the elements of meticulous intensive care with the specific interventions needed to 
manage the brain dead, is required if the optimum outcome is to be achieved. This also 
means that donors managed in this standardised, objective manner form an ideal 
population base for evaluating potentially improved preservation techniques, as is 
evidenced by the influence of HRT on providing uniformity in haemodynamic function 
(Table 3.6). 
3.5 CONCLUSIONS 
The most important factor to emerge from this work has been the necessity to employ 
comprehensive monitoring which provides objective data on which to base optimal 
donor management and objective assessment of cardiac function. This reduces the 
risks of retrieving unsatisfactory organs and excluding potentially satisfactory organs. 
The specific interventions, outlined above, provide a mechanism for improving peri- 
operative cardiovascular function. This has a particular relevance to the quality of 
CH3 DONOR HEART RESUSCITATION STUDIES 66 
retrieved donor hearts, but has important implications for the viability of all 
transplantable organs. This study suggests that the numbers of satisfactory donor 
hearts may be increased by up to 30% and that the functional quality can be improved 
without compromising recipient outcome. It also means that this approach is essential 
if other potentially beneficial therapies are to be evaluated. 
The following chapters explore a strategy for identifying potentially beneficial 
techniques in the more controlled environment of the laboratory. The more promising 
of these could then be subjected to clinical trial, using the regime described above in a 
standardised and managed clinical population. 
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WORKING HEART MODELS 
4.1 BACKGROUND 
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It has been broadly acknowledged that clinical studies of potentially improved therapies 
are difficult to evaluate in areas of medicine, such as transplantation. Numbers of 
patients are relatively small and the study environment very difficult to control. The 
author believes that the approach described in Chapter 3 is helpful in minimising these 
problems. However, before taking the step between theory and clinical trial, some 
form of pre-clinical testing is imperative. The following chapters detail one such 
possible strategy. 
Methods for measuring myocardial functional integrity range from ultrastructural 
morphology13, enzymology14, biochemistry56, histochemistry39, and 
electrophysiology97 to some measure of mechanical function15. Whilst the former may 
be useful in determining causes of specific malfunction, ultimately the heart is a pump 
which must be capable of performing sufficient work to maintain the normal circulation. 
Some reproducible measure of cardiac contractile function must therefore rank high on 
the list of desirable outcome measures in the assessment of cardiac preservation. 
Cardiac contractile function can be assessed in many preparations within the 
laboratory, ranging from the whole heart within intact animals47, to the single 
myocyte16. The isolated perfused heart model was first published by Langendorff in 
1895 "7 and has the distinction of having been in laboratory use, without interruption, 
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since that time. The basic model makes use of retrograde perfusion only, in either a 
constant-pressure or constant-flow modality. The most commonly used mode is that of 
constant pressure, since this is probably the best approximation to normal 
physiology118. Using a constant head of pressure in the aorta, and hence the coronary 
arteries, enables coronary flow to become one of the outcome measures19. 
Mechanical methods of sustaining isolated organs go back to Frey and Gruber120 in 
1885, who developed the principle of thin film blood-gas exchange, which continued to 
be developed by early twentieth century physiologists, culminating with Alexis Carrel 
and Charles Lindbergh's121 pulsatile perfusion machine. Lindbergh had been 
stimulated to design a mechanical blood pump by his sister's, then untreatable, heart 
disease and he teamed up with the vascular surgeon Carrel at the Rockefeller Institute 
to produce a perfusion machine, eventually perfected in 1935. This device was capable 
of maintaining a functional guinea pig heart for 24 hours. This was the forerunner for 
the first clinical heart-lung machine developed by Gibbon and used successfully in 
1952122. 
Further development in the perfusion of isolated organs, beyond the interests of the 
pharmacologists and physiologists, languished until around 1960 when the burgeoning 
interest in transplantation really began. Given that, at this time, the concept of brain 
death had not been accepted, it was recognised early on that the availability of a 
suitable organ perfusion system may enable many more organs to be salvaged. The 
deteriorating toxic milieu represented by a donor dying from circulatory arrest 
secondary to haemorrhage, respiratory arrest, poisoning etc. meant that it was difficult 
to obtain viable organs. Physiologically the main benefits to be gained from perfusing 
an organ are the supply of oxygen and nutrients, and the removal of carbon dioxide 
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and toxic metabolites. However, from a functional evaluation standpoint, some method 
of measuring work potential was required. 
Contractile function is one of the most common end-points in studies of the effects of 
both pharmacological agents and pathophysiological processes in the heart. Three 
categories of cardiac functional assessment may be distinguished: 
" Ventricular Performance which denotes the pumping process of the heart and 
may be measured in terms of cardiac output or work. 
" Ventricular Function which relates ventricular performance to measures of 
preload, such as end-diastolic volume or end-diastolic pressure. 
" Myocardial contractility which refers to a fundamental capability of the muscle to 
perform work. 
A large number of different measurements have been used to provide approximate 
measures of contractility in intact hearts. Contractile force may be measured using an 
isotonic lever which is usually attached to the apex123. A better method for smaller 
hearts is to use a method which is not strictly isometric but rather auxitonic. The left 
ventricle is fixed rigidly to a strain gauge arch by two sutures and the right ventricle is 
connected to a force transducer. This arrangement allows the more circular 
distribution of the heart's force development to be registered124. Unfortunately, all 
show some degree of load dependence. The least load dependent techniques appear 
to be those derived from pressure-volume relationships 125, which give both qualitative 
and quantitative information on both systolic and diastolic function. However, these 
techniques are impractical in small mammalian hearts. Contractile function in small 
isolated hearts is most commonly assessed using an intra-ventricular balloon, 
26 but 
this method has a number of problems: - 
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1. The endocardium may be compromised by direct pressure. 
2. The balloon may produce a false compliance. 
3. The pattern of systolic shortening (against an effectively infinite afterload) is 
unphysiological. 
4. The balloon may interfere with the mitral valve apparatus. 
5. Balloons frequently produce rhythm disturbances. 
However, this method is relatively simple and provides reproducible results127. Despite 
being in use for some 100 years, there is considerable diversity and conflict within the 
literature concerning the measurement of function in small mammalian hearts. These 
problems appear to be due to a combination of both methodological and semantic 
difficulties. In a recent survey of 50 publications from four leading Journals, published 
between 1986 and 1990, which used contractile function as a primary end-point, no 
two authors reported using identical methodology of preparation, perfusion or 
assessment128. This situation plays a role in the often conflicting results which arise 
from such publications. 
Working heart preparations get around many of the limitations of the classical 
Langendorff model, described above. The first experiments using a working isolated 
perfused heart were described by Rigler in 1931 but most modern systems are based 
on that of Fallen et aI129. In this preparation the Langendorff mode can be converted to 
the working mode by diverting perfusate into the left atrium and allowing ejection to 
occur via the aorta, in the usual fashion. 
Working heart preparations, do get over many of the problems raised above but have a 
number of limitations of their own: - 
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1. It is difficult to separate afterload from coronary perfusion pressure as both are 
determined by the height of the afterload reservoir. 
2. Flow through the left atrial cannula can limit cardiac output since filling only 
occurs in diastole; the LV diastolic pressure must be overcome, and fluid inertia 
may be a problem at high rates. 
3. The aortic cannula has to offer minimal resistance if a stenotic obstruction is not 
to be produced. 
4. Ventricular volume is not known and cannot be controlled, making it difficult to 
isolate systolic from diastolic functional changes. This is most pronounced 
following ischaemia130 
Taking account of the above points, and using preload dependent Function Curves as 
the primary outcome measure, it is possible to have a reasonably sensitive model, with 
some measure of diastolic function. The technique does provide the overwhelming 
advantage of allowing large numbers of closely controlled experiments to be conducted 
quickly and relatively inexpensively, allowing control over the experimental procedure 
in the absence of the myriad of variables present in the clinical environment. In this 
way, the work reported in this chapter allowed a controlled study of key factors, the 
relevance of which will need to be determined in the clinical setting. The model 
described below was therefore developed as the primary discriminating measure for 
potentially improved preservation methods, in these experiments. Later on in these 
studies a large mammalian (and human) working heart system was developed as a 
potential pre-clinical model. 
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4.2 PERFUSION APPARATUS DESIGN CONSIDERATIONS 
The apparatus was designed for testing adult guinea-pig hearts and is based on an 
earlier design which had demonstrated good stability and reproducibility13'. A 
schematic of the system is illustrated below. 
ISOLATED WORKING HEART MODEL 
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Figure 4A Schematic of the Guinea Pig working heart model developed for the screening of 
improved preservation methods. Perfusate is re-circulated, after an initial 
washout period and the preload is variable. Both antegrade and retrograde 
perfusion modalities are possible with this model. Cardiac function is measured 
by measuring aortic flow, with an electromagnetic flow meter, coronary flow by 
timed volume collection and the measurement of aortic and intra-ventricular 
pressures. Using these measurements, Function Curves can be constructed. 
Essentially, the model consisted of a Constant Head Reservoir, which supplied both 
the aorta, during Langendorff perfusion, and the Preload (left atrial) Reservoir, during 
working mode. The height of the Preload Reservoir could be varied in relation to the 
left ventricle. Connection to the left atrium was via a3 mm (ID) cannula which allowed 
a free flow of > 300 ml/min with a pressure head of 7.4 mm Hg (more than double the 
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maximum cardiac output). During the working mode, perfusate flows from the left 
atrium and is ejected into the working circuit via an electromagnetic flowmeter and a 
non-compliant 50 ml capacitance vessel placed 30 cm above the heart, which had a 
volume of 6.5 ml of air added. This was connected to an Afterload Reservoir, usually 
placed 70 cm. above the heart. Ejected fluid was collected from the Afterload Reservoir 
into a graduated chamber as was the coronary effluent. 
Once the preparation was stabilised, the effluent perfusate was pumped back into a 
Main Reservoir, via a filter (Millipore SM 0.5 micron), where it was equilibrated with a 
95/5% oxygen/carbon dioxide mixture, with further gas exchange taking place in the 
Constant Head Reservoir. To prevent cooling the heart was mounted within a water- 
jacketed chamber (38°C) and all the reservoirs contained heat exchangers supplied 
from the same temperature control system. The components were all connected by 
minimum lengths of 6 mm(ID) silicone rubber tubing. The system was primed with 
some 1.2 litres of perfusate. Since approximately 300 ml was directed to waste at the 
start of each set of function determinations, and a further 200 ml was flushed out 
following cardioplegic induction, about 50% of the perfusate was replaced with fresh 
solution for each experiment. Cardioplegia was administered via a small reservoir 
connected to the proximal aortic outflow, by means of a stopcocked side-arm. This 
reservoir was placed 50 cm above the aortic root. 
Perfusate 
The perfusate used for all of the following experiments, was a modified Kreb's- 
Henseleitt solution with composition as shown below: 
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TABLE 4.1 
74 
COMPONENT g/I mmol/I 
NaCl 6.90 118.00 
KCI 0.35 4.70 
CaCI2 0.28 2.52 
MgSO4 0.14 1.64 
NaHCO3 2.09 24.88 
KH2PO4 0.16 1.18 
D-GLUCOSE 1.09 5.55 
Na-Pyruvate 0.22 2.00 
EDTA 0.185 0.185 
Sodium pyruvate was used as a substrate. 
EDTA was added as a chelating agent for heavy metal contaminants. 
The perfusate was used within 4 hours of having been made up. 
All reagents were high grade Analar. 
Cardioplegic Solutions 
All cardioplegic solutions used in these and the following experiments, were made up 
by the NHS Regional Pharmacy in Ipswich. Some of these required the addition of 
insulin and/or oxygen, before administration. Cooled solutions were kept in the same 
monitored refrigerator pror to administration. Stored hearts were kept in a monitored 
cold room. 
4.3 METHOD 
The heart was instrumented with a Gould electromagnetic flowmeter, placed just distal 
to the aortic cannula. The aortic pressure signal was obtained from the distal aortic 
line, and the left ventricular pressure signal from a 20 swg needle placed in the lumen 
of the left ventricle. Both pressures were recorded via saline filled polyethylene 
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manometer lines to Gaeltec pressure transducers matched to a Roche Monitoring 
system. The frequency response of the system was well within the range required by 
the measurements (flat to < 20Hz). The heart rate was obtained from the aortic 
pressure signal via an instantaneous ratemeter. Electrical signals were recorded on a 
multi-channel hot pen recorder (Devices M19) and these were checked against manual 
records, at each measurement point. The aortic flow was checked against a timed 
graduated reservoir and the coronary flow measured in the same fashion. 
Measurements 
1. Cardiac Output was calculated from the sum of the Aortic and Coronary flows, 
meaned over a1 minute interval. 
2. Stroke Volume was calculated from the following relationship: 
Mean Cardiac Output ml. min-l. beat-1 
Mean Heart Rate 
3. Left Ventricular Stroke Work was calculated from: 
(Stroke Volume x Mean Left Ventricular Pressure) x 0.0136 g. m. 130 
4. Initially dP/dt max was used but this was later abandoned in favour of the 
simpler and more sensitive measurement of Stroke Work132. The intra- 
ventricular pressure measurement was used in order to record mean left 
ventricular and end-diastolic pressures. 
5. Heart weight was measured before and after drying in an 84°C oven for >24 
hours. All flow derived parameters were standardised to dry heart weight. 
6 Control measurements were obtained for each animal for each experiment, in 
this series. Each heart therefore became its own control. 
CH4 WORKING HEART MODELS 
Preparation 
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Male Dunkin-Hartley guinea-pigs (450-600g) were anaesthetised with intra-peritoneal 
Pentobarbitone. Approximately 25 minutes after administration, and following 
assessment of corneal reflexes, the animals were ventilated with air via a 
tracheostomy using a volume cycled ventilator. A sternotomy was performed and the 
major thoracic vessels isolated. The animal was heparinised (3mg/kg). The heart and 
lung block was removed under inflow occlusion (both cavae were ligated) and rapidly 
immersed in ice cold saline. Keeping the organs covered in cold saline, the pulmonary 
veins were ligated at their left atrial junctures, the pulmonary artery transected at the 
bifurcation and the lungs removed. The aorta was cannulated and the heart mounted 
on the working heart apparatus. The process of excision to mounting on the apparatus 
was typically accomplished in under 5 minutes. 
Procedure 
Having mounted the heart on the apparatus, retrograde flow from the header reservoir 
was allowed to flow under reduced pressure (29.6 mmHg) for about two minutes, 
before allowing full pressure to be applied. It was usual for spontaneous defibrillation to 
occur within 3 minutes of re-perfusion. During this period the coronary effluent was 
discarded to waste. 
The heart was allowed to beat, under retrograde perfusion for 5 minutes, during which 
time the left atrial appendage was cannulated. To switch from retrograde Langendorff 
mode to working mode, the preload reservoir was adjusted to +3.7 mmHg, and the 
afterload limb of the circuit opened whilst still keeping the retrograde circuit open. After 
a few minutes the retrograde limb of the circuit was clamped and the preparation fully 
converted to the working mode. Following stabilisation for a further 5 minutes, function 
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curves were generated by incrementally adjusting the preload reservoir between 0 and 
18.5 mmHg in increments of 3.7 mmHg . Values were recorded when stable, usually 
within 2 minutes of each change. At the end of a function curve run, the preload was 
returned to the 3.7 mmHg position. The average duration of a function curve 
measurement sequence was approximately 20 minutes. If cardioplegic arrest was 
required, this was administered via the Cardioplegia Reservoir in the following 
sequence: 
1. The heart was returned to non-working mode by clamping the LA line. 
2. The cardioplegia stopcock was opened while simultaneously clamping the 
distal aortic line. 
3. The coronary effluent was directed to waste. 
4.4 PILOT STUDIES 
A series of pilot studies were carried out to prove the method in terms of default 
settings, reproducibility and stability (Figures 4B to 4E). Six guinea pig hearts were 
studied with respect to; heart rate, cardiac output, stroke volume and stroke work, over 
a sixty minute period in order to assess the stability and reproducibility of the model. 
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Figure 4B Heart rate remained relatively stable over the one hour evaluation 
period. Mean values for six hearts are shown above. 
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Figure 4C Six hearts were studied over a period of 60 minutes. Function studies were 
conducted every 15 minutes (Figs 4D and 4E), at which time the maximum 
heart rate and cardiac output was recorded. Mean cardiac output values are 
shown above. 
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Figure 4D Stroke volume changes in response to incremental changes in left atrial 
pressure were measured at 15 minute intervals, up to 1 hour, in six guinea pig 
hearts. In between function curves the hearts were left in working mode at a left 
atrial pressure of 3.7 mmHg (1 cm H2O preload = 0.74 mmHg). Only the 15 
minute and 60 minute curves are shown, for clarity. 
FUNCTION CURVE DATA TABLES 
MEAN STROKE VOLUME VS LEFT ATRIAL PRESSURE WITH TIME 
P ERFUSION TIME Minutes 
LAP mmHg (cm H2O) 0 15 30 45 60 
3.7 ( 5.0) 0.701 0.752 0.825 0.843 0.837 
SEM (0.112) (0.118) (0.093) (0.071) (0.085) 
7.4 (10.0) 0.925 0.949 0.966 0.977 0.981 
SEM (0.103) (0.112) (0.093) (0.072) (0.063) 
11.1 (15.0) 1.097 1.201 1.189 1.197 1.178 
SEM (0.108) (0.110) (0.082) (0.077) (0.059) 
14.8 (20.0) 1.300 1.350 1.365 1.355 1.342 
SEM (0.101) (0.067) (0.077) (0.062) (0.059) 
18.5 (25.0) 1.221 1.232 1.257 1.249 1.263 
SEM (0.119) (0.110) (0.091) (0.069) (0.085) 
0 2.5 5 7.5 10 12.5 15 17.5 20 22.5 25 
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Figure 4E Stroke work changes in response to incremental changes in left atrial pressure 
were measured at 15 minute intervals, up to 1 hour, in six guinea pig hearts. In 
between function curves the hearts were left in working mode at a left atrial 
pressure of 3.7 mmHg (1 cm H2O preload = 0.74 mmHg). Only the 15 minute 
and 60 minute curves have been shown, for clarity. 
MEAN STROKE WORK VS LEFT ATRIAL PRESSURE WITH TIME 
11 PERFUSION TIME Minutes 
LAP mmHg (cm H2O) 0 15 30 45 60 
3.7 ( 5.0) 0.097 0.104 0.099 0.098 0.094 
SEM (0.031) (0.028) (0.029) (0.029) (0.032) 
7.4 (10.0) 0.128 0.139 0.136 0.134 0.135 
SEM (0.033) (0.030) (0.031) (0.024) (0.027) 
11.1 (15.0) 0.164 0.179 0.181 0.179 0.176 
SEM (0.029) (0.032) (0.031) (0.027) (0.024) 
14.8 (20.0) 0.179 0.184 0.188 0.186 0.189 
SEM (0.038) (0.037) (0.039) (0.026) (0.025) 
18.5 (25.0) 0.168 
L 
0.164 0.169 0.174 0.171 
SEM ( 0.032) (0.037) (0.029) (0.028) (0.032) 
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Having evaluated the model with respect to reproducibility it was necessary to 
determine a storage time which would produce significant post storage depression of 
function without rendering the model unreliable. Twenty four hearts were divided into 4 
groups of six. Control function curves were obtained, as described above, following 
which the hearts were arrested with St Thomas' cardioplegia (15 ml/kg body weight) at 
4°C, and stored for periods of 1 to 4 hours in saline at 4°C. 
Following storage the hearts were remounted on the apparatus and function curves 
generated as before. On completion, the hearts were removed from the aortic cannula, 
blotted dry, weighed and placed in an 84°C oven for > 24 hours. 
The function curves illustrated below (Figures 4F and 4G) demonstrate the deleterious 
changes in function which occur with increasing ischaemic times, using one of the 
standard cardioplegic solutions for myocardial protection. 
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Figure 4F Twenty four guinea pig hearts were mounted on the working heart model and 
control function curves obtained for stroke volume at incremental changes in left 
atrial pressure. The hearts were arrested with St. Thomas' and stored at 4°C in 
saline. The hearts were randomly assigned to 4 groups for storage for 1-4 hours, 
after which post storage function curves were obtained. Values obtained at 3 and 4 
hours were statistically significantly different from the control values (p< 0.01). 
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Figure 4G This figure utilises the same data as that for Figure 4F but uses the end diastolic 
pressure generated at each LAP increment, to illustrate the change in diastolic 
compliance. 
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DATA TABLES RELATING TO 
THE WORKING HEART FUNCTION CURVE FIGURES 
MEAN STROKE WORK VS LEFT ATRIAL PRESSURE WITH STORAGE TIME 
STORAGE TIME HOURS 
LAP mmHg (cm H2O) 0 1 2 34 
3.7 ( 5.0) 0.097 0.089 0.084 0.060 0.043 
SEM (0.013) (0.011) (0.009) (0.009) (0.008) 
7.4 (10.0) 0.128 0.129 0.116 0.081 0.062 
SEM (0.013) (0.012) (0.011) (0.008) (0.006) 
11.1 (15.0) 0.164 0.165 0.154 0.108 0.081 
SEM (0.012) (0.013) (0.009) (0.009) (0.006) 
14.8 (20.0) 0.179 0.169 0.160 0.112 0.087 
SEM (0.016) (0.013) (0.012) (0.007) (0.007) 
18.5 (25.0) 0.168 0.151 0.144 0.104 0.079 
SEM (0.013) (0.016) (0.011) (0.006) (0.008) 
MEAN END DIASTOLIC PRESSURE VS LEFT ATRIAL PRESSURE WITH 
STORAGE TIME 
STORAGE TIME HOURS 
LAP mmHg (cm H2O) 0 1 2 34 
3.7 ( 5.0) 2.93 3.10 3.81 3.93 4.88 
SEM (0.00) (0.10) (0.80) (0.70) (1.60) 
7.4 (10.0) 5.15 5.25 6.31 7.44 8.98 
SEM (0.70) (0.80) (1.20) (1.10) (2.10) 
11.1 (15.0) 7.23 7.92 9.81 13.80 14.21 
SEM (1.20) (1.10) (1.20) (1.80) (2.20) 
14.8 (20.0) 9.65 10.24 11.65 15.93 16.92 
SEM (1.40) (1.60) (2.30) (1.20) (3.10) 
18.5 (25.0) 12.4 13.20 15.72 17.93 21.61 
SEM (2.80) (2.10) (3.10) (3.90) (4.30) 
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For statistical purposes the outcome measures of Cardiac Output, Stroke Volume and 
Stroke Work can be expressed as maxima or in terms of means across the preload 
range, as a measure of systolic function. As an indication of diastolic function the 
preload at which the maxima is achieved (LAPmax) can be used, or the left ventricular 
end-diastolic pressure can be plotted against the systolic parameter (Figure 4G). For 
most studies the pre-storage value has been used as the covariate. 
4.6 HUMAN WORKING HEART MODEL 
Whilst the model described above provides a valuable inexpensive and fast method 
for screening potentially improved preservation methodologies, it suffers from a 
number of deficiencies when relating to the clinical situation. These revolve around 
species differences and the use of a non-haem perfusate. The author therefore 
considered it prudent to develop a human working heart model to use for pre-clinical 
screening of the most promising techniques, identified using the small animal 
working heart. 
With this in mind, the author initially developed a derivative of the Westerhof three 
element Windkessel model133 attracted by the ability to tune the afterload to near 
physiological characteristics' 34 . However, after a 
few attempts to obtain measurable 
work from explanted human hearts mounted on this apparatus, it was abandoned 
because of the technical difficulties associated with supplying sufficient blood flow to 
the left atrium. The simplified system, described below, was developed as an 
alternative. 
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The system illustrated in Figure 4H was developed from an earlier device designed as 
a normothermic perfusion preservation system135. The circuit comprised a4 litre 
polycarbonate chamber with a flexible silicone rubber lid through which the vascular 
connections to the heart were made. Effluent perfusate flowed to a flexible reservoir 
from where it was pumped by a paediatric centrifugal pump back to the aorta via an 
infant membrane oxygenator, heat exchanger and 40 micron filter. There was a shunt 
line which allows the perfusate to be circulated without the heart in circuit. Connectors 
in the arterial line allowed for pressure, temperature and perfusate flow monitoring and 
for samples to be aspirated. Additional monitoring was provided for monitoring 
carbogen flow to the oxygenator and temperature control of the waterbath, which 
supplied the heat exchanger. 
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PRESSURE RECORDING 
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Figure 4H The above schematic illustrates the large (human) working heart apparatus 
constructed from paediatric perfusion equipment. The system is capable of 
supporting functioning hearts for more than 16 hours. 
A series of pilot studies with sheep and pig hearts were carried out in order to establish 
a suitable perfusate and operating protocol. The composition of the final perfusate is 
given in Table 4.2. Blood was obtained by exsanguination from the animals and from 
the cardiopulmonary bypass machine, with additional crossmatched concentrated red 
cells, for the human experiments. All blood products were washed in a cell washer 
before reconstitution with the remainder of the perfusate, and then divided into two 
equal volumes. One half was used for the control study while the second was 
refrigerated pending the post storage studies. 
""""""""""""""" PRESSURE 
""""""""""""""" TEMPERATURE 
...................... FLOW 
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TABLE 4.2 
PERFUSATE COMPOSITION 
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COMPONENT VOLUME ml 
Washed Autologous Red Cells 800 
Ringers' Solution 1000 
Mannitol 20% 40 
Glucose 50% 40 
Sodium Bicarbonate 8.4% 30 
Insulin 0.4 IU 
The perfusate was constituted to the above formula before initiating perfusion. Half of the 
solution was used for the control studies and the other half refrigerated for the post storage 
studies. Once the circuit had been primed and brought up to temperature, oxygenator gas 
flow was adjusted, potassium, calcium and sodium bicarbonate added, if required, to 
establish normal values. An insulin infusion of 1 IU/hr was maintained throughout the course 
of the perfusion. 
Hearts were arrested in situ with St Thomas cardioplegia and then transferred to the 
perfusion machine in cold saline. While the circuit was being primed and brought up to 
temperature a balloon was mounted onto a delrin ring which was secured in the mitral 
valve annulus by means of a purse string suture. Access to the balloon lumen was by a 
central luer port, connected to a manometer line and hence pressure monitoring 
equipment. Pacing wires were inserted in the left ventricle. A disc shaped aortic 
cannula was secured in the aortic root and the heart suspended from the flexible lid by 
means of this cannula and atrial sutures. 
The heart was then connected to the circuit and reperfusion commenced with an aortic 
pressure of 20 mmHg and temperature of 35°C for the first minute. The perfusion 
pressure was subsequently increased in 10 mmHg increments each minute up to 50 
CH4 WORKING HEART MODELS 88 
mmHg. The perfusion pressure was then stabilised at 50 mmHg for five minutes, the 
temperature increased to 37°C and ventricular pacing commenced at 60 bt/min. The 
pressure was increased to 60 mmHg for a further 5 minutes and the heart defibrillated 
if spontaneous defibrillation had not occurred. 
The pressure was next increased to 70 mmHg, pacing rate to 90 bt/min and 
maintained at these values for the duration of these subsequent experiments. 
Following optimisation of biochemistry and blood gas values, control function curves 
were obtained. 
Functional evaluation involved the generation of pressure/volume curves by measuring 
systolic and diastolic pressure changes in response to incremental balloon volume 
changes. Volume increments were continued until there was no further increase in 
developed pressure- The balloon volume was subsequently returned to zero and the 
heart arrested with the technique under investigation. 
During the storage period the perfusion system was emptied and flushed with Ringers 
solution. If the storage period was more than about two hours the system would be 
sterilised with Renalin (an oxidising solution used for renal dialysis filter sterilisation). 
Following storage, the heart was connected to the circuit in exactly the same manner, 
as described above, except that an initial flush volume of approximately 200 ml was 
discarded during the first phase of reperfusion. 
Post storage functional studies were conducted as per the control studies. 
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Using the above method it was possible to obtain measurable function following up to 
12 hours preservation of the diseased human hearts and 16 hours in the animal hearts. 
Results 
Overall 32 large hearts were studied. These comprised 15 sheep, 12 pig and 5 human 
hearts. These pilot studies were conducted with a view to establishing the model, using 
four different types of preservation solution, in order to explore the limits of the 
technique. Having established the model a series of experiments, comparing a variety 
of preservation techniques were set up. 
Figures 41-4K illustrate some representative results from each species in these studies. 
In the controls the maximum balloon volume was limited to that which produced an 
End Diastolic pressure of 25 mmHg, so as to avoid over distending the ventricle, prior 
to storage. 
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Figures 4/a and 4/b These figures shows the incremental balloon pressures, in systole 
(Figure 41a) and diastole (Figure 41b), in response to incrementally 
volume loading the intraventricular balloon. Studies were conducted 
prior to and following 8 hour storage of a sheep heart in Plegisol, in this 
instance. Both systolic and diastolic function can be seen to be 
depressed. 
See Chapter 5 
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Figures 4Ja and 4Jb These figures show comparative results with a pig heart subjected to 
identical experimental conditions as that shown in Figures 41a and 41b. 
Overall functional preservation was much better sustained in this 
species. 
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Figures 4Ka and 4Kb 
These figure shows the equivalent results with a human heart, 
explanted because of end stage dilated cardiomyopathy. Despite 
advanced disease it was possible to obtain reasonable work from this 
preparation. 
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For comparative purposes systolic function can be compared with respect to 
differences in the systolic pressure at a given preload or the developed pressure 
(systolic - diastolic) at a given preload. Diastolic function can be compared with respect 
to compliance differences (balloon volume/EDP). An illustration of this is given in Table 
4.3. Values are for balloon volumes of 20 ml in the sheep, 30 ml in pigs and 60 ml in 
humans. 
TABLE 4.3 
FUNCTIONAL EVALUATION 
PARAMETER DIFFERENCE BETWEEN PRE - POST STORAGE 
VALUE 
SHEEP PIG HUMAN 
SYSTOLIC PRESSURE 15 5 16 
mmHg 
DEVELOPED PRESSURE 33 7 42 
mmHg 
COMPLIANCE 0.33 0.75 1.18 
ml/mmHg 
4.7 DISCUSSION 
There are a number of laboratory based methods of evaluating myocardial viability and 
function, some of which could have a bearing on donor heart preservation. 
Organ bath studies on various heart fragments, such as papillary muscle, ventricular or 
atrial strips, or septal preparations can provide the facility for looking at large numbers 
and provide a means of investigating human tissue. In the case of the latter there is a 
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limitation in that the material will invariably come from diseased human hearts and in 
the former, there is little advantage over the intact whole heart. A general criticism is 
that the tissue is perifused rather than perfused136 
A number of studies into the mechanisms of anoxia and ischaemia have been 
undertaken using cultured preparations of either foetal hearts or cell monolayers. The 
use is somewhat limited with respect to surgical studies; foetal hearts differ from adults 
with respect to both electrophysiology and energy metabolism137. Cell monolayers are 
however useful for studies of toxicity138. 
Studies of isolated intact cells and subcellular organelles have, for many years, formed 
the basis for basic biochemical investigation into cellular and organ function. These 
preparations can be used for the study of ion flux and enzymology, but oxygen 
deprivation can only be studied by anoxia, rather than ischaemia. However, it is also 
worth bearing in mind that the interpretation of these studies has to take into account 
the interrelationships between various organelles, not represented by these models138. 
Any process of tissue damage or impairment of myocardial function must ultimately 
have it's origins in cellular chemical changes. Hence, biochemical markers can both 
identify the nature of an injury and potentially give an index of the degree of damage. 
This may take the form of unusual accumulations of ions in the extracellular, 
cytoplasmic or intravascular space. The most useful of these are those materials 
involved in the energy metabolism of the cell. Of particular prominence amongst these, 
are the high energy phosphates. There is considerable evidence in several species 
and models that ATP is a major factor in, and possibly a determinant of, tissue 
139 injury 
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However, the use of these substances as markers in the surgical setting is fraught with 
difficulties; compartmentalisation may give spurious results, the substances are very 
labile with rapid cellular turnover times, and low levels may be determined more by 
140 precursor availability rather than cellular integrity 
Myocardial enzyme leakage has long been used for the assessment of tissue injury, 
particular in relation to myocardial infarction. Cardiac specific isoenzymes such as 
creatine kinase MB have the potential for giving semi-quantitative information on the 
degree of tissue damage, but the assay is technically difficult and prone to error. 14' 
Morphological studies, principally using electronmicroscopy142, give useful information 
on ultrastructural integrity, pointers to possible calcium metabolism anomalies or other 
reasons for dysfunction and some index of oedema. However, the method is prone to 
the introduction of artefact and only provides a snapshot of conditions at the time of 
biopsy. Cytochemical methods, such as quantitative birefringence39 can be more 
useful in estimating in vitro contractile potential, but the method is only semi- 
quantitative and is operator dependent. 
Changes in the electrocardiogram and the transmembrane action potential have been 
used to monitor ischaemic damage and recovery in the setting of clinical myocardial 
infarction143. However, the application of these techniques to surgically induced 
ischaemia is more difficult due to the complexity of the situation, the associated ionic 
disturbances and the presence of hypothermia. 
A number of electronic techniques can be used to provide evidence of metabolic status 
and tissue integrity. These range from microelectrodes to measure tissue gas tensions 
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and pHl«, ion specific electrodes145, mass spectroscopy146 and nuclear magnetic 
resonance147. These latter techniques however, require large and expensive 
equipment, the resolution time of which may limit the measurement of dynamic 
processes. 
As outlined above, a wide variety of models exist for the study of myocardial protection. 
These are in vivo, ex vivo or in vitro preparations, using tissue from a wide variety of 
species, including man. Differences clearly exist between models and species. 
Extrapolation from one to the other, and particularly to the clinical situation, requires 
caution. The selection of a particular model necessitates a compromise between 
suitability of the model and a host of practical considerations. It is the opinion of the 
author that whilst all of the above techniques may add complimentary information, 
particularly with respect to mechanisms, ultimately an intact working heart is required 
to screen cardiac preservation techniques. 
The working small heart model described in this chapter performed with similar 
characteristics to other models reported in the literature, with respect to absolute 
values of functional parameters and to stability131'148149 This model, however, has the 
additional feature of being designed to produce preload dependent function curves 
The small animal working heart model, however, does suffer from a number of 
deficiencies in terms of representing the conditions pertaining to a clinical donor heart; 
the animals used were not brain dead and no attempt was made to simulate the 
physiological effects of this50, as described in Chapter 3. The model employs functional 
measurement of the left ventricle only and assumes that the interventions under 
investigation will have equivalent effects on right sided function9'. A blood based 
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perfusate is not used, thus eliminating any cell mediated reperfusion phenomena which 
might have an effect on subsequent function150, and last but not least, the guinea pig 
may not adequately represent man in important aspects related to myocardial 
preservation. 
The human working heart model was therefore developed as a method for pre-clinical 
screening for promising solutions and techniques identified with the small animal 
working heart. The primary intention was to have a model in which human hearts could 
be functionally evaluated. The only human hearts used in these preliminary pilot 
experiments were those diseased hearts explanted from transplant recipients. These 
hearts were obviously compromised by the underlying disease for which the patient 
was being transplanted, but conversely, had not been affected by the metabolic 
consequences of brain death. An additional constraint of the present model is the 
necessity of using a recognised clinical cardioplegic solution (St Thomas') for the initial 
in situ cardioplegic arrest. 
The large animal hearts were used as a means of developing the model. Ultimately it is 
envisaged that the model might be used with donor hearts from multi-organ donors 
from whom hearts are refused for clinical use, on the grounds of age; currently over the 
age of 60 years. This would provide a method for evaluating techniques and solutions 
on human hearts from brain dead donors. 
An interest in organ perfusion techniques was developed very early on by the scientific 
transplant community. In vivo normothermic perfusion, not surprisingly, provides ideal 
conditions for preserving organs and Angell and Shumway151 demonstrated this 
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technique of an intermediate host in a dog model for 3 days in 1966. However, it is 
difficult to see how this may be translated into a clinically relevant technique. 
In vitro perfusion is a more realistic approach, and beginning with Langendorff117, has a 
history of over 90 years. However, despite an enormous experience with variants of 
this model there remain many unresolved problems, as is evident from the lack of 
widespread clinical application. 
Normothermic perfusion is the most physiological, and by the same count, the most 
difficult technique to achieve for a clinically useful time. Using blood as a perfusate the 
system must be closed in order to keep infection at bay, the supply of substrate and 
the removal of toxic metabolites need to be addressed. Normothermic perfusion is, 
however, imperative for functional testing. 
A variety of attempts have been made to effect a compromise in this situation; 
Robicsek152(1968) has used a simple gravity system to maintain blood perfused hearts 
for up to 12 hours. Tam153 extended this to 24 hours in 1971, by dialysing intermittently 
with cross circulation from another animal. Pitzele and Dobell' A also reached 24 hours 
using a membrane oxygenator and frequent changes of blood. It is clear that whilst this 
may be a method for physiologically resuscitating and evaluating a heart, it is not a 
realistic method for preservation. 
Perfusion preservation has been used experimentally for many years. Hypothermic (2 
- 10°C) perfusion of the in vitro organ benefits from the reduction in metabolic rate at 
lower temperatures and enables a simplified perfusion system to be employed. Flow 
requirements are reduced, damage to the perfusate minimised and bacterial growth is 
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inhibited. The use of blood as a perfusate is fraught with problems at low temperatures 
and there is little benefit in doing so since crystalloid solutions are capable of delivering 
sufficient oxygen at these low temperatures. 
In 1968 Belzer 155, after many problems with plasma as a hypothermic perfusate for the 
kidney, accidentally found that if the cryoprecipitate which resulted from thawing frozen 
plasma, was filtered out, the resultant perfusate was capable of maintaining kidneys 
viable for up to 3 days on a perfusion preservation machine. In 1969 Feemster and 
Lillehei156, used the same technique, with the addition of hyperbaria to 3-4 
atmospheres, to successfully preserve dog hearts for up to 24 hours. Subsequently the 
technique was used to preserve the dog pancreas for 24 hours and the liver for 48 
hours159. Belzer's early success in perfusion preservation underpinned what might be 
called the physiological approach to organ preservation. 
However, Proctor and Parker158, called into question this physiological approach, 
arguing that for organs which have evolved to function at a very different and closely 
controlled temperature, normal physiology was irrelevant. Instead they adopted an 
empirical approach and developed a simple low-flow (pressure controlled) system 
employing a base Kreb's solution with added glucose and dextran. Copeland and 
Stinson159 were later able to use this technique to obtain long term survivors after 48 
hour preservation followed by orthotopic transplantation in dogs. 
The technique was later adopted by Wicomb160, in Cape Town using a much more 
complicated perfusate. After a series of successful 24 hour storage experiments in a 
baboon model, the system was used clinically in 1981, but with poor results. More 
CH4 WORKING HEART MODELS 100 
recently Wicomb 161 has turned his attention to a technique of micro perfusion, for 
extended organ preservation. 
It is the opinion of the author that none of these techniques will find a place in the 
clinical arena unless a very simple and reliable system can be devised. This is 
exemplified by experience from renal transplantation where perfusion preservation 
systems have largely fallen into disuse, despite the fact that superior results have been 
obtained with these systems162. 
The message emerging from this would seem to be that normothermic in vitro 
perfusion provides the promise of providing the basis for a method of functional 
evaluation with the possibility of metabolic and physiological resuscitation. Perfusion 
preservation, on the other hand, is probably the most fruitful avenue to explore in an 
effort to obtain safe extended preservation times. However, for this to enter the clinical 
arena the device would have to provide simplicity and safety. 
4.8 CONCLUSIONS 
Having taken into account the various limitations of small working heart models, a 
system was devised and tested which seems to provide a simple yet effective 
mechanism for screening hearts subjected to global ischaemia. The model provides a 
stable preparation for at least 40 minutes, which is approximately twice the time 
required for the measurements described above. The ischaemic storage studies 
suggest that a storage time of 3 hours should provide adequate discrimination between 
methods. 
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Whilst this model has a number of limitations when compared to the clinical situation, 
the circumstances surrounding the conduct of multi-organ donor retrieval operations, 
as outlined in earlier chapters of this thesis, make it almost impossible to carry out well 
controlled targeted research. It is for this reason that the integrated approach adopted 
in these studies, is advanced as a mechanism for making progress in this difficult area. 
This small animal working heart model makes a significant contribution as a simple, 
fast and cost effective method of screening potentially useful new solutions and 
techniques163. Studies, using this model, are described in chapters 5,6, and 7. 
The feasibility of using a human working heart model for functional studies has been 
demonstrated. This could provide a pre-clinical validation model using hearts from 
multi-organ donors whose hearts are not deemed suitable for clinical transplantation, 
mainly on the grounds of age. This would provide hearts from brain dead individuals of 
the same species, thus removing many of the confounding elements present in current 
donor preservation models. In this scenario, it would be possible to obtain pre-excision 
functional data (Chapter 3 and Bibliography F) and to use the preservation technique 
under investigation. The author believes that the combination of this approach together 
with the improved donor management regime detailed in Chapter 3, provide the means 
for making a significant impact on what has been a most refractory problem, over the 
past 25 years. 
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The normothermic human heart tolerates complete ischaemia for less than 30 minutes, 
after which profound functional and morphological injury becomes evident'M165. The 
early pioneers of cardiac surgery recognised that oxygen consumption declined as 
temperature fell'66 and this opened the way for the first generation of cardio-pulmonary 
bypass machines, which could not sustain nomiothermic oxygen delivery' 67, but could 
manage the reduced flow and oxygen transfer required under hypothermia. The 
technique was taken to it's ultimate in the use of hypothermic circulatory arrest, to 
facilitate surgery for complex congenital defects in children168. 
Selective myocardial hypothermia has been shown to extend the period of safe anoxic 
arrest, in the setting of corrective cardiac surgery, by more than one hour, by several 
authors 165,169 Several studies have demonstrated a two to four-fold decrease in 
myocardial oxygen consumption in the non-arrested heart, as the temperature falls 
from 37°C to 15°C10'12. However, since 80% of myocardial oxygen consumption 
arises from mechanical work173, chemical arrest of the heart contributes to a very 
substantial further decrease in oxygen consumption, of the order of a further four-fold 
reduction 174,175, and the two are additive (Figure 5A). Once coronary blood flow has 
been interrupted, therefore, it is important that cardioplegic induction be achieved 
rapidly, with the minimum of energy, and hence substrate consumption, and without 
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physical or chemical injury. Following reperfusion, there should be a resumption of 
normal electromechanical function. 
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CARDIOPLEGIA vs EMPTY BEATING HEART 
Figure 5A The curves illustrated above have been produced for data abstracted from the 
quoted references. Differences between the authors are mostly related to 
slight differences in experimental conditions but, overall it can be determined 
that the Q10 is approximately 2 and that the addition of chemical cardioplegia 
decreases the oxygen consumption by a factor of 6, at higher temperatures 
and by a factor of 2 at temperatures in the 4°C. range. 
The concept of elective cardiac arrest was developed by Melrose and Bentall176 in 
London in 1955. This was to overcome the problem during cardiac surgery, posed by a 
moving heart and an operative field obscured by coronary venous blood which was the 
consequence of keeping the coronary arteries perfused. After occluding the aorta they 
rapidly injected a 2.5% solution of potassium citrate in blood, into the aortic root to 
arrest the heart. They had previously shown, in a variety of animal models, that once 
05 10 15 17 18 20 22 26 28 30 32 35 37 
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the aortic clamp was released potassium was washed out of the coronary system and 
the flaccid asystolic heart rapidly resumed normal electro-mechanical action. 
The technique was taken up by numerous centres on both sides of the Atlantic177'19. 
At the end of the 60's, however, doubts began to be expressed about the safety of this 
procedure. A number of investigators reported associated experimental and clinical 
evidence of myocardial injury culminating in the findings reported from Bethesda'8° in 
which the hearts from 19 patients who had died following cardiac surgery showed 
marked myocardial necrosis in those who had received potassium citrate cardioplegia. 
The damage was subsequently shown to be due to the high potassium concentration 
in the Melrose solution (>250 mmols). The result was that cardioplegia effectively 
disappeared from the surgical literature for the subsequent 15 years. 
The return of elective cardiac arrest, or cardioplegia as it had now been christened, 
was again the result of a European initiative. The concept had been kept alive in 
Germany mainly by Bretschneider18' who published the principal of keeping the heart 
arrested with sodium-poor, calcium-free, procaine containing solutions. The rationale 
behind this formulation was that a sodium concentration equal to the intracellular 
sodium content would prevent the excitation potential, the lack of calcium ions would 
prevent activation of the contractile system, and that procaine would stabilise the cell 
membrane potential. Osmolarity was maintained with mannitol. Subsequently histidine 
was added as a buffer, because of it's superior buffering capacity at low temperatures. 
Sondergaard182 reported the first series of surgical cases using the Bretschneider 
approach, in 1975. A number of other Europeans adopted a similar approach as 
exemplified by Kirsch183 who worked on the principal that an ideal solution should 
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primarily have Adenosine Triphospate (ATP) sparing characteristics and should 
therefore not contain calcium, potassium or sodium. Local anaesthetics and 
magnesium, being membrane stabilising agents, were believed to slow the decay of 
organic phosphate in the cell. The Kirsch magnesium-aspartate-procaine bolus solution 
came into regular use in several German centres during the early 70's. 
Stimulated by this work, Hearse'84, working in London, tested the individual 
components of the Bretschneider and Kirsch solutions on an isolated working rat heart 
model. However, Hearse was unhappy with the unphysiological nature of these 
solutions and he advocated the principal that cardioplegic solutions should retain, as 
closely as possible, extracellular rather that intracellular concentrations of ions, with 
only those additions which could individually be shown to be effective, in their optimal 
concentrations. He proposed the St. Thomas' solution, based on a Ringers' base, to 
which was added 16 mmols potassium chloride, to effect rapid arrest, 16 mmols of 
magnesium chloride, which had, in this concentration been shown to have a marked 
additive effect and 1 mmol of procaine hydrochloride. This solution was introduced into 
clinical open heart surgery in 1975. More recently a variant of this solution, St. 
Thomas' 2, with half the calcium and a lower potassium concentration, was introduced 
under the commercial name of Plegisol. 185 
Several workers in the USA began to report on a variety of potassium and magnesium 
based cardioplegic solutions' 86'187 such that by the end of 1978, coronary perfusion, as 
a means of preserving the myocardium during surgery, had virtually disappeared from 
clinical practice. The discussion was then not whether, but what sort of cardioplegia 
should be used. There were three geographical groups in this respect; the continent of 
Europe, particularly east of the Rhine, used sodium-poor, calcium-free, magnesium 
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and procaine solutions, the UK and much of western Europe used the Ringer's based 
extracellular solutions and the USA used primarily potassium-enriched solutions 
containing little or no magnesium and no local anaesthetic. 
With the advent of cardiac transplantation in the early 70's it was recognised that the 
heart was only tolerant to relatively short global ischaemic times. This meant that the 
early operations were all carried out with the donor and recipients in adjoining 
operating theatres13. However, in the late 70's the cardioplegic solutions being used for 
routine open heart surgery began to be used for preserving donor hearts, so as to 
avoid the logistical, ethical and emotional problems of transporting brain dead donors 
to the recipient hospital188. The fact that conditions prevailing during ischaemia for 
routine heart surgery and those during donor heart preservation and transport are very 
different, was ignored in the face of the security of adopting practices which seemed to 
work satisfactorily. With the rapid expansion of heart transplant centres there was a 
tendency not to challenge the existing techniques but merely to adopt the entire 
package. The group in Cape Town46 was one of the few who attempted to develop 
transplant specific solutions and techniques, borne more out of necessity, due to their 
relative geographical isolation, than intellectual curiosity. 
In this chapter, the effects of hypothermia alone are compared with hypothermia plus 
one of four different cardioplegic solutions, on the efficacy of cardioplegic induction for 
heart transplantation. The four solutions; Bretschneider HTP, St. Thomas' No. 1, 
Plegisol and Wicomb were chosen as representatives of the solutions discussed 
above. Wicomb solution represents the only solution developed experimentally for 
donor heart preservation and is essentially a glucose/insulin solution with Verapamil as 
a calcium antagonist. 
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The compositions of these solutions are given below in Table 5.1. 
TABLE 5.1 
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CARDIOPLEGIC SOLUTIONS 
Solution Bretschneider Plegisol Wicomb St Thomas 
HTP No. 1. 
(mmol/I) 
Sodium Chloride 15 110 102 144 
Potassium Chloride 8 16 10 20 
Magnesium Chloride 8 16 - 16 
Magnesium Sulphate - - 14 - 
Calcium Chloride - 1.2 1.1 2.2 
Dextrose - - 278 - 
Mannitol 20 - - 
Sodium Bicarbonate - 10 - - 
Histidine 180 - - ' 
Histidine Hydrochloride 15 - - 
Tryptophan 2 - - ' 
Verapamil (µg) --1.5 - 
Insulin (I U) -- 
20 - 
Osmolarity (mosmlkg) 1 287 1 300 1 385 1 350 
pH at 4°C (pH units) 1 7.3 1 7.5 1 7.3 1 6.8 
This Table gives comparative compositions of the four cardioplegic solutions investigated. 
Concentrations are expressed as milli mots per litre apart from Verapamil, which is expressed in 
micrograms and Insulin, which is expressed as International Units. Bretschneider and Wicomb 
base solutions were made up at the Regional Health Authority Central Pharmacy, 
in Ipswich. St. 
Thomas' No. 1 and Plegisol were obtained as commercial solutions from Macarthy Ltd, England. 
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5.2 METHOD 
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Heart-lung blocks were removed from 24 anaesthetised male Dunkin-Hartley (450-600 
g) guinea-pigs, using the technique described in Chapter 4. Control function curves 
were obtained, prior to arrest, in order to confirm normal function. Cardioplegic 
induction was achieved with one of four solutions: 
1. Bretschneider HTP 
2. St-Thomas' 1 
3. Plegisol 
4" Wicomb 
Cardioplegic induction was carried out in identical fashion for each heart. This 
consisted of. 
" Returning the heart to Langendorf (non-working) mode. 
" Clamping the distal aortic outflow. 
" Administering 15ml/kg (body weight) cardioplegia, at a pressure of 40 mm Hg, 
at 4°C. 
The groups were compared with respect to: 
a. Time to arrest TARR 
b. Coronary Resistance CR 
c. 31P-NMR Spectroscopy 
Coronary flow is not reported on, since this is reflected in the measurement of coronary 
resistance, with a fixed perfusion pressure. 
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These hearts were subsequently stored at 4°C for 3 hours, after which they were re- 
mounted on the working heart apparatus and post-storage function curves obtained, as 
described in Chapter 7. 
Nuclear Magnetic Resonance (NMR) Spectroscopy provides a noninvasive method of 
following intracellular changes in high-energy phosphate levels and the accumulation 
of protons (decrease in pH). This means that functional studies can be performed on 
the same heart. In this study only limited access was available to the magnet, so 
limiting the number of experiments which could be conducted, precluding statistical 
analysis of results. 
NMR Measurement method 
The studies were performed using a Bruker AM-360 spectrometer with a vertical 8.5 T 
magnet. The radio frequency coil was tuned to 100.18 MHz for protons, to shim the 
static magnetic field and to the 31P frequency of 40.65 MHz. Field homogeneity was 
adjusted using the water 'H signal189''90. The 90-degree pulse length for 31P was 80 
usec, and most spectra were accumulated with 50 usec pulses applied at intervals of I 
second. Spectra were obtained by means of the Fourier transformation after 14 Hz line 
broadening. Gross baseline distortions were first corrected by manual subtraction of a 
quadratic polynomial fit. Simultaneously, Phosphocreatine (PCr) peaks were shifted to 
the same frequency for automatic processing comprising a baseline least-square linear 
fit. When PCr was not present water was effectively used as the reference 
frequency'89. Peak area errors were in the 7% range. Values for pH were determined 
for the chemical shift difference between the inorganic phosphate and phosphocreatine 
signals, at 4°C with the following formula190. 
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pH=6.88+Loglo 3.35 
5.6 0 
Errors for the pH estimations were in the 0.15 pH unit range. 
Eight additional hearts (two hearts from each group) were subjected to the same 
protocol as above and then analysed by NMR spectroscopy for intracellular energy 
metabolism and pH, measured at 20 minutes post arrest, having been stored at 4°C 
during this period. The NMR measurements were carried out by Dr. David Reid at 
Smith Kline Beecham. 
A further series of 6 experiments were conducted to obtain qualitative information on 
the efficacy of hypothermia alone, as an inductive agent. For these experiments 4°C 
Kreb's solution was used as the perfusate. 
Statistical Analysis 
The outcome measures of TARR, and CR were analysed by analysis of variance, taking 
into account the type of solution used. If a solution was found to have a statistically 
significant effect, then the solutions were compared pairwise, using Fisher's LSD 
method19'. 
5.3 RESULTS 
TARR 
There was a statistically significant difference between the times to electromechanical 
arrest of the hearts induced with the four solutions (p<0.001). 
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The hearts arrested with Bretschneider HTP solution took approximately three times 
longer to arrest than those hearts induced with the other three solutions. Within these 
three remaining solutions, the hearts induced with St. Thomas' 1 took less time than the 
Plegisol (11 seconds) and Wicomb (7 seconds) less, respectively (Figure 5B). 
CARDIOPLEGIC INDUCTION STUDIES 
MEAN TIME TO ARREST 
Seconds 
100 
80 
60 
40 
20- 
0 
15m1/kg at 40 mm Hg n=6 in each group 
Figure 5B Histogram showing the differences in mean time to arrest with the four 
cardioplegic solutions, administered under identical conditions of volume, 
temperature and pressure. It is clear that Bretschneider HTP solution is much 
less effective than the other three solutions, as an inductive agent. 
The mean time to arrest for the four solutions are ranked as follows: 
St. Thomas' No 1< Womb < Pleoisol < Bretschneider HTP 
Bretschneider Plegisol Wicomb St. Thomas'l 
82 28 24 17 
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In the above and in the following comparisons, solutions underlined by the same line 
are NOT statistically significantly different. 
Figure 5C shows representative left ventricular pressure traces for each solution, which 
illustrates both the temporal differences in induction, produced by each, but also the 
nature of electromechanical work performed, during the anoxic period of induction. 
Bretschneider HTP solution showed gradual bradycardia with no loss of developed 
pressure and abrupt arrest. Plegisol and Wicomb solutions showed gradual 
bradycardia and an associated loss of developed pressure, before standstill. St. 
Thomas' 1, on the other hand, showed no bradycardia and an increase in developed 
pressure before an abrupt arrest. 
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Figure 5C. 
Cardioplegic Induction Each solution was administered at 4°C and at a pressure of 40 mm 
Hg. The same volume -7 ml - (representing 15 ml per kg 
body 
weight) - was administered during 
the period between arrows. 
Mean time to arrest, mean flow and mean coronary resistance is 
given next to each trace. 
ARREST: 24 secs 
FLOW. 15 m&min 
RESISTANCE: 33.3 dyn s cros 
ARREST: 17 secs 
FLOW: 13.7 mI/min 
RESISTANCE: 38.5 dyn $ cros 
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CR 
There was a statistically significant difference between coronary artery resistances 
between the induction groups (p<0.001). 
The hearts induced with Bretschneider HTP solution showed an approximate threefold 
increase in resistance compared with the other three solutions (Figure 5D). 
CARDIOPLEGIC INDUCTION STUDIES 
MEAN CORONARY RESISTANCE 
4 
3.5 
3 
2.5 
2 
1.5 
1 
0.5 
0 
Resistance dyn s cm-5 
15mI/kg at 40 mmHg n=6 in each group 
Figure 5D Histogram showing the differences in coronary resistance between the four 
solutions. As with time to arrest, the hearts arrested with HTP solution 
showed a much higher resistance. St. Thomas' 1 showed a significantly lower 
resistance compared with Plegisol. 
Bretschneider HTP Plegisol Wicomb St. Thomas'l 
2.87 1.11 0.99 0.89 
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The mean coronary resistance for the four solutions are ranked as follows: 
St. Thomas' No < Wimmb < Pie isol « Bretschneider HTP 
TABLE 5.2 
SOLUTION TARR 
seconds 
CR 
dyn s cm-5 
Bretschneider HTP 78 106.4 
Plegisol 
Wcomb 
r 
28 
24 
40.7 
33.3 
St. Thomas' 1 17 36.5 
STANDARD DEVIATION 3.1 12.6 
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The above Table shows the large differences between the solutions with respect to their efficacy 
at cardioplegic induction. Whilst the major effect would seem to be flow related their are also 
differences related to the chemical composition. 
Hypothermia Alone 
Using Kreb's solution delivered at 4°C and at a pressure of 40 mmHg, it was 
established that guinea-pig hearts undergo a series of stepwise reductions in 
electromechanical activity, at 26°C, 24°C and final standstill at 17°C. The time taken to 
cool these hearts, by coronary perfusion alone, is a function of coronary resistance, 
which was approximately 3 times as high as that of the high potassium solutions. At a 
delivery pressure of 40 mmHg it was not possible to cool these hearts below 23°C 
without external cooling (Figure 5E). 
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Effects of Hypothermia Alone 
116 
oc 
2 4.2 7 10 ml 
Vertical axis 20mm = 100mmHg 
Volume of Kreb's Solution 
30 SECS 
ýs ýs vý z7 ý9 27 2s ? 4.4 ?. ' 17 
Vertical axis 20mm = 100mmHg 
Figure 5E Using hypothermia alone, as an inductive agent, demonstrates stepwise 
changes in activity at approximately 26°C, 24°C and standstill at 17°C. (Upper 
trace). In the lower trace 4°C Kreb's solution is administered at 40 mmHg as 
an inductive agent. However, the coronary resistance is too 
high to allow 
effective cooling, without external lavage (Lower Trace). 
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31 P-NMR Spectroscopy 
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Spectral analysis of these hearts, 20 minutes after arrest, showed normal levels of high 
energy phosphates in the Wicomb perfused group, but significantly reduced levels in all 
of the other solutions. Whilst statistical analysis was not performed on this data, 
because of the small numbers, the qualitative differences seen in the spectra are 
impressive (Figure 5F). Ranking for ATP and Phosphocreatine were: 
Wicomb > Plegisol > St Thomas' No. 1» Bretschneider HTP 
There were also differences in intra-cellular pH measured at 20 minutes. These were: 
St. Thomas'No. 1 7.35. Plegisol 7.30. 
Wicomb 7.25. Bretschneider HTP 7.0 
In these spectra the chemical shifts are assigned in parts per million (ppm) relative to 
the phospocreatine (PCr) signal, which is assigned a value of 0 ppm. Signals are 
assigned to the beta, alpha and gamma phosphates of ATP, PCr and inorganic 
phosphate (Pi). The peaks at 3 ppm and at 6 to 7 ppm are from phosphodiesters and 
phosphomonoesters, respectively. 
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Figure 5F The above NMR spectra were obtained following 20 minutes of storage in each 
solution. Wicomb solution exhibited the best preservation of both 
phosphocreatine and ATP with St Thomas' I and Bretschneider HTP solutions 
showing early degradation. 
Pi = Inorganic Phosphate PCr = Phosphocreatine 
ATP = Adenosine Triphosphate NAD = Nicotinamide 
Adenosine 
Dinucleotide 
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5.4 DISCUSSION 
In the course of cardiac transplantation, there are five major stages which impact on 
donor heart function; initial donor management, cardioplegic induction, cold storage, 
global ischaemia during implantation, and reperfusion. Hyperkalaemic, hypothermic 
cardiac arrest has remained the cornerstone of all modern methods of cardioplegia, 
despite an ongoing debate over many other aspects of composition, temperature and 
mode of delivery. However, none of the cardioplegic solutions in current clinical use 
was expressly designed for donor heart preservation. 
In biological systems the strong depressant effect of cooling is often expressed by 
the van't Hoff rule, which relates the rate of a particular reaction at one temperature 
(T1) to that of the same reaction at a temperature difference of 101 C- the so-called 
Q, o relationship192. 
Qio = rate at T, + 10°C/rate at T, 
For many biological reactions the Q10 values are 2 or more. It is on this powerful 
relationship that the beneficial effects of cooling tissues for clinical preservation are 
based. However, this depressant effect is not selective and those processes 
responsible for maintaining the constituent tissues are also affected. 
When the logarithm of the rate of a simple chemical reaction is plotted as a function 
of the reciprocal of absolute temperature (Arrhenius plot), a straight line relationship 
is produced, the slope of which depends on the activation energy of the reaction 193 
In typical biological reactions in tissues, however, each step will almost certainly 
have a different activation energy, making the overall effect unpredictable, and 
. 
discontinuities have frequently been reported in plots of biological processes' 
94 
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However, as working methods for quantifying the effects of temperature on biological 
process, both the Arrhenius and van't Hoff relationships have proved invaluable. 
The effects of cooling on cellular metabolism and membrane transport are therefore 
complex' 95''96. These complex effects extend to changes in physical properties 
brought about by cold, as exemplified in the lipid phase changes in membranes' 97 
and deleterious effects on the cytoskeleton'98'199 Most biological reactions have a 
structural-functional interrelationship which can be disrupted by spatial changes, 
sometimes leading not only to a loss of function but the possible creation of aberrant 
processes as in the production of oxygen free radicals200 
Cooling influences both the energy available for cellular activities such as ion 
pumping and protein synthesis, but also limits the rate of energy production, such as 
high energy phosphate synthesis201. Inhibition of active and facilitated membrane 
transport systems reduces the uptake of substrate and causes ion distribution to be 
disturbed202. This effect extends to the maintenance of the intracellular ionic gradient 
which, at normothermia, results from a balance between the passive flux of ions 
down their electrochemical gradients and the activity of energy-dependent ion pumps 
working against gradients202. The net result is that at lower temperatures the rate of 
ion pumping is usually unable to match the rate of passive ion fluxes and, owing to 
the charge carried by intracellular proteins, there is a net gain of sodium and chloride 
ions within the cell, leading to cellular oedema207. This means that there is a need to 
understand how cooling affects integrated cellular metabolism and select the best 
compromise. This has not generally been the case in clinical organ preservation. 
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In the experiments described in this chapter, the coronary resistances developed as 
a consequence of perfusing guinea pig hearts at a constant pressure were shown to 
vary threefold between solutions. The reasons for this wide disparity are probably 
related to potassium mediated vascular tone changes rather than viscosity 
differences, since Wicomb solution was the most viscous of the solutions, and 
Bretschneider HTP has a substantially lower potassium content. Resistance curves 
(at a range of perfusion pressures) were not contructed as this was not pertinent to 
the experiments described, in which it was necessary to keep as many of the 
conditions as possible, constant. 
The use of a cardioplegic solution for intra-operative myocardial protection, has some 
significant differences from the application for donor heart storage. Induction usually 
takes place after active body cooling has been initiated via the cardio-pulmonary 
bypass machine (CPB) and likewise the CPB crystalloid prime has reduced the 
haematocrit to around 30%. Mean arterial pressures are usually low and the heart has 
usually had a period during which full perfusion with cold oxygenated blood has 
coincided with a period of cardiac decompression. Following cardioplegic induction, 
whether antegrade, retrograde, warm or cold, the cardioplegia will be eliminated from 
the coronary vascular bed by the collateral circulation, within 10-15 minutes. 
In this chapter the differences between four representative solutions were investigated 
with regard to their efficacy in achieving rapid diastolic arrest, with minimal substrate 
consumption (as measured by NMR), in a setting representative of donor heart 
retrieval. There was more than a fourfold difference in time to arrest between the most 
rapid (St. Thomas' 1) and the slowest (Bretschneider HTP) inductive solution. Possibly 
more importantly, NMR indicated better high energy phosphate levels in both Wicomb 
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and Plegisol solution, after 20 minutes of hypothermic storage. The use of NMR is a 
particularly useful method of monitoring preservation since the intracellular 
environment can be monitored for both high-energy phosphate depletion and the 
accumulation of acid metabolites. A few preliminary experiments also confirmed that it 
would be possible to carry out the low-flow perfusion within the magnet. 
Whilst ATP levels are not the only factor controlling viability, high energy phosphates 
do play a central role in active transport processes204. This view is underlined by the 
increased use of NMR as a powerful technique in non-invasive studies of energy 
metabolism during both warm and cold ischaemia2o5-ZOs 
Bretschneider HTP solution was chosen to represent the middle European solutions 
which follow an intracellular composition together with histidine, which is a more 
effective buffer at low temperatures. St Thomas' No. 1 solution represents the most 
popular generic group of extracellular solutions and Plegisol is a more recent variant in 
which the ionised calcium content has been halved and the potassium content 
reduced. Wicomb solution is an experimental dextrose based solution, containing lower 
potassium and magnesium levels, together with the calcium antagonist Verapamil. 
Insulin is included to facilitate the anaerobic metabolism of dextrose. The solution was 
designed specifically for donor heart preservation by the Cape Town group21. 
The results show Bretschneider HTP solution to be particularly ineffective for donor 
heart preservation, in this model. However, since these experiments were conducted 
the solution has been modified (designated HTK) 209 and the delivery method 
considerably altered210; perfused volume has been increased to 36 ml/kg and the 
solution is delivered first in an oxygenated form, followed by a non oxygenated 
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solution. A recent retrospective multicentre study suggests that HTK now offers similar 
protection to other solutions in common usage 211 
Lowering the calcium content and reducing the potassium concentration may make 
Plegisol a more effective solution than St. Thomas' 1. The hyperkinetic phase prior to 
arrest is avoided but this would seem to be offset by the more rapid onset of diastole in 
the case of St. Thomas' 1, as evidenced by the NMR data. Surprisingly, normal pH was 
better maintained in the St. Thomas' group despite the theoretical superiority of 
histidine buffering in Bretschneider HTP. In an NMR study of the effects of sodium and 
calcium levels on ATP, Perrot found that calcium levels in the 1-0.25 mmol range 
gave best substrate preservation but that this was linked to maintaining high levels of 
external sodium, since a rise in the potassium: sodium ratio enhances calcium influx to 
the cytosol and hence energy consumption 212. In a study comparing four similar 
solutions, English found that whilst initial substrate levels were better preserved with 
the extrace//u/ar solutions, as was pH, Bretschneider HTP solution was superior to 
St. Thomas' 1 after 4 hours preservation (the rates of degradation were different). 
However, a similar dextrose based solution to Wicomb (designated CP5) was found to 
be more effective, overall, after 24 hours storage22. In addition, these hearts were 
perfused with much higher volumes of cardioplegia (60 ml/kg), a feature which seems 
to be important for the Bretschneider compositions. 
5.6 CONCLUSIONS 
This study indicates that of the solutions tested, the dextrose based Wicomb solution 
provides the most effective method of cold cardioplegic arrest. This chapter does not 
seek to address whether or not a solution which provides effective induction is also 
capable of providing the optimal protection required for long term global ischaemia for 
CH5 CARDIOPLEGIC INDUCTION 124 
donor heart preservation applications. This question is investigated in the following 
Chapters. 
CH6 DELIVERY METHOD AND OXYGENATION 
CHAPTER 6 
DELIVERY METHOD AND OXYGENATION 
6.1 BACKGROUND 
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In the previous chapter the relative efficacies of a range of generically representative 
cardioplegic solutions were investigated with respect to cardioplegic induction. This 
chapter explores one aspect of functional preservation, during the global ischaemia 
which accompanies donor heart storage. 
Oxygenated cardioplegia has recently been employed with both blood based213 and 
crystalloid solutions214, as a means of providing better myocardial protection during 
routine cardiac surgery. This has resulted from the knowledge that whilst hypothermia 
and hyperkalaemic cardioplegia may greatly reduce myocardial oxygen demand, there 
is still a finite oxygen requirement of some 0.5 ml. min"1.100g-' of muscle at 4°C215. If 
this demand is not met, anaerobic metabolism can support myocardial viability for a 
period, limited by; the existance of available substrate, a reduction in high-energy 
phosphates, an increase in acidosis and the accumulation of toxins and inhibitory 
metabolites216. Which of these is most important, is unclear. It may be sufficient to 
remove waste products with an appropriate flow, without attempting to meet the 
aerobic oxygen and substrate demand. On the other hand, oxygen and substrate 
delivery may be paramount. 
During routine cardiac surgery cardioplegia may be delivered by single flush186, 
intermittent perfusion217 or by continuous perfusion218. In donor heart preservation 
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single flush followed by hypothermic storage is almost exclusively used (Appendix A), 
mostly for logistical reasons. In this chapter the interactions between delivery method 
and level of oxygenation, using a single crystalloid cardioplegic base solution, was 
investigated. St Thomas' 1 cardioplegia was chosen as being representative of the 
most commonly used generic hyperkalaemic solutions, that is, a balanced electrolyte 
solution with increased potassium in the 16 to 20 mmol range. 
Since it is unclear what the relationship between perfusion and oxygen delivery is, 
these experiments were conducted in two phases; the first examined the effects of 
increased oxygen supply by three different delivery methods, and the second 
examined the effects of keeping the oxygen delivery constant whilst changing the rate 
of perfusion. 
6.2 MATERIALS AND METHODS 
The isolated perfused working heart model, as described in preceding chapters, was 
used for these studies. Guinea pig hearts were arrested with 15 ml/kg of the 
cardioplegic solution under test, following control function curves. The work was 
carried out in two phases; Study 2 was designed to further investigate the continuous 
perfusion mode of delivery. 
Study I 
Seventy two isolated guinea-pig hearts were randomised into 9 groups and studied 
before and after arrest and storage with a standard cardioplegic solution (St. Thomas' 
1) for three hours at 4°C. 
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Three methods of cardioplegic delivery were used: 
1. Continuous low-flow perfusion (4 ml/hr) (CP) 
2. Intermittent perfusion (1 ml/min for 2 minutes every 30 minutes) (IP) 
3. Single flush (15 ml/kg) (SF) 
Solutions with three different oxygen tensions were used: 
1. P02 of 240 mmHg. (Low) 
2. P02 of 560 mmHg. (Medium) 
3. p02 of 950 mmHg. (High) 
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These levels of oxygenation were chosen to represent typical levels for atmospherically 
equilibrated solutions (Low), bubble oxygenated solutions (Medium), and 
hyperbaricaliy oxygenated solutions (High). 
Oxygenation was achieved by prewarming followed by variable hyperbaria, a method 
which was developed by the author and validated to provide crystalloid solutions with 
stable predetermined oxygen contents219(Bibliography D). 
Study 2 
Following this first study a further 42 hearts were studied; 24 Constant Flow (as in 
Study 1), and 18 Adjusted Flow, in which the flow rate was adjusted for oxygen 
content, so as to maintain a constant oxygen delivery. These groups were designated 
CF and AF respectively. The CF group was equivalent to the CP group from Study 1. 
Each group was further sub-divided according to the P02 of the solution, as before. 
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The number of experiments in each treatment regime is shown in Table 6.1. 
TABLE 6.1 
DELIVERY METHOD 
LOW 
MEDIUM 
HIGH 
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STUDY I STUDY 2 
CP IP SF CF AF 
8* 8* 8* 8 6 
8 8 8 8 6 
8 8 8 8 6 
Delivery methods and oxygenation were randomised. 
* One heart in each of these groups failed to eject against the 50 mmHg afterload, post storage, 
and was excluded from the analysis. 
Oxygenated cardioplegic flow rates for the CP group were determined by theoretical 
calculation of myocardial oxygen consumption based on 0.15 02. min-1.100g-' 176,220 
This gives a calculated consumption of 0.18 mis of oxygen/hr for a hyperkalaemically 
arrested 2. Og guinea pig heart at 4°C (Figure 6A). The flow required to meet this 
demand using the High oxygen solution (950 mmHg) would be 3.3 ml/hr. (Figure 6B). 
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Figure 6A The effect of temperature on the mean myocardial oxygen demand for 
hyperkalaemically arrested hearts, and the oxygen content of crystalloid solutions at the 
three gas tensions under investigation. 
The value for available oxygen dissolved in asanguinous solutions, were derived from 
221 solubility constants for oxygen, adjusted for temperature. 
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Figure 6B With a knowledge of the oxygen demand and the oxygen content, with respect to 
oxygen tension, the required flow curves can be plotted for the three oxygenated 
solutions under investigation. These flows are calculated to meet the demands of a 2g 
heart. 
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These estimations were checked on three hearts by measuring coronary effluent P02 
whilst reducing perfusion flow from 6 ml/hr by 0.5 ml/hr every 30 minutes. There was a 
sharp decrease in coronary sinus P02 between 3.5 and 3.0 ml/hr, suggesting that 
oxygen consumption exceeded supply between these flows. A flow of 4 ml/hr was 
therefore chosen for the CP group in Study 1. 
For Study 2 the perfusion flows were adjusted to maintain the same oxygen delivery, in 
Group AF. The individual flows for the three levels of oxygenation were: 
LOW =8 ml/hr MEDIUM =6 ml/hr HIGH =4 ml/hr 
Analysis 
Function curves were produced for each heart pre and post storage. 
Each curve was summarised by calculating: 
1. Mean stroke volume at LAP 5 to 25 cmH2O (3.7 to 18.5 mmHg) 
2. Maximum stroke volume. 
3. LAP where maximum stroke volume occurs (LAPmax). 
Each of these parameters from the post storage function curve was analysed 
separately by analysis of variance (ANOVA), taking into account the delivery method 
and the amount of oxygenation. The respective parameter value from the pre storage 
function curve was used as a covariate. 
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Cardiac output was not analysed as it was highly correlated with Stroke Volume, and 
the latter was used in this study so as to remove the effects of heart rate. These 
hearts were not paced. 
6.3 RESULTS 
Study I 
Function curves were constructed for each delivery mode and level of oxygenation. 
Figures 6C, 6D and 6E illustrate the effects of different delivery methods combined 
with the three levels of oxygenation. 
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SINGLE FLUSH DELIVERY 
EFFECTS OF OXYGENATION 
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Figure 6C The Stroke Volume is plotted for each 5 cm increase in preload post 3 hour 
storage following single flush preservation. The pooled pre-storage curve is 
shown for comparison. All post storage curves show an approximate 40% loss 
of function with the MEDIUM group giving the best results. (1 cm preload = 0.74 
mmHg) 
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INTERMITTENT DELIVERY 
EFFECTS OF OXYGENATION 
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Figure 6D With Intermittent delivery there is a more pronounced difference between the 
post storage curves, depending on oxygenation. The LOW group only achieves 
approximately 50% of pre-storage function. ( 1 cm preload = 0.74 mmHg) 
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Figure 6E Continuous delivery shows a marked difference between the LOW oxygen 
group (< 50% of pre-storage) and the other two groups which were able to 
maintain about 80% of pre-storage function. ( 1 cm preload = 0.74 mmHg) 
05 10 15 20 25 
LAP cm H2O 
CH6 DELIVERY METHOD AND OXYGENATION 
Mean Stroke Volume 
135 
There was a statistically significant interaction between the effects of the different 
methods of delivery and the amount of oxygen on the mean Stroke Volume (p = 
0.002). For the Continuous perfusion delivery method, Stroke Volume increases with 
increasing oxygenation. However, for the Intermittent and Single Flush methods, the 
highest mean Stroke Volumes were observed at a P02 of 560 mmHg. 
Continuous perfusion (CP) with oxygenation at 950 mmHg produced the highest mean 
Stroke Volume of all methods in Study 1 (0.94 mI/bt) (Table 6.2). 
TABLE 6.2 
MEAN STROKE VOLUME (ml. bf1. g-') 
DELIVERY METHODS 
Oxygen 
LOW 
MEDIUM 
HIGH 
SD 
Study I Study 2 
CP IP SF CF AF 
0.52 0.60 0.72 0.57 0.69 
0.86 0.90 0.78 0.92 0.78 
0.94 0.71 0.61 0.97 0.95 
0.0489 0.0557 
Maximum Stroke Volume 
The results for maximum Stroke Volume were very similar to that of the mean. There 
was a statistically significant interaction between the effects of the different methods of 
delivery and the amount of oxygen (p = 0.004). Maximum Stroke Volume increased 
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with the amount of oxygenation for the Continuous method. However, for the Single 
Flush and Intermittent methods the highest maximum Stroke Volumes were observed 
at 560 mmHg (0.90 ml and 1.05 ml/bt, respectively). 
Continuous perfusion (CP) with oxygenation at 950 mmHg produced the highest 
maximum Stroke Volume of all methods (1.12 ml/bt) (Table 6.3). 
TABLE 6.3 
MAXIMUM STROKE VOLUME (ml. bf-1. g"') 
DELIVERY METHODS 
Study I Study 2 
Oxygen CID IP SF CF AF 
LOW 0.62 0.67 0.83 0.66 0.79 
MEDIUM 0.97 1.05 0.90 1.02 0.91 
HIGH 1.12 0.86 0.75 1.15 1.09 
SD 0.0555 0.0633 
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There were no statistically significant interactions between the effects of the 
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different methods of delivery and the amount of oxygen on the pre-load at which 
maximum Stroke Volume was obtained (p > 0.05). This suggests that the trend in the 
effect of oxygenation was similar for all three methods of delivery (Table 6.4). 
TABLE 6.4 
LAP,,,, (mmHg) 
DELIVERY METHODS 
Oxygen CID IP SF CF AF 
LOW 13.3 11.1 12.6 11.8 10.4 
MEDIUM 11.1 11.8 11.1 10.4 13.3 
HIGH 12.6 11.1 14.1 11.8 11.8 
SD 2.8 2.7 
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CONTINUOUS DELIVERY 
EFFECTS OF OXYGENATION 
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Figure 6F This group was treated in exactly the same way as the continuous group in 
Figure 6E but in Study 2, conducted at a later time. The results parallel those in 
the earlier study. (1cm preload = 0.74 mmHg) 
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FLOW ADJUSTED DELIVERY 
EFFECTS OF OXYGENATION 
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Figure 6G In this group the continuous flow was adjusted, according to oxygen content, in 
order to deliver the same oxygen supply in all three cases. Functional 
preservation can be seen to improve with increasing oxygen content. 
(1cm preload = 0.74 mmHg). 
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In the second group of experiments the impact of providing equivalent amounts of 
oxygen by different delivery methods, was compared. Function curves of the two 
delivery methods were constructed as illustrated in Figures 6F and 6G. 
Mean Stroke Volume 
There was no statistically significant interaction between the different methods of 
delivery and the different levels of oxygen on the mean Stroke Volume (p = 0.313). Nor 
was there a statistically significant effect between the different delivery methods alone 
(p= 0.832). 
However, there was a statistically significant effect between the different levels of 
oxygen on the mean Stroke Volume (p< 0.001). The mean Stroke Volume increases 
with increasing oxygen level (Table 6.2). 
Maximum Stroke Volume 
There was no statistically significant interaction between the different methods of 
delivery and the different levels of oxygen on the mean Stroke Volume (p = 0.367). Nor 
was there a statistically significant effect between the different delivery methods alone 
(p= 0.896). 
There was a statistically significant effect between the different levels of oxygen on the 
mean Stroke Volume (p< 0.001). The mean Stroke Volume increases with increasing 
oxygen level. 
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The delivery method with constant flow and altered oxygen content (CF), with HIGH 
(950 mmHg) oxygen tension produced the highest maximum Stroke Volume (1.15 
mI/bt), as in Study 1 (Table 6.3). 
LAP 
max 
There was a statistically significant interactive effect between the different delivery 
methods and the levels of oxygen on the pre-load at which maximum Stroke Volume 
was obtained (p = 0.032). This suggests that the effect of oxygen was dissimilar for 
both delivery methods. For the constant flow mode of delivery (CF), the lowest LAPmX 
was with the MEDIUM (560 mmHg) level of oxygen, and the highest at the LOW (240 
mmHg) level of oxygen. For the constant level mode of delivery (AF), the lowest 
LAPmax was obtained with the LOW (240 mmHg) level of oxygen, and the highest at 
the MEDIUM (560 mmHg) level of oxygen (Table 6.4). 
6.4 SUMMARY 
In summary, the method of cardioplegia delivery was shown to be interactive with the 
oxygen content of the solution such that High oxygen is beneficial with the continuous 
methods of delivery, whilst Medium oxygenation gives improved functional 
preservation with all methods of delivery. Perfusion with Low levels of oxygen seems 
to be detrimental, whilst perfusion with High levels of oxygenation gives the best 
results. Figure 6H summarises the percentage recovery of maximum stroke volume 
for each method, with respect to control values. 
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COMPARATIVE FUNCTIONAL RECOVERY 
DELIVERY METHODS AND OXYGENATION 
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Figure 6H The percentage changes (from pre-storage controls) in maximum Stroke 
Volume are illustrated across the treatment groups. It is clear that function is 
increasingly better preserved with increasing oxygen content, in the continuous 
perfusion methods but medium levels of oxygen give better preservation with 
non-continuous delivery. 
In Study 2, which looks more carefully at the continuous methods of delivery 
decreasing the oxygen level is shown to be detrimental (lower means, maximums and 
flatter curves) regardless of delivery method. Conversely, ensuring sufficient oxygen to 
support aerobic metabolism did not seem to offer an advantage per se, but a higher 
flow at low oxygen levels seemed to be an advantage. The preload required to produce 
the maximum output varied with both the delivery method and the oxygen level 
(Figures 6F and 6G). 
6.5 DISCUSSION 
Oxygen inhalation therapy has long been used in the treatment of patients with acute 
myocardial ischaemia, particularly when ischaemia is complicated by hypoxaemia. It 
SF IP CP AF 
PRESERVATION METHOD 
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seemed logical therefore, that increasing oxygen delivery during the induced ischaemia 
required for open heart surgery, would be beneficial. 
This has resulted in a recent trend during routine open heart surgery to provide oxygen 
, 
with cardioplegic perfusates, initially by use of cold blood based solutions220 
subsequently by bubble or membrane oxygenation of crystalloid solutions222, and now 
more recently, by continuous warm blood cardioplegia223. There remains a 
considerable controversy, however, as to the optimal method229. The implementation 
of these techniques acknowledges the fact that whilst cold chemical cardioplegic arrest 
is associated with much reduced oxygen consumption, there is still a finite requirement 
which may be detrimental if not met. How much oxygen needs to be provided is still 
unclear. Coetzee225 studied the effects of delivering cold intermittent oxygenated (P02 
440 mmHg) crystalloid cardioplegia in isolated rat hearts compared with the same 
aerated solution, at both 4°C and at 20°C. The hearts receiving the oxygenated 
solution showed marked superior post storage function and high energy phosphate 
preservation. Interestingly, the group stored at 20°C with oxygenated solution, had the 
best overall results. The studies of Bodenhamer19 also showed overwhelming 
improvement with oxygenated crystalloid cardioplegia in an ischaemic dog model. 
Guyton214 performed studies on dogs with the same qualitative results and went on to 
carry out prospective randomised clinical studies on patients undergoing routine 
coronary artery surgery. These latter studies showed marked differences in the 
isoenzyme CK-MB release between the groups, at aortic clamp times in excess of 28 
minutes. These findings, along with similar literature reports, prompted investigations 
into the use of blood as a cardioplegic vehicle. 
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A number of studies, with conflicting results, have been published; Engelman226 used 
an in-vivo isolated pig model to compare oxygenated and aerated crystalloid solutions, 
delivered at 4°C, with an oxygenated blood cardioplegia, delivered at 15°C. The blood 
based solution demonstrated superior high energy phosphate preservation, following 3 
hours intermittent perfusion. In a study using an isolated in-vivo dog heart preparation 
Magovern227 compared aerated crystalloid with blood cardioplegia, with both solutions 
delivered at 4°C, 10°C and 20°C. The crystalloid group delivered at the two colder 
temperatures showed equivalent preservation to blood cardioplegia at 20°C, which was 
inferior to crystalloid at the colder temperatures. These studies serve to illustrate that 
whilst blood can carry much more oxygen than crystalloid solutions, at temperatures 
below 15°C the leftward shift of the oxyhaemoglobin dissociation curve severely limits 
oxygen delivery228. 
The above testifies to the limitation of blood as a cardioplegic base for donor heart 
preservation, although washed erythrocytes may be a useful additive due to their 
increased buffering capability229 and their rheological benefits230 
Recent studies by Wcomb14', who was able to obtain successful 24 hour preservation 
of rabbit hearts, suggest that only enough oxygen to support anaerobic metabolism is 
required and that even lower flows may be sufficient. However, the inclusion of an 
effective colloid seems to be essential for this approach to be effective. Microperfusion, 
as described by this group, involved perfusion rates of only 0.25 ml. g"1.24 hrs-1 of non 
oxygenated perfusate (modified University of Wsconsin)23, compared with 48 ml. g"'. 
24 hrs 1 in the CP group in the above studies and perfusion flows of over 1.5 I. g-1.24 
hrs"1 in conventional perfusion preservation techniques. However, Wicomb found that a 
high molecular weight polyethylene glycol (PEG20) was the only colloid which allowed 
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these impressive results to be achieved, and that the storage temperature needs to be 
close to zero. The group ascribe the success of the technique to the ability of PEG to 
ensure uniform perfusion, the provision of substrate and enough oxygen to support 
glycolysis and a flow rate just high enough to prevent acidosis and ensure the removal 
of waste products. However, PEG20 turns out to be an unstable solution, giving rise to 
doubts over the reliability of this technique. 
Despite the increased interest in the application of oxygenated solutions for routine 
cardiac surgery only 5% of Centers surveyed reported using oxygenated solutions for 
clinical donor heart preservation (Appendix A). The renewed interest in continuous 
perfusion has likewise not been reflected in donor preservation practice, for the same 
reason. The differences between cardioplegic delivery in routine cardiac surgery and in 
the setting of donor heart retrieval, have been discussed in Chapter 5. However, even 
for those Centres which believe in the efficacy of delivering oxygen during global 
ischaemia, and in perfusion preservation, the implementation of these techniques is 
limited by the logistical constraints of providing a suitable methodology. 
The choice of a storage time of three hours, used in the studies described in this 
chapter, was based on previous experience with this model (Chapter 5) which has 
shown that better than 95% of hearts stored, using the worst preservation method, 
perform measurable post storage work, after storage for 3 hours. This study produced 
post storage functional differences of between 49% and 81 % of controls, so achieving 
adequate sensitivity (Figure 61). 
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POST STORAGE FUNCTION 
DELIVERY AND OXYGENATION 
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Figure 61 In this illustration the current clinical technique of single flush low oxygen (SF 
low) is compared with the oxygen level giving the best results in each of the 
other delivery methods. The pooled pre-storage curve is displayed for 
comparison. It is clear that all of the alternative techniques offer the prospect of 
improved systolic and diastolic functional preservation. 
The studies described in this chapter underscore the fact that the provision of oxygen 
to globally ischaemic hearts is generally beneficial, and this finding is increasingly 
confirmed in the literature 214,231, with the exception of Wicomb. Figure 61 illustrates 
the differences between the current technique of SF with LOW oxygen, as used at 
Papworth and most other transplant centres (Appendix A) and the improvement 
possible with low flow oxygenated delivery of the same solution, CP HIGH. It also 
demonstrates that oxygen delivery, under these circumstances, is a much more 
complex issue than merely meeting oxygen demand, and that the method of delivery is 
clearly interactive with oxygen tension, and possibly other characteristics of the 
solution. This finding is also reported in a recent study by Cason232 who used a pig 
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model in which the left anterior descending coronary artery was selectively cannulated, 
thus allowing flow and oxygen content to be studied separately. 
The application of perfusion techniques to donor heart preservation for clinical 
transplantation has involved the use of heart-lung auto-perfusion systems233, portable 
hypothermia machines140 and more recently, continuous machine blood perfusion at 
34°C137. All these techniques are relatively complex and expensive, thus limiting their 
application. Low-flow perfusion has been applied by others to organ preservation210'234- 
236 
with some promise. 
6.6 CONCLUSIONS 
This Chapter focuses on the important interactions between oxygenation and method 
of delivery. The results clearly show that enhanced oxygen delivery can be beneficial, 
but that delivery method is equally important, possibly due to the effects of removing 
metabolites from the vascular system. Solutions with a high oxygen content offer an 
approximate 20% improvement in function, when delivered by continuous perfusion, 
compared with unoxygenated single flush delivery. However, the combination of high 
oxygen content with non-continuous delivery seems to be detrimental. Intermediate 
levels of oxygenation give improved post storage function with all methods of delivery. 
In the following chapter the effects of combining this delivery technique, with improved 
solutions, are explored. 
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Extending the preservation time limits of the donor heart has become an elusive goal 
to researchers in cardiac transplantation. The extent to which donor factors rather than 
pure preservation factors, are involved, has been unclear, as discussed in earlier 
chapters. The introduction of strikingly different solutions, such as University of 
Wisconsin (UW) has enabled this goal to be realised for intra-abdominal organs31'32 but 
the results for thoracic organs have been disappointing237. In the previous chapter the 
author was able to show that the delivery of oxygen to globally ischaemic guinea pig 
hearts, has the potential to improve post storage function by about 20%, using a basic 
hyperkalaemic cardioplegic solution, as a vehicle. However, there is now an impressive 
literature23'2a' 237-240 which shows that this type of solution, whilst perfectly satisfactory 
for uncomplicated routine cardiac surgery, offers sub-optimal protection for donor 
hearts. This is reflected in the universally accepted cold storage limit of approximately 
4 hours for human donor hearts37. The differences in the prevailing conditions during 
open heart surgery compared with donor heart storage, have been discussed in earlier 
chapters. The effects of varying numerous constituents and conditions have been 
widely explored in the laboratory such as the influence of extracellular compared with 
intracellular composition 240, the optimal osmolarity26 and pH241,242, the use of different 
buffers27, the addition of substrates 24,243,2aa the use of various impermeants245'246the 
use of free radical scavengers247, the addition of calcium antagonists248'249 negative 
inotropic agents250, the addition of flavines251, and local anaesthetic agents252 . 
Whilst 
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many of the laboratory studies have been encouraging, a method for significantly 
improved clinical donor heart preservation has yet to emerge240 
Our own clinical QBM data showed significant impairment in approximately 40% of 
donor hearts82, the ISHLT Registry19, shows 26% of deaths to be graft related. In this 
chapter four representative solutions (intracellular, extracellular, Histidine buffered and 
low potassium) used for studies of induction in Chapter 5 have been used in 
combination with the best technique (continuous low-flow perfusion with a high oxygen 
content CP HIGH), identified in Chapter 6, so as to explore the effects of increased 
oxygen delivery with different solutions. The author wished to determine whether the 
benefits of increased oxygen delivery, demonstrated with a simple extracellular solution 
would be common to other representative solutions. Since the author expected an 
overall improvement in function, the preservation time was extended to 4 hours in 
order to increase the sensitivity of the model. 
7.2 METHOD 
Twenty isolated guinea-pig hearts were studied before and after storage in one of four 
cardioplegic solutions (n=6 per group); Bretschneider HTP, Plegisol, Wicomb and 
St. Thomas' No. 1, for 4 hours at 4°C. Hearts were arrested with 15ml/kg of the 
cardioplegic solution under test, and subsequently low-flow perfusion stored with the 
oxygenated solution. The composition of these solutions and the methods of organ 
removal, functional evaluation and cardioplegic induction were as described in Chapter 
5, with each heart acting as it's own control. 
Each solution was delivered by continuous perfusion at 4 ml/hr and with a P02 of 950 
mmHg (CP HIGH), as described in Chapter 6. 
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Function curves were generated before and after storage using the procedure 
described in Chapter 4. 
The groups were compared with respect to : 
1. Mean Stroke Volume (LAP 3.7 to 18.5 mm Hg) 
2. Maximum Stroke Volume 
3. Mean Stroke Work ( LAP 3.7 to 18.5 mm Hg) 
4. Maximum Stroke Work 
5" LAP max 
6. Myocardial oedema (wet: dry weight) 
7. Heart Rate 
Analysis 
For each animal a pre and post-storage Function Curve for Stroke Volume and Stroke 
Work was conducted. For each of the above parameters the post-storage Function 
Curves were analysed separately by analysis of variance (ANOVA), taking into account 
the type of solution used. The respective parameter from the pre-storage Function 
Curve was used as a covariate. 
If a parameter was found to have a statistically significant solution effect, then solutions 
were compared pairwise, using Fisher's LSD method. 
Heart rate was analysed in this series, as there was an apparent solution effect. 
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Mean Stroke Volume 
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There was a statistically significant difference between mean levels of Stroke Volume 
for the four different solutions (p=0.002). The solutions were ranked as follows: 
ßretschneider HTP < St Thomas' No 1< Plegisol < Wcomb 
In the above and in the following comparisons, solutions underlined by the same line 
are NOT statistically significantly different (p> 0.05). 
A number of the hearts stored in Plegisol or Wicomb, had mean Stroke Volumes 
greater than pre-storage levels (Table 7.1). 
Maximum Stroke Volume 
The results for maximum Stroke Volume are very similar to those of the mean. There 
were significant differences between the solutions (p=0.002) with the same ranking. 
Pre and post storage Stroke Volume Function curves are illustrated in Figures 7A to 
7D 
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Figures 7A-7D The above function curves illustrate the changes in stroke volume in response 
to incremental loading for the four solutions following storage for 4 hours. The 
pre-storage curve is presented for comparison in each case. Note that in 
Wicomb solution post storage function was better than in the controls 
values. (1cm H2O = 0.74 mmHg) 
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LAPmax 
There was no statistically significant difference between the preloads at which 
Maximum Stroke Volume was attained for the four different solutions (p=0.648). Mean 
loading pressures for the four solutions ranged between 11 and 13.3 mm Hg (Table 
7.1) 
TABLE 7.1 
POST STORAGE STROKE VOLUME ml. g''. m''. 
SOLUTION MEAN MAXIMUM LAPS 
BRETSCHNEIDER 0.71 0.82 11.8 
PLEGISOL 1.12 1.26 11.8 
WICOMB 1.24 1.41 13.3 
ST. THOMAS 0.95 1.08 11.1 
SD 0.21 0.23 2.9 
Means and Standard Deviations (n = 6) adjusted for the respective Pre-storage statistic, in 
each case. LAP is in mmHg. 
Mean Stroke Work 
There was a statistically significant difference between the mean levels of Stroke Work 
for the four different solutions (p=0.008). The solutions were ranked as follows: 
Bretschneider HTP < Wicomb < St. Thomas No. 1 < Pleaisol 
Maximum Stroke Work 
The results for the maximum Stroke Work were very similar to that of the mean. There 
were statistically significant differences between the solutions (p=0.011) and the 
rankings were the same as for the mean (Table 7.2). Pre and post-storage Stroke 
Work Function curves are illustrated in Figures 7E to 7H. 
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Figures 7E-7H The above function curves illustrate the changes in stroke work in response to 
incremental loading for the four solutions following storage for four hours. The 
pre-storage curve is presented, for comparison, in each case. (1 cm H2O = 0.74 
mmHg) 
CH7 FUNCTIONAL STUDIES ON FOUR SOLUTIONS 155 
LAPmax 
There was a statistically significant difference between the preloads at which maximum 
Stroke Work for the four different solutions was attained (p=0.052). Maximums in 
Wicomb perfused solutions required higher preloads than the other three solutions 
(Table 7.2). 
The solutions are ranked as follows: 
Bretschneider HTP < St. Thomas No 1< Plegisol < Wicomb 
TABLE 7.2 
POST STORAGE STROKE WORK g. m. g". 
SOLUTION MEAN MAXIMUM LAPS 
BRETSCHNEIDER 0.0715 0.0863 11.1 
PLEGISOL 0.1419 0.1657 12.6 
WICOMB 0.1271 0.1533 15.5 
ST. THOMAS 0.1330 0.1576 12.6 
SD 0.0337 0.0405 2.4 
Means and Standard Deviations (n = 6) adjusted from the respective Pre-storage statistic, 
in each case. LAP is in mmHg 
Myocardial Oedema 
There were no statistically significant differences between the wet: dry weight ratios for 
the four solutions (p=0.738). Mean weight ratios ranged from 7.88 to 8.10 (Figure 71). 
CH7 FUNCTIONAL STUDIES ON FOUR SOLUTIONS 
MYOCARDIAL OEDEMA 
COMPARATIVE CARDIOPLEGIC SOLUTIONS 
WET: DRY WEIGHT 
8.4- 
8.2 
8 
7.8 
7.6 
7.4 
7.2 
7 
BRETSCHNEIDER HTP 
4 HOUR STORAGE AT 4°C 
n=6 
PLEGISOL WICOMB ST. THOMAS' No. 1 
156 
Figure 71 The wet-dry weight ratios, as an index of post storage oedema, showed no 
difference between the solutions. Bars indicate SEM. 
Heart Rate 
The mean heart rate was much lower in hearts perfused with Wicomb solution than the 
other three cardioplegic solutions. This was reflected in the test for solution effect in 
the analysis of variance, where the p value was small (p=0.052) but not quite 
statistically significant. 
However, the same possible outlier in the Bretschneider group, as identified in Chapter 
6, had a post storage heart rate of 160 bts/min. If this value is excluded from the 
analysis, the mean heart rate for the Bretschneider group is increased and the 
variability of the data reduced, by 44%. This reduces the p value to p=0.001 (Table 
7.3). 
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The means for the four solutions are ranked as: 
W-IwM < P1egisol < St Thomas No. I< Bretschneider HTP 
TABLE 7.3 
POST STORAGE MEAN HEART RATES 
SOLUTION MEAN ADJUSTED MEAN 
BRETSCHNEIDER HTP 247 263 
PLEGISOL 240 239 
WICOMB 200 200 
ST. THOMAS No. 1 241 240 
SD 29.7 22.2 
The adjusted mean takes into account the exclusion of a single outlier in the Bretschneider 
Group. 
Summary 
The four solutions had differing effects on the functional preservation of guinea pig 
hearts, stored using continuous low-flow perfusion with oxygenated solution, for 4 
hours at 4°C. 
Bretschneider HTP produced the worst overall preservation of function, in all respects. 
Plegisol and Wcomb produced the best overall results most clearly demonstrated in 
Figure 7J in which End Diastolic Pressure is plotted against Stroke Work. 
Storage in either Wicomb or Plegisol resulted in post storage performance equal to pre 
storage values (Table 7.4). 
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PERFUSION SOLUTIONS 
LAP CONTROL BRET HTP PLEGISOL WICOMB ST THOM 
mmHg (cm H20) NO. I 
3.7 (5.0) 0.102 0.060 0.110 0.093 0.081 
SEM (0.028) (0.029) (0.026) (0.023) (0.035) 
7.4 (10.0) 0.137 0.073 0.141 0.118 0.130 
SEM (0.032) (0.025) (0.036) (0.033) (0.027) 
11.1 (15.0) 0.175 0.086 0.166 0.153 0.157 
SEM (0.036) (0.034) (0.040) (0.027) (0.024) 
14.8 (20.0) 0.181 0.079 0.157 0.149 0.145 
SEM (0.037) (0.043) (0.036) (0.026) (0.025) 
18.5 (25.0) 0.161 0.060 0.142 0.148 0.131 
SEM (0.039) (0.040) (0.039) (0.019) (0.032) 
MEAN END DIASTOLIC PRESSURE VS LEFT ATRIAL PRESSURE 
STORAGE SOLUTIONS 
LAP CONTROL BRET HTP PLEG WICOMB ST THOM 
mmHg (cm H20) NO. 1 
3.7 (5.0) 2.93 3.10 3.31 3.73 4.88 
SEM (0.00) (0.10) (0.80) (0.70) (1.60) 
7.4 (10.0) 5.15 5.25 5.31 5.44 6.38 
SEM (0.70) (0.80) (1.20) (1.10) (2.10) 
11.1 (15.0) 7.23 8.92 7.81 8.44 8.91 
SEM (1.20) (1.10) (1.20) (1.80) (2.20) 
14.8 (20.0) 9.65 10.94 9.25 11.43 12.12 
SEM (1.40) (1.60) (2.30) (1.20) (2.10) 
18.5 (25.0) 12.4 15.20 11.72 13.63 15.32 
SEM (2.80) (2.10) (2.10) (2.90) (3.30) 
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COMPARATIVE POST STORAGE FUNCTION 
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Figure 7J In the above figure all four solutions are compared with their group control (pre- 
storage), following storage for four hours. It should be noted that not only is the 
maximum stroke work decreased in St Thomas No. 1 and Bretschneider HTP 
solutions, but that the function curve is distorted at higher preloads - indicating a 
loss of diastolic compliance. For SEM please refer to Table 7.4. 
The differences in ranking between maximum Stroke Volume and maximum Stroke 
Work can be explained by the difference in heart rates, between the groups. A lower 
heart rate produces the effect of increasing the Stroke Volume and reducing the Stroke 
Work, due to a reduction in cardiac output. 
7.4 DISCUSSION 
This chapter has explored the effects of combining the best method of oxygen delivery, 
as described in Chapter 6, with a selection of different cardioplegic solutions. The 
same working heart model, as previously described, was employed and derived 
parameters from function curves used, as primary outcome measures. The 
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combination yielded an improvement in post storage function from 59% of pre-storage 
maximum Stroke Volume achieved with single flush non oxygenated St. Thomas' No. 1 
(SF LOW) following storage for 3 hours (Chapter 6), compared with 107% of pre- 
storage maximum Stroke Volume seen with the use of low-flow perfusion of 
oxygenated Wicomb solution, following 4 hours storage, as shown in this chapter 
(Figure 7K). In a few tentative additional experiments, this improvement would seem to 
be maintained beyond 6 hours storage. 
It is possible that the optimum oxygen content and mode of delivery, might be different 
for each of the additional solutions and this would need to be evaluated in order to be 
sure that the best combination of characteristics was being employed. However, the 
results do suggest that, independent of the benefits conferred by the formulation of a 
"bespoke" solution such as Wicomb, oxygenation is associated with superior functional 
preservation. 
CH7 FUNCTIONAL STUDIES ON FOUR SOLUTIONS 
OVERALL COMPARISON 
MAXIMUM STROKE VOLUME 
% PRE STORAGE STROKE VOLUME 
I2n 
110 
100 
90 
80 
70 
60 
--AM 
50 
4 HOUR STORAGE 
3 HOUR STORAGE (MEAN) 
SOLUTIONS 
161 
Figure 7K In the above figure the percentage change in stroke volume, with respect to the 
pre-storage value, is compared for the four solutions and the current clinical 
method of single flush non-oxygenated St Thomas' No. 1 cardioplegia 
(SFNOX). It is clear that the use of either Plegisol or Wicomb with oxygenation 
and continuous perfusion offers considerable promise of improvement. 
This finding is not altogether surprising since, as discussed in Chapter 5, whilst all of 
the solutions, other than Wicomb, are commonly used for donor heart preservation, 
only the Wicomb solution was specifically designed for this purpose (but not yet 
clinically employed). 
Other investigators 23.24,237-240 have reported on the limited efficacy of the extracellular 
type formulations, characterised by the St. Thomas' No. 1 solution, in models 
representing donor heart preservation. Gott 240 and associates surveyed US transplant 
Centres in 1990 and found 42% (51% in the author's survey) to be using extracellular 
cardioplegic formulations for donor heart storage. They subsequently showed marked 
BRETSCHNEIDER PLEGISOL WICOMB ST. THOMAS' SFNOX* 
HTP No. 1 
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differences in post storage functional performance of isolated blood perfused dog 
hearts following, 6 hours storage intervals in an extracellular (EC) solution compared 
with the intracellular (IC) formulations of Stanford and University of Wisconsin (UW). 
Only 1/14 of the EC group was capable of adequate response to volume loading whilst 
all of the IC hearts (15/15) performed acceptable post storage work. However, in the 
author's model the only IC solution (Bretschneider HTP) produced the worst results. 
Swanson and colleagues23 also used an isolated canine model to compare UW with 
Stanford and a modified Collins solution (all IC formulations). There were only minimal 
differences after 5 hours storage but after 12 hours only the UW solution allowed rapid 
recovery of function despite similar ATP levels in all three groups. 
Recognising that there are a number of distinct steps which may independently 
account for donor heart damage, Burt and Copeland253 used an isolated working 
rabbit heart preparation to look at the impact of the various stages of retrieval and 
transplantation. Simple cooling and reperfusion caused no loss of function but recovery 
was slow. Cardioplegic induction prior to cooling and reperfusion recovered 95% of 
function whilst the same treatment with ischaemia at 25°C showed 89% recovery. The 
same regime with the addition of 24 hours storage only recovered 84% of systolic 
function and also showed diastolic dysfunction. This suggested that whilst induction, 
ischaemia and reperfusion all play a part in damage to the donor heart, it is the 
protracted storage time which makes the major contribution. In contrast, Minten254 and 
colleagues found that initial cardioplegic induction maintained high energy phosphates 
at approximately 80% of control levels after 3 hours of hypothermic ischaemia whilst 
the same storage conditions without cardioplegic arrest resulted in only 20% of initial 
ATP levels to be maintained. The literature is replete with similar apparent 
contradictions. 
CH7 FUNCTIONAL STUDIES ON FOUR SOLUTIONS 163 
Throughout the literature, however, perfusion preservation has been shown to offer the 
most effective method of protecting the donor heart25,132,158,255,256This had advanced 
to the point where clinical application was used by the Cape Town group140. However, 
of the four clinical hearts, preserved for between 7 and 17 hours using hypothermic 
crystalloid perfusion preservation, only one subsequently recovered normal function, 
on the third postoperative day. These patients would probably all have died had they 
not been using the technique of heterotopic cardiac transplantation, in which the 
inotrope supported patient's own heart kept the patient alive while the donor heart 
recovered. This experience also served to point out the disparity between their baboon 
preservation model, in which they had routinely achieved excellent 24 hour perfusion 
preservation 257, and the clinical situation. 
Evidence that the problem of transfering encouraging laboratory findings to clinical 
therapy, in the case of cardiac donor preservation, can be found in the comparative 
time intervals between the publication of these laboratory findings and the lack of any 
clinical reports of successful applications. Reports of the superior performance of the 
various iterations of UW solutions for cardiac preservation, in the laboratory, appeared 
as early as 198823 but the technique has yet to be used clinically. In contrast to this, 
laboratory reports of the use of UW solution in liver transplantation also appeared in 
1988,258 followed by the first publication of a successful clinical application, in the same 
year259. 
7.5 CONCLUSIONS 
In this chapter the utility of the isolated working heart model, used in the controlled 
environment of the laboratory, has been demonstrated. This was used to explore the 
potential benefits of oxygen delivery, as developed in Chapter 6, used in combination 
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with improved solutions, to provide better functional preservation of donor hearts. This 
approach has allowed an approximate doubling of functional preservation, compared 
with the current clinical technique of flush-store with non-oxygenated St. Thomas' No. 1 
cardioplegia. However, as is evident from the literature quoted above, successful 
transfer of these findings to the clinic requires the integrated approach outlined in the 
early chapters of this thesis. 
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Heart transplantation has been one of the success stories of twentieth century 
medicine, from it's inception in the late 1960's to the present day. Surprisingly, 
however, there has been little progress in clinical donor organ preservation during this 
25 year history8'260 265 despite impressive improvements in Immunosuppression and 
other aspects of patient management. This is in stark contrast to the progress made in 
the preservation of other organs, where the safe storage time has been more than 
quadrupled, 3', 32,266 
The studies described in this thesis were prompted by the frustrations which the author 
encountered as a founding member of the first centre in the UK to establish a heart 
transplant programme, in 1979. Many of the logistical problems associated with the 
peri-operative events surrounding the conduct of the implant have their genesis in the 
constraints imposed by the limited safe time available for donor organ preservation. In 
addition, the possibilities of improved organ matching are similarly constrained by the 
limited available time. Subsequent early morbidity and mortality is also strongly 
influenced by the functional capacity of the transplanted heart'00,262 and this is at a 
level comparable to that caused by the complications of rejection and infection20. More 
recently evidence has been produced to suggest that early peri-operative ischaemic 
damage to the coronary endothelium may be related to the generation of accelerated 
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graft atherosclerosis266, the most significant cause of late mortality in heart transplant 
recipients267-268 
The literature is replete with successful laboratory based solutions to the problem of 
donor heart preservation 21,27,30,46,98,123,132,137,150,158,171,226,231,237,243,247 However, in 
contrast to abdominal organ transplantation, there are no reports of this success being 
transferred into clinical practice. It is the contention of this thesis that the reasons for 
this poor record are predominantly threefold; a failure to address the impact of brain 
death and donor management both on the metabolic state of the donor heart and on 
the interaction of this with the method of preservation. Secondly, the attempt to extend 
the principles of preservation used in different settings or for different organs, to heart 
transplantation, and thirdly, the use of laboratory models in isolation or which 
inadequately reflect the conditions pertaining to heart transplantation. 
The central ethos of this thesis is that a combined approach to the problem of donor 
heart preservation is required; focused laboratory studies using appropriate models, 
together with controlled clinical evaluation within a tightly managed and controlled 
donor population. 
8.2 CENTRAL ISSUES 
As a prelude to the experimental studies described in this dissertation, the author 
conducted an International Survey into contemporary clinical donor heart preservation 
techniques37. The survey revealed a surprisingly diverse number of techniques to be in 
use, reflecting the lack of any one reliable method. None of the techniques reported 
had been designed to meet the specific needs of the globally ischaemic donor heart. A 
limitation of the survey was that only meaned centre data was available for analysis 
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and outcomes could only be crudely assessed by 30 day survival. This study was 
published in the Journal of Heart and Lung Transplantation37 and a plea made for 
donor related data to be included in the Registry database. The author is pleased to 
report that, as of April 1995, this data is now being routinely collected. 
The effects of trauma to the brain on the myocardium have been recognised for more 
than 40 years". However, whilst there is universal agreement that brain death is 
associated with catecholamine mediated cardio toxic effects 45,58,59,72,91 there is less 
of a consensus with regard to HRT as part of the management regime. Various 
groups68-" have verified the fact that, following brain death, serum T3 levels are often 
abnormal. However, some investigators67'71 have contended that there is no basis for 
HRT in organ donors. Closer scrutiny, however, shows the latter conclusions to have 
been made on the basis of inadequate studies. Several other investigatorsa7, as, 50,52, sa- 
67, including the author43,7s, "o7,1'2,2ss have been able to show that the problem of 
neurologically mediated cardiac dysfunction in the brain dead donor can be resolved by 
appropriate management, in most cases, including HRT. 
Chapter 3 provides a review of the literature regarding the impact of brain death on 
myocardial metabolism and function. It was clear that it would be necessary to 
quantitate and, if possible, manage this phenomenon if a significant impact on safe 
preservation was to be made. A secondary, but equally important reason, is that the 
effects of brain death produce a large variability in pre-excision cardiac function, 
making the objective assessment of any potentially improved technique impossible to 
determine given the small numbers available for investigation. A series of pilot studies 
was therefore undertaken, resulting in the establishment of an improved donor 
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management regime43, and the development of a Nomogram approach to functional 
management and assessment269 
The impact of this regime was subsequently investigated in a study of 150 multi-organ 
donors and shown to result in an improved donor retrieval rate of some 30% together 
with a reduction in the variance of pre-excision functional haemodynamics by up to 
44%. The recipients of these initially poor, managed hearts experienced a post 
transplant recovery at least as good as those receiving donor hearts which had been 
retrieved without any special management techniques107. These studies had taken 
place in parallel with laboratory studies aimed at establishing appropriate models for 
screening potentially improved preservation techniques, and are described in the 
chapters 4 to 7. 
Extending the principles used for routine open heart surgery to donor heart 
preservation, ignores the fact that significant differences exist between these two 
situations. The induction of cardioplegic arrest takes place under very different 
circumstances in routine surgery where the patient is supported on cardiopulmonary 
bypass, which unloads the heart at the same time as initiating cooling, with oxygenated 
blood having a reduced haematocrit. The donor heart is exposed to global ischaemia 
of between 3-4 hours in contrast to the 30-90 minutes of ischaemia in routine surgery 
during which there is also a variable degree of collateral flow to the coronary vascular 
bed. The donor heart is usually exposed to temperatures in the range of 40 C in 
contrast to 15 - 25° C in routine surgery and there always exists a variable degree of 
metabolic dysfunction in the donor heart, as a consequence of brain death. 
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Applying to heart transplantation the principles of preservation successfully developed 
for abdominal organs ignores equally important differences between these organs and 
the heart. Differences which critically influence the adequacy of preservation relate to 
cold sensitivity of cation transport270, membrane permeability to various solutes2", 
specific metabolic pathways for energy production33, and the relative paucity of 
naturally occurring defence mechanisms against oxygen free radicals 34 and to the 
inflammatory response35 in human myocardium. Over and above these important 
differences is the overwhelming necessity for the heart to perform significant levels of 
work within minutes of revascularisation. This means that for preservation of donor 
hearts a number of cardiac specific principles need to be addressed. In essence these 
are; the prevention of cellular oedema, limitation of calcium overload, the reduction of 
oxidative damage and the provision of substrates for energy production. 
Tissue oedema has long been recognised as a complication of cold storage. This 
occurs because both anaerobiosis and hypothermia inhibit the sarcolemmal 
sodium/potassium pump, thereby allowing the entry of sodium and chloride ions down 
their concentration gradients, as well as subsequent cellular swelling as water 
passively migrates to equalise transmembrane osmotic gradients33. A method of 
preventing this is to include a cardiac specific impermeant, such as Mannitol or a high 
molecular weight carbohydrate 240. Assuming that the calculated osmotic force derived 
from the intracellular proteins and nondiffusible anions is in the range of 100 to 140 
mosmols/kg, then a similar concentration of impermeant in the storage solution will 
prevent this complication. 
Calcium overload is a major feature of ischaemia/reperfusion injury which substantially 
impairs post ischaemic recovery of function by a contracture-related increase in 
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diastolic stiffness269. This has been observed by several investigators272 and was 
demonstrated by the author in the studies reported in chapters 6 and 7. The problem 
can be counteracted by appropriate electrolyte manipulations which include; lowering 
the calcium concentration in the solution to around 0.25 mmol/l, the avoidance of 
potassium concentrations in excess of 20 mmol/1273 (probably the threshold beyond 
which membrane depolarisation elicits a rise in cytosolic free calcium), the 
maintenance of a sodium concentration in the extracellular range (to prevent calcium 
entry via the sodium/calcium exchange) and the addition of magnesium as this ion 
competes with calcium at both sarcolemmal and intracellular sites274. In addition, 
keeping the pH slightly acidotic inhibits calcium entry via the sodium/calcium and 
sodium/hydrogen ion exchange mechanism275. Finally, the use of calcium channel 
blockers might also be useful51. 
There is now overwhelming evidence that oxygen-derived free radicals are important 
mediators of myocardial damage200,273,27s This can be most easily demonstrated 
during post ischaemic reperfusion but may also occur during perfusion. Free radical 
damage can be expected to occur during heart transplantation in which two 
superimposed episodes of global ischaemia (one during storage and the other during 
implantation) occur before being abruptly reperfused with highly oxygenated recipient 
blood, via the extracorporeal bypass machine. The protective effects of both 
interventions which interfere with free radical generation277 or subsequent free radical 
activity278, have been shown, experimentally. However, it is important to ensure that 
279 thiol based agents are used in their reduced states. 
An additional important feature of a preservation solution is the provision of substrates 
or precursors which can limit tissue injury by making possible the production or 
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conservation of high-energy phosphate compounds, during ischaemia33. In the 
experiments reported by the author in chapters 5,6 and 7, oxygen was supplied to the 
tissue by the use of high oxygen containing solutions, allowing oxidative metabolism to 
proceed at a reduced rate. However, adenosine, aspartate or glutamate (the latter is 
able to enter into transamination reactions yielding ATP under ischaemic conditions) 
have also been shown to improve ischaemic tolerance during global ischaemia. In the 
normal perfused and functioning heart there is a pool of adenine nucleotides of 5-7 
9mol/g wet tissue, with ATP being by far the largest fraction280. The tissue 
concentration of total creatinine is two to four times higher than that of the adenine 
nucleotides and 35% to 50% of this is phophorylated to creatine phosphate. In 
laboratory animals the CrP: ATP exceeds the value of 1 whilst the human myocardium 
has smaller relative concentrations of CrP than that of animals (ratio<0.9) but is rich in 
glycogen. However, the tissue concentrations of many substrates, metabolites and 
enzymes vary in different regions of the heart, there are species differences and 
differences relating to age, diet and stress281. Steady state tissue concentrations reflect 
an equilibrium between synthesis and supply, on the one hand, and demand and 
utilisation on the other. There is a high degree of coupling and therefore any significant 
disturbance on either side of the equation will render steady states impossible. The 
interpretation of the significance of any level of tissue substrate therefore has to be 
cautious282. This supports the author's view that, whilst biochemical markers may give 
useful insights into mechanisms, the best way to measure myocardial functional 
performance is to measure function. 
The addition of oxygen to cardioplegic solutions has gained popularity in the last few 
years borne out of the recognition that whilst hyperkalaemic cardioplegia can bring 
about an approximate ten to twenty fold decrease in oxygen demand, there is still a 
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finite requirement of some 0.5 ml. min"'. 100g"' at 4°C215. The mode of delivery has 
been somewhat controversial in the setting of routine cardiac surgery with cold blood 
initially being the favoured vehicle220, but more recently either crystalloid222 or warm 
blood vehicles223 have predominated. The emphasis was initially on the superior 
oxygen transport of blood226 until it was realised that, at temperatures below about 
15°C the leftward shift of the oxyhaemoglobin dissociation curve228 severely limits 
oxygen delivery. However, washed erythrocytes may prove to be a useful additive due 
to their increased buffering capacity229 and their superior rheological properties230, and 
this was the base chosen by the author for the human working heart model. 
A number of investigators23,27 have recently recognised that the above characteristics 
are necessary features of solutions suitable for donor heart preservation and that the 
use of either solutions designed for short-term cardiac surgical applications, or 
solutions designed for the preservation of abdominal organs, are unlikely to yield 
satisfactory results. Accordingly, a multi-centre clinical trial of at least one of these 
bespoke solutions has been underway since April 1994 but the results have yet to be 
presented. 
Working heart preparations have been used by physiologists and pharmacologists to 
unravel functional and metabolic mechanisms, for the past 90 years. However, unlike 
other forms of transplantation, the donor heart is required to perform significant work 
within minutes of being transplanted. A relevant model therefore needs to evaluate 
myocardial functional reserve. In Chapter 4 the development of a small working heart 
model is described in which volume loading is used to stress the heart. Subsequently a 
human working heart model was established, for pre-clinical evaluation of promising 
techniques. 
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This small working heart model was used in the subsequent three chapters to 
investigate the comparative efficacy of four representative solutions in establishing 
cardioplegic induction, the interaction of different levels of oxygenation and delivery 
modes of a storage solution, and lastly the impact of combining the best of these with 
an improved solution. Oxygen delivery was chosen as a representative method of 
improving post storage function, from the wide range of potentially effective agents, 
and this was then comprehensively investigated. A novel method for oxygenating 
crystalloid preservation solutions was developed219 to facilitate these studies and to 
provide a simple yet reliable and practical means of incorporating oxygenation of these 
storage solutions into clinical practice. 
This series of studies demonstrated the potential for more than doubling the current 
safe preservation time for donor hearts and served to illustrate the utility of this 
approach. 
8.3 IMPLICATIONS 
This thesis has focused on a strategy, rather than attempting to provide a solution to 
the problem of donor heart preservation. The author has established that the supply of 
donor organs is the most significant factor limiting the expansion of what is currently 
the only effective therapy for end-stage heart disease. Evidence has been presented to 
show that the problem of improved donor heart preservation, and retrieval rates, has 
been resistant to solutions shown to be effective for other transplantable organs. The 
author has further demonstrated that the use of a donor management regime has both 
improved the donor retrieval rate and the function of donor hearts. Parallel laboratory 
studies demonstrated that the use of a small animal working heart model, used as a 
screening device for potentially improved preservation methods, together with a human 
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working heart model for pre-clinical screening, offers a potential solution to this 
dilemma. This work suggests that only by a combined approach is a significant impact 
on the problem likely to be forthcoming. 
8.4 FURTHER INVESTIGATIONS 
There are a number of promising avenues to which the principles outlined above could 
be applied. The issue of controlled reperfusion283 was not addressed in the models but 
this could be accomplished by interposing cross-perfusion, with a donor animal, or in 
the case of the human heart, with fresh human blood, to study this phenomenon. The 
hearts could subsequently be mounted on the model, for functional evaluation. Specific 
free radical scavengers2M could be used to further analyse the interaction of 
oxygenation and delivery method, shown in Chapter 6. and the issue of the relative 
importance of perfusion as distinct from oxygen delivery, determined. 
It is likely that both the constitution and the temperature of the induction and the 
storage solutions need to be different285 since it is known that hyperkalaemic 
cardioplegic solutions damage the endothelium286'287 and are toxic13, with extended 
contact times. The use of hyperpolarising288 rather than depolarising induction solutions 
are more energy efficient, and should be investigated. The optimum storage 
temperature289 is probably higher than the default temperature of 4°C, which is almost 
universally used, and it would therefore be helpful to conduct a series of experiments to 
bracket the optimum temperatures for induction and storage. The implications of this 
are that some form of active temperature control would be necessary. A suitable device 
has been developed and used clinically by the author, for the past 15 years 279. 
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This work, and the work of others'58'161290,291, suggests that a perfusion preservation 
method would be superior to cold storage but that a simple, safe methodology would 
need to be developed before clinical adoption would be likely. 
It is also clear that solutions with an intracellular composition are superior to those with 
an extracellular composition24° and that the use of a large molecular weight 
impermeant is also effective246. It would therefore be worthwhile to reconsider an 
optimum solution, specifically designed for donor heart preservation, rather than 
tinkering with solutions which were designed for other purposes. 
Recently the phenomenon of preconditioning has attracted widespread attention 
although the finding that short periods of ischaemia, prior to a longer ischaemic 
episode, confers protection to the myocardium, has been known since the late 
1980's29z 
Several groups30,292-2ss are currently investigating the mechanisms in humans, with a 
view to finding a clinical method for exploiting this effect. Evidence comes mostly from 
the short ischaemic periods produced during coronary balloon inflation during coronary 
angioplasty, but this is difficult to extrapolate to global ischaemia. Other human studies 
have retrospectively examined whether a period of angina, 24 to 48 hours before an 
acute myocardial infarct confers a protective effect297. Recent work suggests that the 
mechanism involves endogenous ligands such as adenosine, initiating an intracellular 
pathway by acting on G protein-linked receptors which leads to the activation of protein 
kinase C and the ATP-dependent potassium channel. The opening of these channels 
is thought to lead to an influx of potassium into the cell, which shortens the action 
potential, limits ATP depletion and reduces calcium influx298. This mechanism has 
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been pharmacologically exploited using the agent aprikalim to produce a 
hyperpolarised cardioplegia288,299 in animal models, to good effect. 
There are also a number of other promising pharmacological agents which may have 
some utility in protection from the effects of global ischaemia, in particular the 
analogues of adenosine 300 300,301 which may be acting through the mechanism outlined 
above. The use of nonvasoactive concentrations of a nitric oxide synthetase inhibitor, 
which stimulates glycolysis from exogenous glucose, has shown promise in an animal 
model of ischaemia302. Platelet-activating factor antagonists303 have also been shown 
to be effective in blocking the platelet mediated inflammatory reactions induced by 
ischaemia-reperfusion, by competing for PAF receptor sites. The flavonoids, a group of 
substances which can interact with the cytochrome P-450 system, have recently been 
shown to be useful adjuncts to cadioplegic solutions used for global ischaemia251. The 
effects on the cytochrome system are thought to be related to promoting increased 
enzyme-substrate affinity and improvements to the electron transport mechanism. 
However, flavones are also known to act as antioxidants304 and antiinflamatory 
agents305 
Apart from the increasing use of NMR190 as a method of evaluating the energy status 
of tissues a number of new methods pertaining to global ischaemia are now becoming 
available. Whilst studies of ischaemia/reperfusion have concentrated on myocyte 
injury, damage to the microvasculature is equally important. It is now recognised that 
there is a spectrum of microvascular injury ranging from no reflow in areas of myocyte 
necrosis to more subtle functional changes which result in sub-optimal perfusion289. 
The technique of nuclear track emulsion303 makes it possible to study microvascular 
competence and hence unravel the causal relationship between perfusion and 
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myocyte viability. The toxic effects of cardioplegic solutions on the endothelium 288,307 
have also long been recognised. Whilst this is not a problem during routine surgery, 
since collateral flow removes the solutions within 20 minutes, in the setting of cardiac 
transplantation where contact times are typically between 3-4 hours, this issue 
assumes a new importance. This lends further emphasis to the need for different 
inductive and storage solutions for donor heart preservation. Optical methods for 
tracking peri-operative ischaemia may also be useful such as the recently developed 
technique of laser-induced fluorescence 308 which is both sensitive and specific. 
During the past two years the UK has been divided into 9 regional zones, centred on 
transplant units and based on population density, for the purposes of donor heart 
retrieval. In the first year of this arrangement some 300 hearts were retrieved309 in the 
UK. Following publication of the results of the donor management regime43 described 
in Chapter 3, there has been increasing national (and international) acceptance of this 
approach. This means that we are now uniquely positioned to carry out meaningful 
clinical donor preservation studies on a nationally collaborative basis. 
The strategy which the author proposes thus consists of; using the small working heart 
model to screen the most promising techniques, solutions and pharmaceutical agents 
and selecting the best of these for further study on the perfused human working heart 
model. Experimental human hearts could be obtained from multi-organ donors who 
either fail to meet transplant age criteria or who demonstrate an unacceptable level of 
coronary artery disease. Baseline functional data could be obtained, as described in 
Chapter 3. This provides a means of testing new techniques on human hearts, from 
brain dead donors, as a prelude to clinical trials. Multi-centre, fully randomised clinical 
trials could then be undertaken, with all participants using exactly the same 
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management and assessment protocols. This would ensure adequate numbers of 
patients in an experimental environment which reflects clinical practice. 
8.5 CONCLUSIONS 
Further progress in heart transplantation is donor limited. Efforts to improve the supply, 
and functional quality of donor hearts has met with little success, despite considerable 
effort, over the past 25 years. This dissertation has provided information on current 
clinical practice. A regime for improved donor management has been established and 
shown to be effective. A laboratory based system for screening potentially improved 
preservation methods has been demonstrated and validated. A strategy for combining 
these laboratory studies with clinical trials is advanced. It is suggested that adoption of 
the above approach offers a way forward in what has been a most refractory problem 
within an area of medicine that has, in other respects, been a spectacular success 
story. 
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Donor Heart Preservation Survey 
Dereck Wheeldon, MIBio!, " Linda Sharpies, BSc, ' John Wallwork, FRCS, ' and 
Terence English, FRCS, PRCS' 
A questionnaire requesting information on donor heart preservation technique and outcomes 
during the first 6 months of 1990 was circulated to heart transplantation centers worldwide. 
Seventy-nine usable replies representing 1371 clinical transplant operations were received. 
Twenty-seven percent of the respondents reported using some form of donor pretreatment. 
Most (90%) used single flush cardioplegic induction with the use of eight different types of 
cardioplegic solutions, only 5% of which were oxygenated. Six different types of storage media 
were used, and the coolant was melting ice in 66% of the centers. Storage temperatures 
between 0° C and iC were reported, with 78% of the respondents using 1° C storage. 
Fifty-five percent of the centers used some form of reperfusion modification. No statistically 
significant associations were noted between outcome and technique, apart from the use of 
storage medium in which the use of cardioplegic solution conferred a 2.5 times increase in 
deaths compared with cold saline. The results of this questionnaire provide evidence for the 
diversity of techniques currently used for donor heart preservation, reflecting the lack of any 
one optimal method. J HEART LUNG TRANSPLANT 1992; 11: 986-93. 
In 
contrast to kidney and liver preservation scant 
progress has been made in the field of donor heart 
preservation over the past decade or more. Many 
elegant laboratory studies have been published over 
this time, but their impact on clinical practice has 
been insignificant. This questionnaire was directed 
towards establishing a database against which future 
developments can be compared and in an effort to 
identify methods in current clinical use that may be 
offering advantages and that might be associated 
with poor outcomes. Ninety-two replies were re- 
ceived, of which 79, representing 1371 transplant 
operations, contained information suitable for anal- 
ysis. The questionnaire requested information on 
the following areas: donor pretreatment, cardiople- 
gic induction, transport medium, storage tempera- 
ture and containers, perfusion preservation tech- 
niques, reperfusion, and outcome data. A section at 
the end of the questionnaire asked for comments on 
current technique. A limitation of the analyzed data 
is that only the center, and not the individual 
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patient, data were available for analysis. Donor 
heart availability is the single most limiting factor in 
heart transplantation today and one that is not 
amenable to solution by increased financial resource 
allocation. In addition, the quality of transplanted 
hearts in general is still suboptimal, a fact that is 
reflected by the relatively high mortality from 
primary graft failure and dysfunction. ` The authors 
believe that useful data exist from current clinical 
practice and that the collection and analysis of this 
data in a suitable and useful format is a matter of 
some urgency. 
PATIENTS AND METHODS 
The questionnaire was compiled in June 1989, and 
the original version was circulated to six interna- 
tionally representative transplantation centers for 
comments on content and style. The updated 
version was then circulated to 237 centers, based on 
mailing list information received from the Interna- 
tional Society for Heart and Lung Transplantation 
and the European Society for Organ Transplanta- 
tion. Questionnaires were circulated prospectively 
for data requested for the period January to June 
1990 to alert the centers to the type of data required. 
A reply slip indicating willingness to participate in 
the study was circulated at the same time. In March 
1990 those centers not replying were contacted 
again with the same information. We received 23 
replies indicating either a lack of a transplantation 
center or discontinuation of transplantation activity 
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at that address. Further reminders and telephone calls were made to nonresponding centers in Sep- tember 1990 and again in October 1990. We finally 
received 92 completed questionnaires, of which 79 
were ultimately usable. The remaining 13 were 
rejected because of inadequate information. These 
usable questionnaires represented 1371 transplant 
operations. 
STATISTICAL ANALYSIS 
For descriptive purposes results are expressed as 
numbers and percentages of centers that returned 
questionnaires. The numbers of transplantations these centers represent are given where appropri- 
ate. Continuous measurements are presented as the 
mean and range of the means reported for each 
center. 
When comparing the effects of different preser- 
vation techniques on outcome, the number of deaths 
within 30 days, as a percentage of the number of 
transplantations recorded, was modelled using lo- 
gistic regression and tested with the likelihood ratio 
test. ' 
Logistic regression produces results in terms of 
odds ratios (OR). Given a baseline category to 
compare with a test category, the estimated odds of dying within 30 days if one is within the test category 
compared with the baseline category are expressed 
as an OR; so that 1 represents equal chances and 
more than 1 represents a greater chance of death. The Statistical Package for Social Sciences (SPSS 
Inc., Chicago, I11. ) and EGRET (Statistics and 
Epidemiology Research Corp., Seattle, Wash. ) sta- 
tistical packages were used for analysis. 
RESULTS 
Donor Pretreatment 
Fifteen (19%) responding centers reported using 
some form of pharmacologic pretreatment of the donor. Of these, eight centers (53%) reported the 
use of thyroid hormone (T3/T4), and four centers (27%) used insulin. Altogether nine different treat- 
ment regimes were reported in use, either singly or in combination (Table I). No significant differences 
were noted in 30-day mortality associated with any 
pretreatment regime. 
Cardioplegic Induction 
Seventy-three of the respondents (92%) used single 
flush cold cardioplegic induction, and 69 (87%) of 
these used the technique with the heart in situ. 
Seven respondents (8.9%) reported using multiple 
Donor heart preservation survey 987 
TABLE I Donor pretreatment 
Treatment No. of centers Percentage 
T3/T4 8 55 
Insulin 4 27 
Methylprednisolone 3 20 
Glucose 2 13 
Allopurinol 2 13 
Antidiuretic hormone 2 13 
Vitamin E 2 13 
Mannitol 1 6 
Largactil 1 6 
No clinically significant differences were found with respect to 
30-day mortality. 
Pretreat: odds ratio, 0.7636; 95% confidence bounds. 0.4919 to 
1.185. 
Compared to no pretreatment: p= 0238. 
The use of the following treatment combinations was reported by 
one center in each case: (1) T3/T4, methylprednisolone, allopu- 
rinol, vitamin E; (2) T31T4, insulin, antidiuretic hormone; 
(3) 
T3/P4, methylprednisolone; (4) T3iT4, allopurinol, vitamin E; (5) 
methyiprednisolone, glucose. 
flush techniques, and two (2.5%) reported bench 
perfusion only. A combination of in situ and bench 
perfusion was used by eight of the centers (10%). 
No significant differences were found in 30-day 
mortality associated with the method of induction. 
Cardioplegic Solutions 
Eight types of cardioplegic solutions were used. 
Four of these were standard solutions used by 47 
centers, representing 879 donor hearts (64%). The 
remainder were grouped according to whether they 
were 50% dextrose-based, 
Krebbs/albumin-type 
solutions, Plasmalyte (Baxter Laboratories, Deer- 
field, Ill. )/Krebb's solutions, or blood-based (Figure 
1). Only three centers (4%) reported using oxygen- 
ated solutions. When divided into intravascular and 
extravascular type solutions, 39 centers, represent- 
ing 613 transplantations, reported using intravascu- 
lar solutions with 12 patients (2%) having difficulty 
to wean and 61(10%) 30-day deaths, with one center 
failing to report outcome. 
In the extravascular group 40 centers reported on 
795 transplantations, with 14 (1.8%) having diffi- 
culty with weaning and 71 (9%) 30-day 
deaths, with 
10 centers failing to report outcome. 
No outcome 
differences were noted between individual solutions 
(Table 11). 
Storage Medium 
Use of four major types of storage medium was 
reported; the most common of which was cold 
saline 
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STANF ST. T PLEA BRET DEXT Alb/X PLASMA BLOOD OVERALL 
PATIENTS 191 301 228 184 297 132 103 19 1371 
DEATHS 15 29 15 19 30 13 71 129 
% MORTALITY 8. 10 7 11 r 12 j t0 75i9.41 
SOLUTIONS 
WEIGHTED FOR Tx NUMBERS 
FIGURE 1 Histogram shows the relationship between the percentage of hospital 
mortality (adjusted for transplantation numbers) and the eight major types of cardioplegic 
solutions used. STANF, Stanford solution; ST. T, St Thomas' 1 solution; PLEG, Plegisol; 
BRET, Bretschneider HTK DEXT, dextrose-based (excluding Stanford); Alb/K 
Krebbs-based with albumin; PLASMA, Krebbs-based with Plasmalyte; BLOOD, 
blood-based solutions; T transplantation. 
TABLE II Cardioplegic solutions 
Odds 
ratio* 
95% 
Confidence 
bounds 
Stanfordt 1.570 0.1958-12.59 
St Thomas' It 2.733 0.3514-21.26 
P1egisolt 2.043 2.554 -16.33 Bretschneidert 2.124 0.2683-16.82 
Dextrose base* 1.731 0.2194-13.65 
Krebbs/albumint 2.053 0.2529-16.66 
Plasmalyte/Krebbst 2.864 0.3283 -24.98 Compared to blood based 1.000 p=0.0685 
Intravascular vs extravascular solutions 
Extracellular solutions 1.410 0.9654-2.060 
Compared with intra- 1.000 p=0.074 
vascular solutions 
'Refers to 30-day mortality 
tExtravascular. 
$Intravascular. 
(47%). Nine centers (12%) reported the use of the 
same cardioplegic solution for storage and induc- 
tion. Six centers (8%) reported the use of the 
intracellular Euro-Collins solution for storage. The 
use of cardioplegic solution as a storage medium was 
TABLE III Storage solutions 
Storage medium 
Odds 
ratio 
95% Confidence 
bounds 
Ringer's 1.475 0.7423 -2.930 
Lactated Ringer's 1.652 0.9721-2.808 
Cardioplegia 2.533 1.053-6.093 
Other 2.023 1.262 -3.245 
Compared to saline 1.000 p=0.030 
associated with a 2.5 times (OR, 2.53) increase in 
deaths, compared with cold saline (Table III). 
Coolant and Storage Temperature 
Most respondents (66%) reported using melting ice 
as the coolant. Twenty-seven percent reported using 
iced saline, and a small percentage used an 
ice/alcohol mixture in combination. Only two cen- 
ters reported using a commercial storage device. 
Most centers (73%) reported using 4° C as their 
storage temperature (Figure 2). Only four centers, 
however, reported monitoring this temperature, 
which means that the remainder were actually 
quoting their own estimates of storage temperature 
rather than the actual temperature at which the 
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FIGURE 2 Histogram shows the distribution of storage temperatures reported by the 
responding centers as a percentage of centers. - 
organs were stored. Only one center reported the 
use of a temperature-controlled storage system. 
No statistically different outcomes were associ- 
ated with storage temperature. 
Perfusion Preservation 
One center reported the occasional use of autoper- fusion as a method for donor heart retrieval; another 
reported the use of continuous crystalloid perfusion 
preservation for hearts retrieved from particularly long distances. 
Reperfusion 
Thirty-four centers (55% of those responding to this 
question) reported some type of reperfusion modi- fication, which included secondary blood cardiople- 
gia, pressure control, temperature control, flow 
control, substrate enhancement not associated with 
secondary blood cardioplegia, the use of free radical 
scavengers and osmotic agents, or a combination of 
these (Table IV). No outcome differences were 
associated with reperfusion techniques that could be determined from these data. 
Outcomes 
The mean ischemic time for these data was 151 
minutes, with a mean donor age of 28 years. With 
logistic regression, those centers that stored hearts 
for more than 3 hours had on average a probability 
of 30-day mortality that was one half that of hearts 
stored for less than 2 hours (OR, 0.42). Sixty-four of 
the centers that responded to this question (85.5%) 
reported transplanting all of the hearts retrieved, 
and 71 (95%) reported transplanting at least 90% of 
the hearts retrieved. Nine hundred seventy-five 
(87.4%) of the transplant recipients were weaned 
from bypass without difficulty. One hundred forty- 
nine recipients (17.4%) required additional ino- 
tropes to wean, and a further 230 (26%) required an 
extended cardiopulmonary bypass to wean. Ninety- 
three patients (8.7%) failed to be weaned from 
bypass with these measures, and 52 (5.5%) required 
intraaortic balloon pumping. A further six patients 
(0.7%) required a right ventricular assist device; 
nine (1.0%) required a left ventricular assist device; 
17 (1.7%) required biventricular support, and nine 
(0.9%) required acute retransplantation (Table V). 
In the section that asked for responder's com- 
ments, 49 (69% of responders) reported that they 
were completely satisfied with the technique that 
was currently used in their center. Twenty-two 
centers (31%) reported some degree of dissatisfac- 
tion, however. Of these, 14 centers (64%) expressed 
a desire for longer "safe" preservation times 
(12 to 
24 hours). Four centers (18%) wanted to see the 
pretreatment issue resolved. Two centers 
(9%) 
desired the efficacy of modified reperfusion to 
be 
tested; a further two centers (9%) suggested that a 
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]FIGURE, 3 Relationship of ischernic times to percentage of hospital mortality, adjusted 
for transplant numbers. 
reliable index of function was required for donor 
heart evaluation. Another two centers (9%) sug- 
gested that a reliable method of temperature control 
was required. One center (1%) expressed the view 
that although better preservation methods were 
probably available, keeping the technique simple 
was paramount. One center (1%) made a plea for a 
prospective multi-center randomized trial of the 
most promising techniques identified by this survey. 
DISCUSSION 
Donor organ availability is the most limiting factor 
in the future of thoracic organ transplantation. The 
importance of organ function after implantation 
cannot be overemphasized. Early donor heart fail- 
ure accounts for approximately 26% of the deaths of 
heart transplant recipients. ' Evidence exists that 
some of the problems associated with organ preser- 
vation are related to metabolic changes in the donor, 
consequent on brain death. '--l Novitsky et a!. 6 have 
shown benefits from hormone replacement therapy, 
and recent ongoing studies by our own group show 
similar benefits. This survey showed no advantage, 
however, with respect to 30-day mortality, which was 
the basic outcome measure used throughout the 
survey. 
Careful selection of the donor followed by metic- 
ulous management, effective organ preservation, 
and reperfusion are therefore essential to obtaining 
optimal postimplantation function. Some degree of 
physical size matching is also important. None of 
these is currently well defined, however. Prompted 
by the shortfall in donor organs, several centers have 
reported extension of the "classic" donor criteria 
with respect to age, ischemic time, inotropic sup- 
port, and donor/recipient size matching, "' without 
apparent adverse effects on outcome. Liberalization 
of criteria can, however, produce problems, espe- 
cially if several contraindications are combined. " 
Outcome is also very much related to recipient 
characteristics; the International Society for Heart 
and Lung Transplantation Registry shows that the 
presence of pulmonary hypertension more than 
doubles the posttransplant risk of death, 12 and our 
own risk analysis shows that donor age (increasing) 
and gender recipient mismatches (female into male) 
are associated with higher risk. " 
Many experimental studies have pointed to the 
superiority of one cardioplegic solution over others, 
most notably the proponents of the University of 
Wisconsin (UW) solution14-u and Euro-Collins so- 
lution, " together with the differences between 
extracellular and intracellular formulations. 
" Clin- 
ical evidence of any significant difference is lacking, 
however, in these and in this survey data, except for 
an apparent trend of improved results with 
intra- 
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TABLE IV Number of centers reporting reperfusion modifications` 
Number of centers 
Pressure 
controlled 
Flow 
controlled 
Temperature 
controlled 
Enhanced 
substrate 
Secondary blood Free radical 
cardioplegia scavengers 
Osmotic 
agents 
6 6 - - - -- - 
2 - 2 2 
- - 2 - -- - 3 - - - - 3- - 
1 1 1 - - -- 2 2 
- 2 - -- - 
1 1 - - I -- - 2 2 - - - 2 I 1 - - - -1 - 2 2 - 2 - 2- - 1 1 1 - - 1- - 1 1 1 1 - 1- - 
1 1 1 - - -- 1 1 1 1 - - 1- 
1 
1 1 - 1 - 1- 
I 
1 - 1 I - -- - 
2 - 2 2 - 2- - 
1 - 1 1 1 1- - 
1 -" - 1- - 
1- - 
Total no. of centers 20 Ti 13 2 15 1 5 
'Thirty-four centers (55%) are included. Modified: odds ratio, 1.178; 95% confidence bounds, 0.785 to 1.767. Compared to no modifications: 95% confidence bound, 1.000. With respect to 30-day mortality: p=0.433. 
cellular solutions (Table II). Likewise, various 
perfusion preservation systems have been investi- 
gated experimentally, but only autoperfusion18 and 
hypothermic crystalloid perfusion19 have had any 
notable, but brief, clinical application. Although 
perfusion preservation techniques are likely to offer 
the prospect of more extended preservation times, 
the systems need to be much simpler and more 
reliable than those currently described in the 
literature. 
The optimum storage solution has also been 
debated in recent literature. Although storage in 
intracellular solutions might seem to be more logical, experimental results have not been con- 
vincing. ' Data from this survey suggest that storage in cold saline is superior to storage in Ringers 
solution, cardioplegic solution, or a range of alter- 
natives. 
The optimal storage temperature is also contro- 
versial. "" Most centers use melting ice as the 
coolant and assume that storage temperature is 4° C. 
Much lower temperatures could possibly be ob- 
tained with ice, however. " Direct thermal injur' is 
possible, and biologic integrity may be seriously 
TABLE V Outcomes and mortality 
outcomes* 
N/No. of 
transplants i (%) 
30-Day 
mortality (%) 
Weaned without diffi- 975/1115 (87.4) 46(4.7) 
culty 
Additional inotropes 149/854 (17.4) 28 (18.8) 
Prolonged bypass >I hr 230/884 (26.0) 28 (12.2) 
Prolonged bypass >2 hrs 70/653 (10.7) 7 (10) 
IABP 52/948 (5.5) 8 (15.4) 
RVAD 6/898 (0.7) 4 (66.7) 
LVAD 9/907 (1.0) 3 (33.3) 
BiVAD 17/1030 (1.7) 11 (64.7) 
Acute retransplantations 9/981 (0.9) 5(55.6) 
L4BP, Intraaortic balloon pump; RVAD, right ventricular assist 
device; LV . 
D, left ventricular assist device; BiVAD, biventricular 
assist device. 
`These groups were not mutually exclusive. 
tTransplant numbers refer to patients' data from respondents to 
this question. 
compromised. " Only one center reported the use of 
a temperature-controlled transport medium. 
' 
Modified reperfusion techniques have gained 
in 
popularity for routine open heart surgery over the 
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past few years, 26 and applying these techniques to 
hearts subjected to much longer ischemic times 
would seem logical. A proportion of the respondents 
(55% representing 70% of transplant patients) did 
report some form of reperfusion modification with 
most using secondary blood cardioplegia. No signif- 
icant benefit could be detected from the data 
provided, however. 
Total global ischemic time did not correlate with 
outcome as has been shown in the Registry figures 
(Figure 3). Conversely a trend was towards better 
outcome with increasing ischemic times. The reason 
for this is uncertain but may reflect a preponderance 
of more active centers as respondents to this survey. The superior (compared with the Registry) overall hospital mortality figure of 9% in this survey may 
reflect the same bias. In addition, individual isch- 
emic times were not available, and the mean for each 
center may possibly mask effects of increasing 
isctiemia. 
The data did reveal some waste of donor hearts, 
possibly reflecting a more liberal attitude towards 
selection in an effort to increase the numbers. Some 
of the questionnaires were completed by nonmedi- 
cal staff, and the degree of satisfaction expressed 
with current preservation methods may not be a true 
overall reflection of current clinical opinion. 
CONCLUSION 
This survey provides some basic information on 
current clinical practice for donor heart preserva- 
tion. A surprisingly diverse number of techniques 
are in use, possibly reflecting the lack of any one 
good reliable method. The only clear difference to 
emerge from this survey was the influence of storage 
medium. Other influential factors may exist that 
could not be discerned from this type of analysis, 
which used only center data presented as the mean. 
To have more subtle outcome measures than 30-day 
mortality, which is affected by many other factors, is 
also an important need. The authors suggest that 
much of the data requested for this survey could be 
routinely collected as part of the Registry data on an 
individual patient basis. Clearly from the scant 
progress that has been made in donor heart pres- 
ervation, despite considerable efforts by many work- 
ers, accurate models for assessing this are not 
currently available. Possibly a more detailed and 
careful analysis of prospective clinical data may be a 
more productive method of advancing our knowl- 
edge of organ preservation than a reliance on animal 
experimentation, which has yielded comparatively 
little over the past 20 years. 
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TABLE N Number of centers reporting reperfusion modifications` 
Number of centers 
Pressure 
controlled 
Flow 
controlled 
Temperature 
controlled 
Enhanced Secondary blood 
substrate cardioplegia 
Free radical Osmotic 
scavengers agents 
6 6 - - -- -- 2 
- 2 - -- -- 2 
_ - 2 -- -- 3 - - - -3 -- 2 
- - - -- -2 1 1 1 - -- -- 2 2 - 2 -- -- 1 1 - - 1- -- 2 2 - - -2 -- 1 1 - - -- 
1 
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`Thirty-four centers (55%) are included. Modified: odds ratio, 1.178; 95% confidence bounds, 0.785 to 1.767. Compared to no modifications: 95% confidence bound, 1.000. With respect to 30-day mortality: p=0.433. 
cellular solutions (Table 11). Likewise, various 
perfusion preservation systems have been investi- 
gated experimentally, but only autoperfusion1e and 
hypothermic crystalloid perfusion" have had any 
notable, but brief, clinical application. Although 
Perfusion preservation techniques are likely to offer 
the prospect of more extended preservation times, 
the systems need to be much simpler and more 
reliable than those currently described in the literature. 
The optimum storage solution has also been debated in recent literature. Although storage in 
intracellular solutions might seem to be more 
logical, experimental results have not been con- 
vincing. 20 Data from this survey suggest that storage 
in cold saline is superior to storage in Ringers 
solution, cardioplegic solution, or a range of alter- 
natives. 
The optimal storage temperature is also contro- 
versiaL3O. 21 Most centers use melting ice as the 
coolant and assume that storage temperature is 4°C. Much lower temperatures could possibly be ob- 
tained with ice, however= Direct thermal injury= is 
Possible, and biologic integrity may be seriously 
TABLE V Outcomes and mortality 
Outcomes* 
N/No. of 
tmnsplantst (%) 
30-Day 
mortality (%) 
Weaned without diffi- 975/1115 (87.4) 46(4.7) 
culty 
Additional inotropes 149/854 (17.4) 28 (18.8) 
Prolonged bypass >1 hr 230/884 (26.0) 28 (12.2) 
Prolonged bypass >2 hrs 70/653 (10.7) 7 (10) 
IABP 52/948 (5.5) 8 (15.4) 
RVAD 6/898 (0.7) 4 (66.7) 
LVAD 9/907 (1.0) 3(33.3) 
BiVAD 17/1030 (1.7) 11 (64.7) 
Acute re transplantations 9/981 (0.9) 5 (55.6) 
L4BP, Intraaortic balloon pump; RVAD, right ventricular assist 
device; LVAD, left ventricular assist device; BiVAD, biventricular 
assist device. 
'These groups were not mutually exclusive. 
tTransplant numbers refer to patients' data from respondents 
to 
this question. 
compromised. " Only one center reported the use of 
a temperature-controlled transport medium. 
' 
Modified reperfusion techniques have gained 
in 
popularity for routine open heart surgery over 
the 
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past few years, =6 and applying these techniques to hearts subjected to much longer ischemic times 
would seem logical. A proportion of the respondents (55% representing 70% of transplant patients) did 
report some form of reperfusion modification with 
most using secondary blood cardioplegia. No signif- icant benefit could be detected from the data 
provided, however. 
Total global ischemic time did not correlate with 
outcome as has been shown in the Registry figures (Figure 3). Conversely a trend was towards better 
outcome with increasing ischemic times. The reason 
for this is uncertain but may reflect a preponderance 
of more active centers as respondents to this survey. The superior (compared with the Registry) overall 
hospital mortality figure of 9% in this survey may 
reflect the same bias. In addition, individual isch- 
emic times were not available, and the mean for each 
center may possibly mask effects of increasing 
ischemia. 
The data did reveal some waste of donor hearts, 
possibly reflecting a more liberal attitude towards 
selection in an effort to increase the numbers. Some 
of the questionnaires were completed by nonmedi- 
cal staff, and the degree of satisfaction expressed 
with current preservation methods may not be a true 
overall reflection of current clinical opinion. 
CONCLUSION 
This survey provides some basic information on 
current clinical practice for donor heart preserva- 
tion. A surprisingly diverse number of techniques 
are in use, possibly reflecting the lack of any one 
good reliable method. The only clear difference to 
emerge from this survey was the influence of storage 
medium. Other influential factors may exist that 
could not be discerned from this type of analysis, 
which used only center data presented as the mean. To have more subtle outcome measures than 30-day 
mortality, which is affected by many other factors, is 
also an important need. The authors suggest that 
much of the data requested for this survey could be 
routinely collected as part of the Registry data on an 
individual patient basis. Clearly from the scant 
progress that has been made in donor heart pres- 
ervation, despite considerable efforts by many work- 
ers, accurate models for assessing this are not 
currently available. Possibly a more detailed and 
careful analysis of prospective clinical data may be a 
more productive method of advancing our knowl- 
edge of organ preservation than a reliance on animal 
experimentation, which has yielded comparatively 
little over the past 20 years. 
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Multi-organ transplantation: donor management 
Janet A. Pickett, Dereck Wheeldon*, and Arno Oduro 
Departments of Anaesthesia and 'Transplantation, Papworth Hospital, Cambridge, UK 
Many studies suggest that only 30% of potential transplant donors will donate 
organs. Of these, only 70% will become multiple organ donors. On the 
other hand, up to 40% of patients on transplant waiting lists die before 
transplantation. Demand clearly outstrips supply. Of the interventions to 
increase the supply of donor organs, optimal management of the donor patient 
is receiving increasing interest. 
Current Opinion in Anaesthesiology 1994,7: 80-83 
Introduction 
The majority of potential organ donors have sustained irreversible cerebral injury as a result of trauma or 
spontaneous intracranial haemorrhage. Whatever the 
mechanism of injury as soon as brainstem death has been confirmed, there should be an immediate change in the emphasis of management from that of minimiz- ing the neurological insult to that of maximizing organ function. This is supported by the fact that failure to 
provide adequate physiological support to potential donors accounts for at least 25% of lost donor organs (1]. 
The adverse effects of brain death on the heart were demonstrated as early as 1954 [21, and more recent 
studies in both experimental animals (3,4] and clinical donors [5,6] have suggested that brain death has major histopathological and functional effects. Consequently, 
without specific intervention, circulatory collapse will 
usually take place within 72 h of brain death [7]. It is therefore essential that a thorough understanding of the physiological mechanisms involved is attained by those managing the potential donor, if the best use of 
a scarce resource is to be made. Anaesthetists and in- 
tensivists, with their knowledge of cardiovascular and 
respiratory physiology, are well qualified to make a sig- 
nificant contribution to the care of the donor patient. 
This review addresses the main problems which arise in the potential donor and the management strategies to deal with them. 
Management of the donor 
Cardiovascular dysfunction 
Hypotension 
This is the most commonly occurring complication in 
organ donors (8). At the time of brain death, many 
donors are already volume-depleted from previous 
therapeutic interventions used to treat raised intra- 
cranial pressure, such as fluid restriction, or use of the 
osmotic diuretic, mannitol. 
Brainstem death itself leads to cardiovascular instabil- 
ity and hypotension of multifactorial origin. Disturbed 
central regulatory mechanisms cause a loss of vasomo- 
tor tone and result in peripheral vasodilatation. Usually, 
there is an accompanying impairment of myocardial 
function. This is likely to be of similar aetiology to that 
of the catecholamine-induced cardiomyopathy of cere- 
brovascular accidents (6]. Indeed, recently it has been 
suggested that the more acute and the greater the rise 
in intracranial pressure prior to brain death, the higher 
is the catecholamine release, and the more severe is 
the resulting impairment of myocardial function [9""]. 
Impaired myocardial performance owing to hyposia is 
also relatively common, in our experience, and gives 
rise to predominantly right heart failure. Deficiencies of 
plasma hormones may also be implicated in the myo- 
cardial dysfunction and hypotension. Novitzky sug- 
gested that low tri-lodothyronine levels led to defec- 
tive aerobic metabolism and a reduction of myocardial 
energy stores [101. Low levels of anti-diuretic hormone 
(ADH) and insulin may result in the development of 
diabetes insipidus and hyperglycaemia, respectively, 
The ensuing large urinary losses, and electrolyte im- 
balances may further compound the pre-existing low 
arterial pressures. 
Comprehensive invasive haemodynamic monitoring, 
including the use of a pulmonary artery flotation 
catheter (PAFC), is essential in making objective meas- 
urements and optimising management [111. Preload 
should be kept as low as possible, consistent with 
an adequate arterial pressure and cardiac output. 
The choice of replacement fluid remains controver- 
sial, but a regime comprising of 4.3% dextrose/0.25% 
saline + 20 nub[ potassium to replace urinary losses, 
packed cells to maintain a haematocrit level at 
Abbreviations 
ADH-anti-diuretic hormone; PAFC-pulmonary artery flotation catheter. 
© Current Science Ltd ISBN 1-85922-133-5 ISSN 0952-7907 
Multi-organ transplantation: donor organ management Pickett, Wheeldon and Oduro 81 
30%, and adjustment of preload with colloid works Well [121. The afterload should be maintained be- tween 800-1200dynes/s/cm-5 
with a combination of adrenaline and an ADH (arginine vasopressin). The two drugs when combined are synergistic in their effect and thus only minimal amounts of each are needed to maintain the afterload. In any event, doses of adrenaline and ADH should not exceed 0.5 mg/h and 1-2 U/h, respectively. Hypertension should be treated with sodium nitroprusside. If the minimum haemo- dynamic criteria cannot he maintained with preloads <12 mmHg, then the inotrope of choice is dopamine because of the loss of sympathetic tone in the brain dead patient. Inotrope dependency at >10JL /kg/min makes cardiac donation less likely, without more ag- gressive intervention. The minimum criteria for cardiac transplantation are as follows: 
ýl) mean arterial pressure should exceed 60 mmHg and, 
(2) central venous pressure or pulmonary capillary 
wedge pressure should not exceed 12 mmHg 
and, 
(3) left ventricular stroke work index should exceed 15 g/m with, (4) an inotrope dosage of less than 5 µg/kg/min. 
Myocardial dysfunction 
Patients with cardiac disease are obviously unsuitable for cardiac donation and may require more detailed management including a full clinical history and ex- amination in order to yield other transplantable or- gans. Intracranial damage leads to frequent abnormal electrocardiographic changes of a pseudo-infarct type 1131, the only serious finding being that of Q waves. Hypothermia leads to bradycardia and j waves which are of no pathological consequence but may require treatment with an isoprenaline infusion or transvenous pacing. Atropine resistance is common [141. Other dys- rhythmias are usually due to electrolyte imbalances. If available, echocardiography may be useful in those cases where serious doubts exist. Paradoxical septal `Fall motion is a common finding but has no neg- ative prognostic overtones. In older donors, cardiac catheterization and coronary angiography may be justi- led. Ultimately, most cardiac surgeons believe that the most reliable assessment is by direct inspection of the organ at the time of procurement. However, aborting the procedure at this stage carries considerable logistic and financial penalties. Cardiac arrest is not a con- tradindication to cardiac donation, provided that re- suscitation results in subsequent satisfactory function 1151. 
Respiratory dysfunction 
pneumonia, 
aspiration, pneumothoraces, pulmonary oedema and pulmonary collapse commonly occur in Potential donors, and may all contribute to a deteri- oration in respiratory function with subsequent hypo- xaemia. The routine respiratory care of the intensive therapy unit, including chest physiotherapy, should 
continue following brainstem death to avoid these 
problems. Obtaining an early sputum sample for bac- 
teriological assessment and culture is a useful aid to 
decision-making with respect to lung donation. Fluid 
administration is guided by PAFC-filling pressures, 
and the lungs are ventilated with large tidal volumes 
(15 ml/kg) to avoid pulmonary atelectasis. Positive 
end-expiratory pressure may also be used, although 
levels above 7.5 crH, O are best avoided because of 
the adverse effect on cardiac output and increased risk 
of pulmonary barotrauma 116.1. 
Endocrine dysfunction 
Impaired hormone release has already been alluded 
to above. However, the results of hormone replace- 
ment therapy reported by Novitzky et a!. [101 have 
not been universally reproduced by others (171, lead- 
ing to some controversy as to the efficacy of such 
treatments. Howlett et a!. (181 reported posterior pi- 
tuitary dysfunction to be common (77%) whilst pan- 
hypothyroidism was much less consistent. Conversion 
of thyroxine to reversed tri-iodothyronine seems to 
be potentiated by the sympathetic storm which ac- 
companies brain death, and there is also evidence 
that tri-iodothyronine receptor density declines in as- 
sociation with reduced intracellular tri-iodothyronine 
[191. Thyroid function in the donor is thought to be 
more akin to the sick euthyroid syndrome which, al- 
though not usually treated in normal patients, may 
require intervention in unstable donors for the rea- 
sons mentioned above [201. The cardiovascular actions 
of tr-iodothyronine have recently been reviewed [21.1, 
and the importance of the extranuclear effects of the 
hormone on myocardial function highlighted. 
Although ADH is not crucial to the maintenance of vas- 
cular tone in non-brain dead patients, the absence of 
vasomotor impulses in brain death would seem to re- 
sult in a dependency on ADH which has a synergistic 
action with adrenaline [7]. 
Following a number of pilot studies, we have devel- 
oped the regime outlined in Table 1, and have shown 
that this has a marked effect on donors exhibiting 
poor or borderline function, whereas donors with good 
function show little or no benefit (221. The administra- 
tion by continuous infusion is critical to the efficacy of 
the technique. 
In a small proportion of donors, the downward spi- 
ral of decreasing cardiac output, hypoxia, 
hypother- 
mia and acidosis can only be broken by mechanical 
intervention. We have used a modified type of car- 
diopulmonary support which allows the heart to be 
unloaded, the circulation to be fully supported, and 
full 
oxygenation and the restoration of normothermia to 
be 
achieved (23'1. The equipment is easily transportable 
and uncomplicated to set up and operate. 
Hypothermia 
Following brain death, there is a loss of hypothalamic 
temperature control, effectively rendering the 
donor 
poikilothermic (24]. Core temperature can only 
he 
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Table 1. Hormone replacement therapy 
I 
Dose 
7ri-iodothyronine Bolus; 41Lg 
Infusion; 3gg/h 
'DH (Argipressin) 
Bolus: 1U 
Infusion; 1.5 U/h 
Insulin 
Infusion to maintain normal blood 
sugar (minimum I U/h) 
Adrenaline tnrusionß-p. 5 µg/h, depending 
on arterioad 
Hydrocortisone Bolus; 5AgAg 
maintained above 35C by the use of active rewarming 
systems, warmed infusion fluids, warmed and humid- ified inspired gases and warm ambient temperatures. 
Haematological dysfunction 
Clotting abnormalities are known to occur in donor pa- 
tients and their severity may relate to the degree of ini- 
tial brain destruction [251. Management involves trans- fusion of red blood cells, clotting factors and platelets, 
and the maintenance of normal body temperature. 
Management of the donor operation 
During the donor operation, multiple organs are usu- 
ally removed for transplantation. Several medical teams 
are involved and close co-operation is required. More detailed descriptions of the surgical technique can be 
read elsewhere (26,271 and the following discussion 
will concentrate on the points most relevant to the 
anaesthetist. 
Management of the donor during the operative proce- dure is a continuation of the care commenced at the 
time of diagnosis of brain death. The principal aim re- 
mains that of good perfusion and oxygenation of trans- 
piantable organs. To achieve this, close monitoring of 
the donor is still required. Direct arterial pressure mon- itoring and the use of a PAFC must continue. The ar- 
terial cannula should be sited in the left radial artery 
and the PAFC in the right internal jugular vein, as 
the right sub-clavian artery and the innorninate vein 
are ligated early in the operative procedure. Further 
essential monitoring consists of electrocardiography, 
pulse oximetry, end-tidal carbon dioxide and urine out- 
put. Measurement of core temperature is important, as 
are regular checks on arterial blood gases, serum elec- 
trolytes and glucose, and haemoglobin levels. 
The donor operation is a major procedure which may 
take as long as 6 h. Considerable fluid losses usually 
occur. Large bore cannulae should be in-situ, and 
Pressure infuser bags should be readily available for 
the rapid administration of replacement fluid. Ideally, 
4 units of cross-matched blood should be available For 
the start of the procedure. The haemoglobin level is 
maintained at about 10 g/dl to preserve tissue oxygen 
delivery. 
Anaesthesia, by definition, is not required but pres- 
sor responses to stimuli and muscular contractions 
may still be expected. These probably involve intact 
spinal reflex arcs 1281. The donor is therefore paralysed, 
and sodium nitroprusside may be required to manage 
transient hypertension. Blood pressure is usually labile, 
partly as a result of the loss of vasomotor control but 
also because of surgical accidental occlusion of the in- 
ferior vena cava and intermittent direct stimulation of 
the adrenal glands. Ventilation is maintained with oxy- 
gen and air, or with oxygen and nitrous oxide if medi- 
cal air is unavailable. Normally the fraction of inspired 
oxygen should be kept at a level which is required to 
maintain an arterial POS of about 15 kPa. The arterial 
PCO2 should be kept between 4.8 and 5.9kPa. The 
surgical procedure involves initial mobilization of the 
intra-abdominal organs. Once completed, the donor is 
heparinized with a dose of 3 mg/kg of heparin, prior 
to cannulation of major vessels. The PAFC should be 
withdrawn before the superior vena Cava is ligated. It 
is important that the time of aortic cross-clamping is 
noted as this marks the beginning of the ischaemic 
period for the transplantable organs (291. Two major 
methods of heart-lung preservation are in common 
use. The first involves placing the donor on full car- 
diopulmonary bypass with core cooling to 12-15"C, 
followed by exsanguination and removal of all organs. 
The second involves the use of a pulmoplegia solution 
administered directly into the pulmonary artery, with 
or without a prostaglandin infusion 1301. There is some 
controversy as to the ideal gas composition for lung 
inflation, and whether or not to inflate at all, but most 
groups prefer inflating with room air to about 80% to- 
tal lung capacity, having initially checked that all lobes 
have fully expanded. 
In multi-organ retrieval the thoracic organs are re- 
moved first (en bloc) following simultaneous infusion 
of preservation fluids to the thoracic and splanchnic or- 
gans. If separate heart and lung transplantation is to 
take place, division is accomplished on the bench. 
In combined heart/lung/liver transplantation the en- 
tire block is removed without division of the inferior 
vena cava. The liver, pancreas and kidneys (increas- 
ingly en bloc) are removed next and further dissection 
takes place on the bench. 
In the UK, there is now a move to organise organ re- 
trieval by coordinated regional multi-organ retrieval 
teams (Zones), which will do much to minimize the 
inconvenience to the donor hospital and make for a 
more efficient system. 
Conclusion 
Transplantation has become the treatment of choice for 
selected patients with end organ failure. The short- 
age of suitable donors has led to waiting list mortal- 
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ities of up to 40%. Multiple organ donors are clearly a very precious resource and their management requires considerable effort from all those involved. To this 
end, comprehensive invasive haemodynamic monitor- ing, including a PAFC, is essential in making objective decisions and optimizing management. For the sake of the recipients, the best standard of care possible should be provided for donors. 
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DONOR MANAGEMENT AND ORGAN DISTRIBUTION 
Transforming the "Unacceptable" 
Donor: Outcomes from the Adoption 
of a Standardized Donor 
Management Technique 
D. R. Wheeldon, MIBiol, C. D. O. Potter, BA, A. Oduro, MB, BS, MRCP, FRCA, 
J. Wallwork, BSc, MBChB, FRCS(Ed), MA, and S. R. Large, MD, FRCS 
Background: Donor management remains one of the most neglected areas of transplantation. 
A comprehensive donor management regimen has been developed. The results of the 
application of this strategy form the basis of this report. 
Methods: Full hemodynamic data were collected from 150 multiorgan donors between 
October 1990 and August 1993. The data were collected at the time of donor team arrival, 
after insertion of a pulmonary artery floatation catheter and immediately before cardiac 
excision. 
Results: Fifty-two donors (35%) fell well outside our minimum acceptance criteria on arrival. 
Twenty-one of fifty-two had a mean arterial pressure less than 55 mm Hg (mean 47 mm Hg) 
despite inotropic support in most cases; 10 of 52 had a central venous pressure greater than 15 
mm Hg (mean 18.0 mm Hg); 2 of 52 had a high inotrope requirement greater than 20 
µg/kg/min (mean 25 µg/kg/min). After the insertion of a pulmonary artery floatation catheter, 
an additional 13 of 52 donors were found to have a pulmonary capillary wedge pressure 
greater than 15 mm Hg (mean 19.8 mm Hg), and the final 6 of 52 had a low left ventricular 
stroke work index, less than 15 gm (mean 12.8 gm). After optimal management, including 
hormone replacement 44 of 52 donors yielded transplantable organs (29 hearts, 15 heart and 
lung blocks). Thirty-seven of forty-four patients (84%) were alive and well from 13 to 48 
months after transplantation. There were five early deaths (11%) caused by infection (heart), 
adult respiratory distress syndrome (heart), arrhythmia (heart), cerebrovascular event (heart 
and lung), and infection (heart, lung, and liver). Two late deaths (5%) occurred as a result of 
tamponade (3 months, heart) and infection (14 months, heart and lung). Eight of fifty-two 
organs were still unsuitable for transplantation after optimum management during the 
splanchnic dissection as a result of inotrope dependency (n = 4), left ventricular hypertrophy 
(n = 2), and coronary artery disease (n = 2). 
Conclusions: The data indicate that, of the organs which initially fall outside our transplant 
acceptance criteria, 92% are capable of functional resuscitation. Conversely, superficial 
assessment may not show compromised function. Optimizing cardiovascular performance also 
has important implications for the viability of all transplantable organs. This aggressive 
approach to donor management has resulted in the transplantation of 44 donor hearts that 
may otherwise have been turned down or inappropriately managed. J HEART LUNG 
TRANSPLANT 1995; 14: 734-42. 
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TABLE I Donor physiologic 
resuscitation regimen 
Invasive monitoring 
Bolus steroids 
Methylprednisolone 15 mg/kg 
Insulin (+ dextrose) 
Aim for normoglycemia 
Minimum 1 U/hr 
Arginine vasopressin 
1U bolus 
1.5 U/hr 
Tri-iodothyronine 
4 gg bolus 
3 µg/hr 
The 
last two decades have seen tremendous 
advances in the field of heart transplantation. Before 1980 less than 350 operations were per- formed in 17 centers with an operative mortality of 
more than 20% and an overall 1-year survival of 62%. Last year, more than 2500 operations were 
performed in* more than 240 centers with an 
operative mortality of 9.8% and an overall 1-year 
survival of 78%, despite the inclusion of higher risk 
recipients every year. ' 
Although this impressive record has been 
achieved by significant advances in patient manage- 
tnent, and, in particular, improved immunotherapy, 
further development is now universally limited by 
the supply of donor organs, which has plateaued 
over the last few years. The prospect for increasing 
the referral rate is limited to approximately 15%, 
and the overall numbers of potential donors is fall- 
ing, particularly in relation to road traffic accidents. 2 
The major opportunity for improving both the 
numbers and the quality of donor hearts lies with the 
most neglected area of transplant medicine, that of donor management. Early graft failure accounts for 
approximately 26% of acute deaths in heart trans- 
plant recipients. ' In addition there is undoubtedly a 
significant number of patients who are compromised by poor graft function related to inadequate donor 
management or preservation. 
Following literature reports of the metabolic 
consequences of brain death in experimental ani- 
mals3.4 and later reports of clinical studies, 5 we 
carried out a number of clinical pilot studies of the 
efficacy of hormone replacement therapy (HRT) in brain dead donors and showed that donors with 
compromised cardiac function showed improved function in response to HRT, compared with those 
Wheeldon et al. 735 
TABLE II Donor heart acceptance 
guidelines 
Mean arterial pressure >60 mm Hg 
Central venous pressure < 12 mm Hg 
Pulmonary capillary < 12 mm Hg 
wedge pressure 
Left ventricular stroke > 15 gm 
work index 
Inotropes <5i. g/kg/min 
These guidelines are loosely based on the entry criteria for 
mechanically assisted circulation and are used as an approxi- 
mate guide for donor heart acceptance. The "marginal" donors 
referred to in this publication all fell well outside these guide- 
lines. 
donors receiving optimal management without 
HRT. We were able to confirm that brain death is 
accompanied by significant reductions in serum free 
thyroxine, cortisol, arginine vasopressin, and insulin 
and eventually established a regimen which involves 
bolus doses of these hormones followed by continu- 
ous infusions' (Table I). We were further able to 
demonstrate that this approach can result in the 
restoration of normal cardiovascular function in the 
majority of organ donors with previously inadequate 
function. ' 
Prompted by the increasing shortfall of donor 
organs, several centers have reported extensions to 
the classic donor criteria' with respect to age, 9 
ischemic time, " inotropic support, " adverse hemo- 
dynamics, 'Z size mismatching, " cause of death, 14-16 
and infection. " Although some of these experi- 
ments have been successful in individual cases, some 
have not, especially when more than one contrain- 
dication is present. '' 
Having taken a considerable interest in this prob- 
lem, it has become clear that comprehensive hemo- 
dynamic monitoring is essential to making an objec- 
tive assessment of function and for guiding optimum 
management. 19 Failure to provide adequate physi- 
ologic support to potential donors accounts for at 
least 25% of lost donor organs. 20'21 Adopting an 
aggressive approach to donor management 
has al- 
lowed us to increase our donor retrieval rate by 
approximately 30% without prejudicing outcome. 
We suggest that this provides one of the few remain- 
ing methods for safely increasing the 
donor pool. 
PATIENTS AND METHODS 
Between October 1990 and October 1993,150 
multiorgan donors were fully instrumented during 
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FIGURE 1 Mean and individual measurements of arterial pressure, central venous 
pressure (CVP), and inotropic requirements of the 33 donors unacceptable on initial 
inspection compared with the 98 initially suitable donors. Broken lines indicate organs not 
transplanted. Tx, Transplantation. 
the retrieval operation. This involved transport to 
the donor hospital of our own compact monitoring 
ýquipment and the institution of invasive arterial, 
nternal jugular venous, and Swan-Ganz pulmonary 
Lrtery catheterization (Swan-Ganz catheter; Baxter iealthcare Corporation, Edwards Div., Santa Ana, 
Calif. ) as soon as the donor arrived in the operating 
room. Ventilation, fluid replacement, and electro- 
lytes were optimized, and the first set of measure- 
ments were undertaken while the cardiac surgeon 
performed a median sternotomy and visually exam- 
ined the thoracic organs. During this inspection a 
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TABLE III Hemodynamic profiles of the 52 initially unacceptable donors 
Wheeldon et al. 737 
Patient No. AoP RAP Inotropes PCWP LVSWI Not used Deaths 
1 52 8 0 10 12.8 CVA day 16 
2 51 6 0 9 15.5 
3 53 5 0 9 18.7 
4 52 1 0 4 15.1 
5 53 1 5 4 36.7 
6 35 6 5 7 13.8 
7 39 6 0 7 13.9 
8 48 6 2.5 10 19.6 LVH 
9 50 15 5 17 6.1 Infection day 16 
10 50 2 0 5 6.5 
11 42 5 14 3 14.9 
12 40 0 4 2 20.1 
13 44 0 12 7 16.2 
14 49 3 5 1 21.2 
15 54 12 2.5 8 18.9 
16 51 4 3.0 8 35.6 
17 53 9 5 11 18.9 
18 46 1 5.5 2 18.9 
19 48 0 0 3 33.6 
20 50 4 2.5 6 22.5 
21 26 1 15 7 7.9 
22 85 15 0 15 50.0 
23 60 16 8 19 22.1 Tamponade 3 mo 
24 81 17 6.5 20 39.4 
25 62 18 5 23 15.6 Infection 14 mo 
26 114 16 0 20 53.4 
27 60 25 5 11 19.0 
28 79 19 8 19 27.5 
29 62 20 6 20 28.9 
30 65 16 16 9 18.9 
31 112 18 4 24 49.2 
32 56 9 20 7 27.2 Inotrope dep. 
33 60 1 30 11 67.1 
34 55 7 0 22 20.2 
35 140 11 0 17 50.3 
36 71 13 6 20 16.3 LVH 
37 80 13 0 19 34.8 
38 117 9 0 17 96.6 
39 86 10 0 18 24.3 
40 92 10 5 23 42.3 ARDS day 1 
41 65 9 10 24 26.1 
42 76 11 12 17 26.3 Inotrope dep. 
43 75 10 6 16 19.5 CAD 
44 66 14 7 22 38.4 CAD 
45 81 8 2.5 25 15.7 Inotrope dep. 
46 84 6 0 18 21.5 
47 63 7 20 20 10.1 Arryhthmia 12 days 
48 62 6 3 13 14.4 
49 65 10 2.5 11 11.0 
50 72 10 0 11 13.5 Inotrope dep. 
51 78 3 2.5 6 13.3 
52 62 12 0 14 14.9 
Donors were in unacceptable group if they fell well outside acceptance guidelines (Table II) in the order that measurement 
data became 
available - initially without Swan-Ganz catheter data (Baxter Health Care) and later including comprehensive 
data. Cut-off points were: 
mean arterial pressure <55 mm Hg, central venous pressure (CVP) and pulmonary capillary wedge pressure (PCWP) > 15 
mm Hg, 
inotropes > 20 i. g/kg/min, left ventricular stroke work index (LVSWI) < 15 gm. Primary categorization points are highlighted. AoP, Aortic 
pressure; RAP, right atrial pressure; CVA, cerebrovascular accident; LVH, left ventricular hypertrophy; dep., dependent; ARDS, acute 
respiratory distress syndrome; CAD, coronary artery disease. 
k 
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FIGURE 2 Mean and individual measurements of pulmonary capillary wedge pressure 
(PCWP) and left ventricular stroke work index (LVSWI) of the further 19 unacceptable 
donors after full monitoring compared with the 98 initially suitable donors. Broken lines 
indicate organs not transplanted. Tx, Transplantation. 
TABLE N Outcomes for the 98 initially 
suitable donors 
Donors accepted 
After inspection 98/150 
Transplanted 89/98 
Not transplanted 9/98 
Coronary artery disease 4/9 
Inotrope dependent 3/9 
Right heart failure 1/9 
Lignocaine poisoning 1/9 
comprehensive set of measurements were per- 
formed and HRT was commenced. During the 
splanchnic dissection further sets of measurements 
were taken, as a guide to management. Once the 
splanchnic dissection was completed, and, with the 
cardiac surgeon back at the table, the final set of 
measurements were taken as a basis for donor organ 
acceptance. A detailed description of our donor 
management regimen has been published else- 
where. 19 
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FIGURE 3 Changes in inotropic requirements by group according to functional 
impairment compared with the 98 initially suitable donors, 63% of the entire group 
required a mean inotropic dose of 6.8 µg/kg/min which reduced to 45% requiring a mean 
dose of 4.8 µg/kg/min by the end of the procedure. CVP, Central venous pressure; AoP, 
aortic pressure; PCWP, pulmonary capillary wedge pressure; LVSWI, left ventricular stroke 
work index. 
TABLE V Survival and causes of death in the 89 
recipients of hemodynamically suitable donors 
Suitable donors 
Alive and well 68/89 (76%) 
30-day mortality 11/89 (12%) 
3 Elevated PVR 
3 graft failure 
1 Pancreatitis 
1 Infection 
I CVA 
1 Arrhythmia 
1 Pulmonary embolus Late deaths 10/89 (1%) 
2 CVA 7 and 25 mo 
1 Pancreatitis 3 mo 
4 Coronary disease 5, 
7,9,16 mo 
1 Malignancy 4 mo 
1 Multiorgan failure 3 mo 
1 Infection 4 mo 
13-48 mo after transplan- 
tation 
Heart 
1 Heart, 2 heart/lung 
Heart/lung 
Heart/lung 
Heart 
Heart 
Heart 
Heart and heart/lung 
Heart 
Heart 
Heart 
Heart/lung 
Heart/lung 
PVR, Pulmonary vascular resistance; CVA, cerebrovascular ac- 
cident. 
Of the 150 multiorgan donors, 133 yielded trans- 
plantable thoracic organs; 87 heart and 46 heart and 
lung blocks, together with splanchnic organs. 
There were 52 of 150 donors falling well outside 
TABLE VI Survival and causes of death in the 44 
recipients of initially unacceptable donors 
Alive and well 37/44 (84%) 13-48 mo after transplan- 
tation 
30-day mortality 5/44 (11%) 
Arrythmia Heart 
Infection Heart 
Acute respiratory distress Heart 
Cerebrovascular event Heart and lung 
Infection Heart/lung and liver 
Late deaths 2/44 (5%) 
Tamponade 3 mo Heart 
Infection 14 mo Heart and lung 
our acceptance guidelines (Table II). On initial 
inspection, 33 of 52 donors were judged to be 
"unacceptable": 21 on the grounds of low mean 
arterial pressure (mean 47 mm Hg), 
10 on the 
grounds of a high central venous pressure 
(mean 18 
mm Hg), and 2 requiring high inotropic support 
(25 
µg/kg/min). Figure 1 shows the individual and mean 
values at the start and end of the procedure 
for these 
groups, compared with the mean values 
for the 
remaining donors. 
With full monitoring results, an additional 19 of 
52 donors fell well outside our acceptance guidelines 
(Table III): 13 on the grounds of high pulmonary 
CVP AoP PCWP LVSWI 
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FIGURE 4 Comparative actuarial survival curves for recipients of the marginal and 
suitable organs, compared with the International Society for Heart and Lung 
Transplantation Registry figures since 1985. Tx, Transplantation. 
capillary wedge pressure (mean 19.8 mm Hg) and six 
on the grounds of a low left ventricular stroke work 
index (12.8 gm). Figure 2 shows the individual and 
mean values at the start and end of the procedure for 
these groups, compared with the mean values for the 
remaining donors. In the 13 patients with high 
pulmonary capillary wedge pressures, a significant 
left/right imbalance was observed: mean central 
venous pressure of 10.2 mm Hg with a mean 
pulmonary capillary wedge pressure of 19.8 mm Hg, 
which would not have been detected without full 
monitoring. Table III gives full hemodynamic pro- 
files of all of the donors in the unacceptable group. 
An improvement in function was seen in 48 of 52 
of these donors, which brought them back within our 
guidelines. Figure 3 shows the changes in inotrope 
support for the entire group, together with each of 
the unacceptable groups. Overall, 63% of donors 
initially required inotropic support with a mean dose 
of 6.8 p. g/kg/min; this percentage was reduced 
to 45% of donors, requiring a mean dose of 4.8 
99/kg/min, at the end of the retrieval procedure. 
However, four donors remained inotrope depen- 
dent. An additional four hearts were turned down 
on the grounds of cardiac disease, despite accept- 
able function: two with palpable coronary disease 
and two with significant ventricular hypertrophy. 
Our management regimen resulted in 44 initially 
marginal hearts being successfully transplanted. 
Of the 150 donors, 98 were within or close to our 
hemodynamic criteria on inspection. Of these, nine 
were not transplanted: four were rejected on the 
grounds of significant coronary artery disease, three 
became inotrope dependent, one developed right 
heart failure during the procedure, and one was 
poisoned with an overdose of lignocaine (Table IV). 
Accordingly, only 5% overall were refractory to our 
management regimen. 
RESULTS 
The overall survival in the group of 89 recipients who 
received organs from initially acceptable donors was 
76% over a follow-up period of 13 to 48 months. 
There were 21 deaths; 11 (12%) of these were early: 
three from an elevated pulmonary vascular resis- 
tance, one from graft failure (heart), two from graft 
failure (lung), one from arrhythmia, one from 
infection, one from pancreatitis, one from a pulmo- 
nary embolus and one from a cerebrovascular 
accident. There were 10 (11%) late deaths (Ta- 
ble V). 
Of the 78 of 89 patients surviving to discharge, 
there were 52 heart and 26 heart and lung recipients. 
The overall survival in the group of 44 recipients who 
received hearts from unacceptable donors was 84% 
over the same follow-up period of 13 to 48 months. 
There were five (11%) early deaths: one from an 
arrhythmia (heart), two from infection (heart and 
heart-lung and liver), one as a consequence of acute 
respiratory distress syndrome (heart), and one from 
a cerebrovascular accident (heart and lung). There 
were an additional two (5%) late deaths: one from 
V 
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tamponade (heart) at 3 months and one from 
infection (heart and lung) at 14 months (Table VI). 
As is evident from the previously noted list, only one 
of these deaths could be directly attributed to a 
cardiac cause. These results compare well with those 
of the International Society for Heart and Lung 
Transplantation Registry 30-day mortality figures of 
9.8% (hearts) and 21% (heart and lung) and 1-year 
Registry mortality figures of 78% (hearts) and 60% 
(heart and lung). ' Actuarial survival curves show no 
statistical differences between our two groups and 
the Registry heart transplant survival since 1985 
(Figure 4). 
DISCUSSION 
The donor management regimen described in this 
article has been developed over the past 4 years. 
This regimen was originally inspired by the Cape 
Town group, 5 with subsequent influence by publi- 
cations from Japan with respect to the key role of 
vasopressin. 22 The importance of changing the focus 
of management from that of minimizing the effects 
of cerebral trauma to that of optimal cardiovascular 
support has been recognized elsewhere '23,2" 
but a 
crucial change in our own practice has been the 
inclusion of a cardiac trained anesthetist as a 
member of the donor team. The use of continuous 
infusions of HRT has also been shown to be 
important. Despite our best efforts, however, a small 
number of donors (5% in this study) were still 
refractory to this management regimen. We have 
recently investigated the potential for physiologi- 
cally resuscitating these donors by means of normo- 
thermic support bypass -with some success. 
26 
Given the interactive nature of preload, afterload, 
and inotrope therapy on cardiac function, it is 
difficult to find a single comprehensive descriptor. 
However, in this study, marginal donors have been 
differentiated on the basis of wide deviation from 
our general acceptance criteria despite being clas- 
sified according to the first major condition by which 
they fail (Table III). We do not seek to delineate the 
effects of HRT from optimal cardiovascular man- 
agement with this report because our previous 
studies have already provided us with sufficient 
evidence of the efficacy of HRT in donors with 
compromised cardiac function. 
The most important factor to emerge from our 
experience has been the necessity to use compre- 
hensive monitoring which provides objective data on 
which to base optimal donor management and 
objective assessment of cardiac function. This moni- 
toring reduces the risks of retrieving unsatisfactory 
organs or the exclusion of potentially satisfactory 
organs. 
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The specific interventions, outlined previously, 
provide a mechanism for improving perioperative 
cardiovascular function, which has a particular 
relevance to the quality of retrieved donor hearts but 
has important implications for the viability of all 
transplantable organs. This study suggests that the 
numbers of satisfactory donor hearts may be in- 
creased by up to 30% without compromising recipi- 
ent outcome. Overall perioperative cardiovascular 
function is improved providing the opportunity for 
increased viability and function of all transplantable 
organs. 
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Introduction 
Numerous 
experimental and clinical studies have demonstrated that the oxygenation of cardioplegic 
solutions is beneficial since although hypothermic cardioplegic arrest provides a marked reduction in 
myocardial oxygen demand, there is still a small but finite consumption of oxygen and substrate. In an effort to meet these metabolic demands the use of blood-based cardioplegic solutions has 
gained some popularity over recent years and 
more recently still, systems for oxygenating crys- talloid cardioplegic solutions have been developed by several manufacturers. Whilst most of the delivery systems are effective, they are both 
complex and expensive. Analysis of replies to a 
recent perfusion safety survey revealed a disturbing increase in the number of serious 
Perfusion accidents related to cardioplegic delivery systems. 9 
We describe a novel technique for the oxy- 
genation of crystalloid cardioplegic solutions 
which allows control of oxygen content whilst 
remaining both simple and inexpensive. 
Address for correspondence: Mr DR Wheeldon, Surgical 
Unit, Papworth Hospital, Papworth Everard, Cambridge CB3 
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Method 
One litre Viatlex bags of Ringer's solution are 
placed in a warming oven (45°C) overnight. This 
causes the nitrogen content to fall from approxi- 
mately 2.3 vols% to 1.1 vols%. The air which has 
been driven out of the solution is removed by 
needle and syringe and the cardioplegia concen- 
trate added to the Ringer's solution. Pure oxygen 
is then added via a filter (Millipore 0.2 microns) 
to a pressure according to the required oxygen 
content and the Viaflex bag is refrigerated at 4°C. 
From Figure 1 it is evident that there is a steep 
increase in pO, related to the internal pressure, 
up to about 55mmHg, after which there is little 
further increase in oxygen content with increasing 
oxygen pressure. Solutions prepared in this way 
have been shown to be stable for more than 20 
days. In addition, the pH remains unaltered in 
bicarbonate buffered solutions. 
Using the same technique without prewarming 
results in a lower oxygen content (3.5 vols% 
compared with 5.4 vols%) and the application of 
external pressure (400mmHg) can be used to 
speed up the equilibrium (Figure 2). 
Cardioplegia delivery is then achieved by simple 
external pressurization of the Viaflex bag. The 
only precaution required is to keep the bag cold 
between infusions when using higher oxygen 
content solutions, since oxygen tends to come out 
of solution with rewarming. The use of a 
hydro- 
philic-hydrophobic cardioplegia filter provides 
additional security. 
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Discussion 
The oxygen demands of the nonworking heart 
(vented and beating or fibrillating) have been 
reported to be approximately 4ml/min/100; at 
37°C, falling to 0.5m1/min/1008 at 4°C. The use of 
hyperkalaemic cardioplegia reduces this demand 
to l. 5ml/min/lOOg at 37°C and 0. l5ml/min/1008 at 
4°C (Figure 3). 3 
Although blood-based cardioplegic solutions 
are capable of transporting more oxygen than 
crystalloid solutions, oxygen delivery is com- 
promised by the conditions under which it is used. 
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Hypothermia, a high pH and reduced red cell 2-3 
diphosphoglycerate all increase the affinity 
between haemoglobin and oxygen to the extent 
that below ? 0°C, most oxygenated crystalloid 
solutions will deliver more oxygen than blood- 
based solutions. "' There may, however, be other 
benefits from using blood as a eardioplegic base. 
not related to its oxygen carrying capacity, but 
these are as yet unclear. 
From Figures 3 and 4 it is evident that the 
oxygen demand of a 250g chemically arrested 
heart at 15'C (approximately S0ml of oxygen/ 
hour) could be met by 21m1 of crystalloid cardio- 
OXYGENATED CRYSTALLOID CARDIOPLEGIA 
INFLUENCE OF HYPERBARIA 
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Figure 1 Oxygen tensions produced as a result of prewarming 
Ringer's solution overnight followed by the addition of oxygen 
at pressures between 0 and 150mmHg. Following the addition of oxygen, the 
Viaflex bag is refrigerated at 4°C for 24 
hours. 
Oxygen tensions were measured at 37°C on an IL blood gas analyser (613). 
This means that PO2 measurements tended 
to be 
lower than the actual tension, particularly at high levels of oxygenation. Tensions at 
4°C are extrapolated between loading 
pressures of 50mmHg and 150mmHg. The actual tension to which the myocardium 
is exposed will fall somewhere 
between 
these two curves, depending on the temperature. 
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plegia at a PO, of 26)mmHg. l 5ml at a PO- of 560mmHo and 9.8ml at a PO, of 960mmHJ. The 
volume and frequency of cardioplegia delivery can 
therefore easily be calculated. 
A number of elegant cardioplegia delivery 
systems are available, but they are all relatively 
complex and expensive. A recent comparative 
study of four such systems suggested that a bubbler oxygenating system has distinct 
advantages over a membrane system based largely 
on differences in the ability to deliver solutions at 4°C. Oxygen carrying capacity for crystalloid 
solutions was 0.56 vols% for nonoxygenated. 3.2 
vols% for bubbler oxygenated, 3.7 vols% for 
membrane oxygenated and for the blood cardio- 
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plegia 11.3 cols°,, with a calculated availability of 
4.2 viols%ä at 12°C. 
The use of bubbler oxygenated systems has 
been associated with calcium paradox due to 
carbon dioxide washout and the resultant alkalin- 
ity. It may therefore be prudent to add calcium 
to these solutions and to ventilate with 5% CO... 
The system which we describe avoids the 
technical and chemical complications described 
above. Oxygen contents of up to 5.4 vols°ö are 
readily obtainable and intermediate contents are 
also easily achieved. Lastly, the system has the 
overwhelming advantages of extreme simplicity, 
low cost and intrinsic safety. 
OXYGENATED CRYSTALLOID CARDIOPLEGIA 
COMPARISON OF THREE METHODS 
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Figure 2 Time taken to reach a steady oxygen tension following loading with oxygen 
to a pressure of 50mmHg with and 
without prewarming and removal of air. Equilibrium can be speeded up by the application of external 
pressure to the Viaflex bag 
(400mmHg). Removal of approximately half of the dissolved air makes a significant 
difference to the final oxygen content of the 
solutions. 
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Introduction 
Approximately 30% of donor referrals for car- diac transplantation are refused on grounds of 
medical unsuitability'. predominantly because of 
apparently poor haemodynamic function, not- 
withstanding significant inotropic support. Following pilot studies on methods of reversing the deleterious metabolic consequences of brain death, during the past 14 months we have been 
able to restore normal haemodynamics in 14 
of 61 fully instrumented (Swan Ganz) donors 
who had unsatisfactory cardiorespiratory func- tion on initial evaluation (CI < 2.0 I/min/m2, PCWP > 12 mmHg, inotropes >5 mcg/kg/min 
against an afterload of 800-1200 dynes "sec"cm-5). A hormone package comprising T3, ADH and insulin was administered as a continuous infusion during the two to three hour donor organ retrieval 
procedure. These 14 pharmacologically 'resus- 
citated' hearts showed a mean post-treatment increase in LVSWI of 73% compared with a decrease of 25% in untreated donors. 
Address for correspondence: Dereck Wheeldon, Papworth hospital. Papworth Everard, Cambridge CB3 SRE. UK. 
We believed that donors refractory to 
pharmacological resuscitation might respond 
to haemodynamic resuscitation on a form of 
cardiopulmonary support (CPS), since this would 
allow the downward spiral of hypoxia, hypother- 
mia and cardiac decompensation to be broken 
whilst providing stability during the splanchnic 
dissection. Bypass has been used by a number 
of transplant teams as a method of total body 
cooling for heart-lung organ retrieval' and was 
used by Barnard to support the first clinical heart 
donor2 but has not previously been reported as 
a method of donor resuscitation. We report 
on what we believe to be the first such use 
of CPS. 
Case report 
Following a road traffic accident a 21-year-old 
male sustained a dislocated hip and subdural 
haematoma leading to diffuse cerebral oedema 
and subsequent brain stem death seven days later. 
During his treatment he received large volume 
infusions of crystalloid and colloid, leading to a 
positive fluid balance of 2.5 litres on 
day seven, 
Edward Arnold 1992 
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Table 1 Perioperative haemodynamic changes. The table shows the cnanges in haemodvnamics and notrocic succor, 
^crr admission to the operating theatre The hormone package brougnt about some improvement after one flour or 
therapy, but `unction was still unacceptable. CPS values were obtained off bypass at the intervals shown 
Theatre One hour post 70 min 170 min Ore cur cost 
hormones CPS CPS transciart 
AoP immHg) 31 42 52 67 73 
CVP (mmHg) 19 11 7 4 6 
PA (mmHg) 21 27 15 17 24 
PCWP (mmHg) 21 20 6 7 12 
CO (1/min) 6.6 14.2 6.9 6.8 76 
Cl (I/min/m2) 3.4 7.4 36 3.5 4.0 
SVR 145 174 525 734 706 
(dynes-sec-cm-5) 
LVSWI (g"m) 5.3 18.7 190 29.2 33 2 
ADH , IU/h) 2 
6 12 9 - 
Dobutamine 40 40 - - - 
Dcpamine 5 5 5 5 5 
Noradrenaiine - - - - 
0 05 
Isoprenaline - - - - 
0 CC3 
Unne output (ml) 0 0 120 460 - 
AcP = aortic pressure; CVP = central venous pressure; PA = pulmonary artery pressure, PCWP = pulmonary cap ltary 
wedge pressure, CO = cardiac output; CI = cardiac Index; SVR = systemic vascular resistance, LVSWI = left ventricular 
stroKe work index; ADH = Anti-diuretic hormone. Values for all notropes are in mcgikgr'min. 
PRESSURES (mmHg) 
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Figure 1 Graphical representation of key parameters mprovements'cllcwing 
hormone therapy followed by 
CPS. LVSW has been shown by our group and others to offer the best single 
indicator of cardiac function. 
PRE-SURG POST HORMONE CPS 70 CPS 170 POST Tx 
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a decreasing urine output and blood pressure 
requiring increasing inotropic support. Relatives 
gave permission for multiorgan donation. The 
ethical aspects of using advanced methods for 
improving the quality of donor organs was dis- 
cussed with our Ethical Committee. 
On transfer to theatre his haemodynamics 
revealed a picture of cardiogenic shock despite 
significant inotropic support (Table 1), and he had 
been anuric during the previous six hours. 
Splanchnic dissection revealed an ischaernic bowel with a blue, congested liver. Cardiac 
inspection showed a distended, poorly contracting 
heart. Treatment with our hormone package was 
commenced and although a significant improve- 
ment in haemodynamics was achieved following 
one hour of treatment (Figure 1), function was 
still unacceptable. It was decided to place the 
donor on CPS. A CPS circuit (Medtronic Inc) 
(Figure 2), comprising a hollow-fibre membrane 
oxygenator with integral heat exchanger and 
centrifugal blood pump was primed with 800 
ml of Plasmalyte A and connected to the donor 
via a single right atrial cannula and high aortic 
Figure 2 CPS circuit. The circuit used was an adaptation of the Medtronic closed chest 
system. The prime one litre bag was used as a reservoir during priming and de-airing and 
thereafter as a buffer reservoir. 
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cannulation. The blood flow was adjusted so as 
to unload the heart whilst still providing pulsatile 
arterial pressure. Blood gases and electrolytes 
were normalized with normothermic perfusion 
at an Index of 1.5 to 1.8 i/min/m2 over the 
intervening three hours. There was a rapid 
improvement in cardiac contractility and in 
the ischaemic appearances of the splanchnic 
vascular bed, together with a resumption in 
urine output after 20 minutes of CPS. After 
70 minutes CPS was weaned and haemodynamic 
function again evaluated. Further improvements 
were noted (Figure 1) but it was decided to 
continue CPS for a further two hours. During 
this period it had been possible to withdraw all 
the dobutamine support, normalize biochemistry 
and blood gases, restore normal urine output 
and unload the heart. Final haemodynamic 
assessment demonstrated very acceptable cardiac 
function. An early decision was made not to use 
the liver for transplantation although a biopsy 
taken post-CPS was reported as normal. Both 
kidneys functioned exceptionally well following 
transplantation and post-transplant cardiac func- 
tion was normal: 
Discussion 
We believe that this case demonstrates one of the 
few remaining methods of increasing the donor 
pool whilst providing a means of improving organ 
function of all transplantable organs. Data from 
the Registry of the International Society for Heart 
and Lung Transplantation reveal that primary 
draft dysfunction still accounts for 26% of post- 
transplant mortality. 3 
Modern bypass equipment makes the applica- 
tion of such a technique a logistical reality in 
terms of transport of equipment to donor hos- 
pitals, and we believe that the more extensive 
application of this technique could yield improved 
post-transplant organ function and make a signifi- 
cant impact on current transplant mortality and 
morbidity. 
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Functional Assessment and Management 
of Heart Donors: A Rationale for 
Characterization and a Guide to Therapy 
C. D. 0. Potter, BA, D. R. Wheeldon, MIBiol, and 
J. Wallwork, BSc, MBChB. FRCS(E), MA 
Background: Traditional methods for the functional evaluation of a donor heart have relied 
on superficial hemodynamic data and visual inspection of the action of the heart at sternotomy. The International Registry has continued to report significant mortality for heart transplant 
recipients from primary graft dysfunction that may be due to donor management, donor organ 
selection, organ preservation, or recipient factors. The literature reports the loss of at least 25% of potential donors because of the provision of inadequate physiologic support. 
Methods and Results: We have now spent several years in establishing and refining a 
strategy for optimizing donor management, which has resulted in the safe expansion of our 
donor pool by approximately 30%. Central to this management regimen has been the use of 
comprehensive perioperative invasive monitoring used by, a cardiac anesthetist who takes 
responsibility for donor management during the retrieval operation. 
Conclusion: This article outlines the technique which has evolved for the functional 
evaluation of a donor heart, which is now used in our institution as a guide to management 
and as a basis for decision making regarding organ suitability. J HEART LUNG TL. t. sPLA. rr 
1995; 14: 59-65. 
Two 
important aspects of cardiovascular function have to be borne in mind with any physiologic anal- 
ysis. The first is that the circulation consists of two 
separate pumps and resistances linked in series, the 
outputs of which must necessarily be the same for 
equilibrium to be maintained. The second is that because flow, volume, and generated pressures are interactive, 
analysis in more than one dimension is 
required for adequate interpretation. In addition, it is necessary to characterize the system by making 
measurements at a minimum of two different points, 
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by adjusting preload, inotropy, or afterload. This 
implies measuring both right-sided and left-sided 
heart pressures and cardiac output (CO), and mak- 
ing the relevant calculations. Adjustment to preload, 
inotropy, or afterload can then be made in the ap- 
propriate direction and the measurements repeated. 
The techniques described in this article are based 
on nomograms, constructed from basic principles of 
physics. The nomograms detail the interaction 
between the left and right ventricles and display the 
trend and current hemodynamic status of the donor 
and thus highlight the effect of individual interven- 
tions. The technique is easily instituted in any 
patient undergoing pulmonary artery CO catheter- 
ization and arterial blood pressure monitoring. 
Similar function charts for the heart have been 
described in the past by Van den Horn et al., ' but 
these have been related to animal experimentation. 
They have concentrated on left ventricular perfor- 
mance only, with an emphasis on maximum effi- 
ciency versus the optimum working point for an 
individual heart. 
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FIGURE 3 Target systemic vascular resistance. Shaded 
section indicates target area. AoP, Mean arterial 
pressure; . 4P, right atrial pressure. 
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FIGURE 4 Optimum static power output for left 
ventricle. Shaded section indicates target area. AoP, 
Mean arterial pressure; RAP, right atrial pressure. 
FIGURE 5 Combined criteria for left ventricle. Shaded 
section indicates target area. AoP, Mean arterial 
pressure; RAP, right atrial pressure. 
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FIGURE 6 Nomogram B: Right ventricular function. 
PAP, Mean pulmonary artery pressure; L4P, left atrial 
pressure. 
Figure 5 combines all the previously mentioned 
criteria for the left ventricle and systemic circulation 
and indicates the area of optimum hemodynamics 
for a donor heart. 
FORMULATION OF NOMOGRAM B 
Nomogram B (Figure 6) describes the hemody- 
namic state of the right ventricle and pulmonary 
circulation for a donor of body surface area of 1.8 
m2. The pressure drop across the lungs (Pulmonary 
Artery Pressure [PAP] - Left Atrial Pressure 
[LAP]) is plotted on the ordinate against CO on 
the abscissa. 
With left and right ventricles pumping in series, 
the minimum CO is maintained at 3.8 L/min. The 
pressure drop across normal lungs is often very small 
but must be finite for blood to flow from the right 
ventricle to the left atrium. Because the pressure 
drop across the lungs should preferentially be as 
small as possible, the minimum criterion is defined 
as 0 mm Hg (Figure 7). 
Figure 8 indicates lines of constant pulmonary 
vascular resistance (PVR). This is calculated as 
follows: 
PVR (in dynes x second per centimeters) _ 
PAP - L`ýP x 79.9 CO 
The maximum normal PVR is selected as 200 
dyne x sec/cros. 
Figure 9 indicates lines of constant right ventricu- 
lar static power, calculated as follows: 
01234507 
Cardiac Output (1/min) 
60 Potter et al. 
120 
AoP - RAP (mmHg) 
l10- 
vaf oollate Reauce Inotroae. 
100- Notmahl. Preload Reduce Preload 
00 - vasopilatr 
e0 - 
Np/maliu Prrload 
_ Inc Waal Inotropfa 
Vaa opilata 
ý! 
' 
70 - - -}` OPTIM U/L 
60 _ 
MEN ocro ICS 
50_ ý 1-}' acv- va. ncon. v mr 
40 vf. pcen. rrmt Normallu P.. lo, a 
JO - Ne. maliu Prflpap Vaaec pn. trýet 
ZO - 
Incrrrrf Inpirc Pl. Np/mfliu Prrlpap 
Incr.... Inptrpeei 
10- 
0, -- 
O 121 456 
Npmev/am A Cardiac Output (1/min) 
FIGURE 1 Nomogram A: Left ventricular function. 
An argument is to be presented with the relation- 
ship between developed pressure (Arterial Pres- 
sure - Atrial Pressure) and CO, together with opti- 
mal resistance and static power for each ventricle. 
With established minimal criteria for each it is 
possible to delineate a "target" area for optimum 
function. By plotting current parameters it is pos- 
sible accurately to describe function and the dispar- 
ity between this and the optimum. In addition, it is 
also simple to predict the intervention required and 
to use the nomograms to chart clinical responses. As 
a trend chart the nomogram for the left ventricle 
(Nomogram A) is used for initial evaluation and 
provided that a normal range of left atrial pressures 
are attainable only the left ventricular nomogram is 
subsequently required. If an element of primary or 
secondary right-sided heart failure is present, then 
it is necessary to optimize this with the right ven- 
tricular nomogram (Nomogram B) before con- 
tinuing. 
Our thesis is that this approach provides a more 
focused method for accurately describing current 
global heart function, measuring and qualifying any 
disparities, and monitoring the efficacy of any 
therapeutic intervention. 
FORMULATION OF NOMOGRAM A 
Nomogram A (Figure 1) describes the hemody- 
namic state of the left ventricle and systemic 
circulation for an average-sized donor with a body 
surface area of 1.8 m'- (nomograms for individual 
patients would normally be generated). The pres- 
sure drop across the systemic circulation (Arterial 
Pressure - Right Atrial Pressure [RAP]) is plotted 
on the ordinate against CO on the abscissa. Each of 
the following figures has a shaded area that indicates 
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FIGURE 2 Minimum criteria for left ventricle. Shaded 
section indicates target area. AoP, Mean arterial 
pressure; RAP, right atrial pressure. 
the optimal hemodynamic state for the criterion 
specified. 
Minimum acceptable hemodynamic criteria se- 
lected for nomogram A include a pressure drop 
across the systemic circulation of 48 mm Hg (a 
minimum mean arterial pressure [MAP] of 60 mm 
Hg with a maximum RAP of 12 mm Hg) and a CO 
of 3.8 L/min (equivalent to a cardiac index of 2.1 
L/min/m2) (Figure 2). These minimal criteria are 
derived from mortality studies of patients with 
cardiogenic shock and postmyocardial infarct=, ' and 
from data from our own donor hemodynamic 
database. 
Figure 3 indicates lines of constant systemic 
vascular resistance plotted on the same axes. This is 
calculated as follows: 
Systemic Vascular Resistance (in dynes x second per 
centimeters) = 
MAPCO RAP x 79.9 
The normal hemodynamic range selected is 800 to 
1200 dyne x sec/cm5. 
Figure 4 indicates lines of constant left ventricular 
static power plotted on the same axes. This is 
calculated as follows: 
Left Ventricular Static Power (in watts) = 
. (MAP - RAP) x CO x 2.2167 x 0.001 
The minimum limit of left ventricular static power is 
taken as 0.4 W, calculated from the minimum 
hemodynamic criteria of a MAP of 60 mm Hg, RAP 
of 12 mm H and CO of 3.8 Umin. A maximum 
value for left ventricular static power is selected to 
be 1.0 W; at levels greater than this unnecessary 
work is being performed by a donor heart. 
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FIGURE 7 Minimum criteria for right ventricle. 
Shaded section indicates target area. ,. P, Mean 
pulmonary artery pressure; LAP, left atrial pressure. 
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FIGURE 8 Target pulmonary vascular resistance. 
Shaded section indicates target area. PAP, Mean 
pulmonary artery pressure; LAP, left atrial pressure. 
Right Ventricular Static Power (in watts) = 
(PAP - LAP) x CO x 2.2167 x 0.001 
Minimum right ventricular static power is estimated 
as 0.01 W, corresponding to a pressure drop across 
the lungs of 1 mm Hg with a CO of 3.8 L/min. The 
maximum right ventricular static power at rest is 
estimated at 0.125 W, corresponding to a pressure 
drop of 15 mm Hg across the lungs (maximum 
acceptable pulmonary pressure drop for orthotopic 
heart transplantation) with a CO of 3.8 Umin. 
Figure 10 combines all the previously mentioned 
criteria for the right ventricle and pulmonary circu- 
lation and indicates the target area of optimum 
hemodynamics. 
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DISCUSSION 
To display the current status of the donor, it is 
necessary to plot the pressure drop against the CO 
for each side of the heart. The resistance and static 
power output of the ventricle are automatically 
displayed without any further calculations. Any 
hemodynamic abnormalities are immediately obvi- 
ous, with both the magnitude and direction of the 
donor from the target area being indicated. The 
trend data show any hemodynamic change since the 
last set of measurements, and the most appropriate 
interventional therapy can then be easily deter- 
mined. 
Figure 11 indicates specific interventions and 
their effects: 
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FIGURE 10 Combined criteria for right ventricle. 
Shaded section indicates target area. PAP, Mean 
pulmonary artery pressure; LAP, left atrial pressure. 
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1. Adjustment of preload moves the status point 
across power bands at an angle and magnitude 
depending on functional integrity. 
2. The addition or withdrawal of inotropes has a 
similar effect but also depends on receptor 
status. 
3. Adjustments to the pulmonary or systemic 
impedance with the use of dilators or constric- 
tors tend to move the status point along power 
bands. The magnitude of these changes de- 
pends on vascular compliance. 
In practice this means that any heart that is 
producing more than the minimum power output 
should be capable of moving into the optimum target 
area by judicious use of dilators or constrictors 
alone, although optimization of preload is also 
beneficial. Gross abnormalities of afterload often 
influences power output by altering the myocardial 
supply/demand ratio, so that optimization may cause 
shifts across power bands in the first instance. 
If minimum power outputs are unattainable at 
maximum preloads of . 12 to 15 mm Hg, then inotropes are indicated. Our criteria exclude any 
heart for transplantation that cannot produce the 
minimum power level with a preload of 15 mm Hg 
with less than 5 i. g/kg/min of dopamine after 
optimum management. Visual inspection of the 
donor heart still plays an important role in excluding 
wall motion abnormalities and hearts with coronary 
artery disease. Obviously, some hearts can be 
excluded if the donor's hospital is able to perform an 
ultrasound study before the donor team arrives. 
For full assessment the heart can be volume 
loaded to determine the response to preload 
changes. Hearts can then be compared by looking at 
the static power at a preload of 10 mm Hg. The 
response to volume loading can then be examined by 
the gradient of the static power curve at a preload of 
10 mm Hg. This technique allows a heart to be 
compared in both the donor and recipient and for 
the functional comparison of different hearts. 
Myocardial overdrive, in situations where left 
ventricular outputs exceed about 1W at rest, usually 
represents inappropriate management for a heart 
that is about to receive ischemic trauma. In these 
cases inotropes can be reduced and the preload 
lowered. 
Nomograms A and B contain suggested treatment 
strategies, in order of priority, for donors in each 
hemodynamic territory. It is normally necessary to 
use only Nomogram A to follow the correction of 
any gross discrepancies. However, if right-sided 
heart dysfunction is significant (primary or second- 
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FIGURE 11 Effects of specific interventions. AoP, 
Mean arterial pressure; RAP, right atrial pressure. 
ary to an elevated PVR), then Nomogram B is first 
used to optimize right-sided function. 
At our institution all donors are monitored with 
an invasive arterial pressure line and a balloon- 
tipped pulmonary artery catheter. Using the nomo- 
gram approach, together with our donor manage- 
ment techniques, ' we have retrieved and success- 
fully transplanted many organs that would otherwise 
have been refused on referral. 5 
The nomograms used are specific to patient size, 
because they are constructed according to actual CO 
data. This avoids the use of standardized index data, 
which are less commonly used within critical care 
environs. The only difference between sized nomo- 
grams is the value for the minimum CO, which is 
adjusted to a cardiac index of 2.1 L/min/m2 for 
each patient. 
This nomogram technique has a general utility 
within the critical care environment. A similar 
nomogram approach for oxygen delivery is being 
developed. 
CONCLUSION 
We contend that the nomogram approach to myo- 
cardial functional characterization and therapeutic 
guidance provides a simple and effective method of 
evaluating the function of a heart. This 
is particu- 
larly important with the retrieval of donor hearts, 
where confidence of good postimplantation function 
is essential. Hearts can be extensively evaluated with 
preload, afterload, and inotropic changes so that 
only hearts with severe functional impairment are 
refused for transplantation. The technique can also 
be applied to the treatment of any critically 
ill 
patient where differential diagnosis becomes 
less 
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EXAMPLE 1 Inotropic change. AoP, Mean arterial 
pressure; RAP, right atrial pressure. 
complicated and ambiguous, the effects of thera- 
peutic intervention are easier for medical and 
nursing staff to comprehend, and trend plots pro- 
vide a useful guide to patient progress. 
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APPENDIX 
The following examples involve multiorgan donors. 
All were at distant hospitals and were therefore not 
being treated by our team until arrival, when a 
pulmonary artery catheter was inserted. The ex- 
amples chosen indicate the changes in hemody- 
namic status after only one alteration in treatment 
between readings. 
Example 1: Inotropic Change 
A 25-year-old man had been admitted and venti- 
lated for 30 hours after a subarachnoid hemorrhage. 
He had a chest infection and ECG changes, includ- 
ing T-wave inversion in lead I and aVL, and was 
receiving 8 µg/kg/min of dopamine and 17 µg/kg/min 
of dobutamine at time of referral. 
EXAMPLE 2 Vasodilation. AoP, Mean arterial pressure; 
RAP, right atrial pressure. 
When a pulmonary artery catheter was placed the 
patient had pulmonary capillary wedge pressure of 
17 mm Hg and required 6 . g/kg/min of 
dopamine 
and 6 µg/kgjmin of dobutamine (point 1). The 
patient showed inotrope dependency with hemody- 
namic profile (point 2) on temporary withdrawal of 
all inotropes with the same preload. The heart was 
therefore deemed unsuitable for transplantation 
and was retrieved for valves only. Note that function 
moved across power lines. 
Example 2: Vasodilation 
A 48-year-old woman had a massive extradural 
hemorrhage and right intracranial hemorrhage af- 
ter she fell at home. She had been in the hospi- 
tal for 12 hours before pulmonary artery cath- 
eterization. 
On inspection the heart was working extremely 
well with pulmonary capillary wedge pressure of 
4 mm Hg and no inotropic support, although sys- 
temic vascular resistance was 2000 dyne x sec/cm5 
(point 1). Sodium nitroprusside was initiated at 
1.4 µg/kg/min and prostacyclin at 4.8 ng/kg/min. 
This reduced systemic vascular resistance to 870 
dyne x sec/cm5 (point 2), with slight improvement in 
power. Sodium nitroprusside dosage was reduced to 
0.9 µg/kg/min, with prostacyclin dosage held con- 
stant. This therapy had the effect of changing 
systemic vascular resistance back to 1000 dyne x 
sec/cros (point 3), increasing power again by a small 
amount. 
This is an example of a heart with normal 
function. Vasodilation causes movement down 
power line with some minimal increase 
in power 
because of improved supply/demand ratio. 
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EXAMPLE 3 Preload change. AoP, Mean arterial pres- 
sure; RAP, right atrial pressure. 
Example 3: Preload Change 
A 17-year-old male patient had been at the hospital 
for 80 hours with fractured skull after a traffic 
accident. On full monitoring pulmonary capillary 
wedge pressure was 23 mm Hg with the heart at the 
top of the function curve (point 1). Overenthusiastic 
venisection reduced pulmonary capillary wedge 
pressure to 9 mm Hg (point 2), causing the hemo- 
dynamic profile to be just acceptable. Additional 
volume increased the pulmonary capillary wedge 
pressure to 11 mm Hg, moving the hemodynamic 
profile into the middle of optimum band (point 3). 
These volume changes moved the hemodynamic 
profile across power bands and provided a simple 
method of hemodynamic optimization in patients 
with normal cardiac function. 
Example 4: Elevated Pulmonary Vascular 
Resistance (Hypoxic) 
A 19-year-old woman had been involved in a traffic 
accident and had required resuscitation by an 
ambulance crew. Extensive hemorrhage had oc- 
curred because of a lacerated liver, and 12 U of 
blood and fresh-frozen plasma were transfused. On 
inspection right atrial pressure was 25 mm Hg with 
pulmonary capillary wedge of 11 mm Hg and PVR 
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EXAMPLE 4 Elevated pulmonary vascular resistance 
(hvpoxic). PAP, Mean pulmonary artery pressure; LAP, 
left arterial pressure; AoP, mean arterial pressure; RAP, 
right arterial pressure. 
of 240 dyne x sec/cm5. Arterial saturation was 79% 
with fractional oxygen concentration in inspired gas 
of 100%. Obvious right ventricular failure resulted 
from elevated PVR, probably caused by hypoxia 
(point 1). The airway was cleared, resulting in an 
increase in arterial saturation from 79% to 99.8%, 
leading to acute drop in PVR to 80 dyne x sec/cm5. 
Right ventricular function improved dramatically, 
with an RAP of 13 nun Hg and pulmonary capillary 
wedge pressure of 10 mm Hg, and left ventricular 
hemodynamic profile moved steeply up across power 
lines (point 2) into the target area. 
